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Abstract
Stereotactic radiosurgery (SRS) is a non-invasive treatment predominantly used for the
management of malignant and benign brain tumours. The treatment can be delivered
by various platforms in a single fraction where a high dose of radiation is delivered to
the target whilst the surrounding healthy tissue is spared. This requires a high degree
of accuracy in terms of the dose level delivered but also in terms of geometric precision.
The purpose of this work was to identify the variations of SRS practice in the UK
and develop a novel method compatible with all practices, capable of assessing the
accuracy of delivery. The motivation behind this e↵ort was to contribute to safety in
SRS delivery, provide confidence through a quality assurance audit and form a basis to
support standardisation in SRS.
A national survey was performed to investigate SRS practices in the UK and to help
guide the methodology of this thesis. This resulted to the development of a method for
an end-to-end audit of SRS. This was based on an anthropomorphic head phantom with
a medium sized target located centrally in the brain, in close proximity to the brainstem.
This realistic patient scenario was presented to all 26 radiosurgery centres in the UK
who were asked to treat it with SRS. The dose delivered was assessed using two novel
commercially available radiation detectors, a plastic scintillator and radiochromic film.
These detectors were characterised for measuring the dose delivered in SRS. Another
established dosimetry system, alanine, was also used alongside these detectors to assess
the accuracy of each delivery.
The results allowed the assessment of SRS practices in the UK and the comparison of
all centres that participated in the audit. The results were also used to evaluate the
performance of the dosimeters used for the purposes of quality assurance measurements
and audit.
Keywords: Medical physics, Radiotherapy, Radiosurgery, Stereotactic Radiosurgery,
Dosimetry, Small fields, Plastic scintillation detector, Radiochromic film, Anthropo-
morphic phantom, End-to-end, Audit, Linear accelerator, Gamma Knife, CyberKnife.
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Chapter 1
Background and Introduction
1.1 Historic developments and background
1.1.1 The origin of stereotaxis
The words stereotactic and stereotaxic are both comprised of the Greek words “stereo”
which means “solid” or “three-dimensional”, and “taxis” which means “order” or the
“orderly arrangement of something”. Therefore, these compound words have been
created to elicit the meaning of the orderly arrangement of a three-dimensional solid
object, within a three-dimensional space.
The word “stereotaxic” appeared probably for the first time in the writings of Horsley
and Clarke in 1906 [1]. It was used to describe the method which they adopted in
investigating the cerebellum of a primate. This method employed the use of a metal
frame attached on the skull of a primate, which provided external coordinates for precise
intracranial navigation. They studied the functions of various anatomical sections of
the brain by destroying them. This method formed the basis for many techniques used
in research and medicine including computer-aided navigation and surgery, robotic
surgery and radiosurgery. We find medical applications in humans of the stereotactic
frame technique as early as 1947, with Spiegel et al establishing the less invasive nature
of this technique compared to previously used techniques for operations on the human
brain [2]. A series of other stereotactic devices were developed in the following years
including the device of Lars Leksell, a Swedish neurosurgeon, who published the design
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of his own stereotaxic apparatus for intracerebral surgery in 1950 [3]. Leksell’s design
fashioned an “arc-quadrant” and an electrode that was inserted in the patient’s brain
in order to perform neurosurgical procedures. This design was a major improvement to
previous devices that used the Cartesian axis system (x, y, z), as this allowed movement
along a polar angle of choice, depth into tissue and anterior-posterior location.
1.1.2 Discovery of ionising radiation
Just over a decade before the invention of the stereotactic frame by Horsley and Clark,
Wilhem Ro¨ntgen was the first to identify electromagnetic radiation in the range that is
today known as X-rays [4]. Within days of Ro¨ntgen’s discovery, the biological e↵ects of
X-rays were noticed and a few weeks later X-rays were being used for medical treatments
in many parts of the world. In the following 50 years many attempts for producing
medical radiation delivery machines, with a variety of engineering approaches, were
published [5–7]. Around the same time that X-rays were used therapeutically for the
first time [8], Henri Becquerel detected the existence of naturally occurring radioactive
materials [9]. Likewise, Becquerel’s discovery raised a lot of interest and radioactive
sources were just as popular for therapy as X-rays were.
1.1.3 Radiation dosimetry
Radiation dosimetry is the science investigating the measurement of absorbed dose in
medical and industrial applications. For the purposes of this thesis, absorbed dose
refers to absorbed dose to water, which is used as a standard in medical applications,
as the human body is mostly comprised of water and its average density is 1 g/cm3.
The unit of absorbed dose, the Gray (Gy), is fundamentally defined as the absorption
of energy per unit mass where 1 Gy = 1 Joule/kg. National standards laboratories,
define dose in this quantity using calorimeters, often referred to as primary standards.
Calorimetry quantifies the increase in temperature over absorbed dose. Secondary
standard dosimeters, usually ionisation chambers, are calibrated against calorimeters
and with the application of suitable factors the recorded quantity can be converted to
absolute dose in Gy. Other detectors can be calibrated against secondary standards
and used as tertiary standards for absolute dosimetry.
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1.1.4 The origin of stereotactic radiosurgery
Stereotactic radiosurgery is a non-surgical, non-invasive treatment that focuses ionising
radiation to an a↵ected area within the brain, whilst sparing healthy tissue.
The idea of cross-firing small radiation beams to elicit a desired biological e↵ect within
the human cranium was proposed in the late 1940’s [10]. Lars Leksell was the first to
propose a method that could accurately guide these beams. By putting together the
developing fields of stereotaxis and radiotherapy he proposed a new method and coined
the term “Stereotactic RadioSurgery” (SRS) to elicit a procedure with geometrical
precision equivalent to surgery [11]. These developments took place in 1951 and were
based upon the principles of his stereotactic apparatus [3]. He replaced the electrode of
his frame with a 200 kVp orthovoltage X-ray unit whilst stating that a beam of higher
energy would have been preferable if available. He defined it as: “The administration,
through the intact skull, of a single high dose of radiation, stereotactically directed to
an intracranial region of interest; May be from X-rays, gamma rays, protons or heavy
particle” [11]. As reported by Leksell, the first time this method was used medically,
was for the treatment of trigeminal neuralgia in 1953 [12]. Since the conception of
this idea, more e↵orts for delivering radiosurgery were undertaken adopting di↵erent
ionising radiation sources. The use of heavy particles and protons was growing in
popularity as the Bragg-Peak energy deposition of these particles in human tissue was
preferred. This was originally suggested in 1946 [13] and it was also then considered
ideal for radiosurgery [14, 15]. Leksell also pursued particle SRS by partnering with
physicists Borje Larsson and Kurt Liden who contributed immensely [16]. Despite the
progress achieved and the clinical success of particle radiosurgery, it appeared that
the synchrotron accelerator that produced the beams was unreliable and impractical
for clinical use. Not long after that realisation, Larsson’s and Liden’s attempts for
radiosurgery were redirected towards a more practical approach which was the use
of Cobalt-60 (60Co) gamma rays. These e↵orts resulted in the first Gamma Knife
(GK) prototype built for clinical research in 1967. This was a machine with a helmet
appliance that contained multiple 60Co sources. It was dedicated for delivering high
doses of radiation into small intracranial volumes and it was predominantly used for
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treating functional, behavioural and mobility disorders; all of these are pathologies
that were previously treated with conventional neurosurgery. It was also tested for the
treatment of malignancies and arteriovenous malformations (AVMs) showing promising
results [12,17]. “Gamma Knife I” was installed at Hospital Sofiahemmet in Stockholm,
Sweden and produced very successful outcomes in its first few years of operation [16].
It was then gifted to University California Los Angeles (UCLA) in the United States
of America (USA) to be used for clinical research for most of the 80’s. A refined
prototype was installed at the Karolinska Hospital in 1975, this time containing 179
60Co sources whose beams were collimated into ellipsoids instead of squares. This
second unit was again used for treating the traditional neurosurgical targets but was
also used to investigate further the treatment of cranial tumours and AVMs [18]. Leksell
reported that the number of patients treated with SRS by 1983 was approximately 700
[16]. It should be noted that this number does not account for all the patients who
received particle radiosurgery at Berkeley and Harvard under the care of physicians
Lawrence and Kjellberg. Also, the newly emerging field of linear accelerator (linac)
radiosurgery was not accounted for either. After further refinement, a third unit with
201 60Co sources was then commercialised and installed in Buenos Aires in the early
80’s. Two identical units, the first radiosurgery machine in the United Kingdom (UK)
was commissioned at Weston Park Hospital in She eld during the summer of 1985
[19] and the first in the US was installed at the Presbyterian University Hospital of
Pittsburgh in 1987 [20].
1.1.5 Linear accelerator radiosurgery
The use of linacs for therapeutic purposes was proposed in the late 1940’s [21], predating
Leksell’s proposal for X-ray radiosurgery. Despite that, the progress was slower and
the first treatment using a linac was performed in 1953 at Hammersmith Hospital in
London using an 8 MeV beam, followed by a 6 MV linac used in Stanford in 1956 [22].
Both of these prototype systems had a fixed beam but with the advent of 360  rotational
gantries by Varian in 1960, linacs became very popular radiotherapy tools [23]. They
had many advantages over 60Co radiotherapy machines therefore more centres were
replacing their equipment. During this period, SRS was also gaining popularity but
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linac systems were unable to provide the geometric and dosimetric accuracy required
to perform such procedures. In 1974, Larsson et al stated that should accelerators
improve and reach the desired level of accuracy they “would seem a most attractive
alternative” to 60Co systems for radiosurgery [24]. Hence, the 1960’s and the 1970’s
was a period where SRS was predominantly used for neurosurgical procedures but it
was also starting to invade into the field of radiation oncology. On the other side,
linac radiotherapy was recognised as a valuable tool in the fractionated treatment of
malignant disease, with a potential future role to play in radiosurgery that had not
yet been pursued. Leksell noticed this trend in 1983 by saying that: “. . . the use of
narrow beams of ionising radiation has little to do with radiotherapy in its conventional
meaning, but the communication lines between the territories must remain open” [16].
It was not until 1982 that the adaptation of linacs to perform radiosurgery was initiated
by Betti and Derechinsky in Argentina using a Varian Clinac [25]. In the same period,
collaborations of neurosurgeons and physicists were happening in many countries of
the world in order to achieve similar results. The list of pioneers includes Winston
and Lutz in Pittsburgh [26], Friedman and Bova in Florida [27], Colombo in Vicenza
[28] and Hartmann in Heidelberg [29]. The aforementioned and others proved the
feasibility of linac radiosurgery and gave the green light for expanding the world of
radiosurgery beyond the GK community. In spite of the evidence, linac-SRS was still
considered unsafe by some attributed to the fact that linacs had more moving parts
than GK units and therefore more sources of uncertainty [30]. Partly due to this reason,
in the early 1990’s e↵orts were focused on developing dedicated SRS linacs with the
first one made by Phillips, the “SRS200” and the second by Varian, the “600SR”.
Linac SRS was becoming more popular, however there were still improvements to be
made. It was a fact that all linac radiosurgery systems used circular collimators that
were not ideal as the target volume was rarely spherical. Leavitt et al identified this
issue and suggested a di↵erent collimation system [31]. These suggestions were later
realised and developed into a commercial micro-Multi Leaf Collimator (MLC) system
by the German Cancer Research Centre that significantly improved beam shaping [32].
In order to keep up with these developments Varian Medical Systems and BrainLab
partnered to develop a dynamic micro-MLC addition to the Varian dedicated SRS linac.
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This collimation system was able to change the shape of the beam every 10  of gantry
rotation, a system later named “Novalis” [33]. This partnership was also imperative in
giving rise to Intensity Modulated RadioTherapy (IMRT). Neurosurgeon Mark Carol
identified the possibility of focusing the beam not just in shaping the beam to match the
tumour shape but also in better conforming dose within the tumour itself [34]. Physicist
Tim Solberg was convinced by the idea and persuaded BrainLab to include IMRT in
their Treatment Planning System (TPS) [33]. The fourth dedicated SRS linac to hit
the market followed a new approach to treatment delivery. This system, envisioned by
Stanford neurosurgeon John Adler, adopted a compact 6 MV linac attached to a robotic
arm and was originally named “Neurotron 1000” to be later renamed “CyberKnife”
(CK) [35]. The robotic arm was able to move around the patient to irradiate the target
from multiple positions in manner similar to the GK. Moreover, the advent of a robotic
arm linac allowed for the first time to take radiosurgical practices outside the cranium
[36], something that was later achieved by gantry linacs as well [30].
1.2 Contemporary stereotactic radiosurgery
1.2.1 Delivery platforms
There are currently a few manufacturers that produce delivery platforms marketed
specifically for SRS. There are also some commercial systems that are capable of per-
forming SRS but are not necessarily designed or marketed for this purpose. Elekta
(Stockholm, Sweden) and Varian (Palo Alto, CA, USA) produce linacs for routine ra-
diotherapy use, which if equipped with additional SRS specific software and hardware,
they are capable of delivering SRS. Also, Accuray (Sunnyvale, CA, USA) has a rota-
tional radiotherapy delivery system called “Tomotherapy”, which although it was not
marketed as a radiosurgery machine, has been used to deliver SRS.
The most prominent SRS systems in the market (at least in the UK) are the GK
(Elekta AB, Stockholm, Sweden), the CK (Accuray, Sunnyvale, California, USA) and
the Novalis (Brainlab, Feldkirchen, Germany). In order to highlight the di↵erences in
SRS delivery methods a brief description is provided for each machine and a compar-
ison table at the end of the section (Table 1.1). While the images below might not
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represent the latest or high-end systems available from their manufacturers, they serve
the purpose of illustrating the major components and the architecture of each unit.
This section focuses on the most common approaches to radiosurgery practices within
the UK.
GK units (Figure 1.1), are equipped with multiple 60Co sources (the “Perfexion” model
has 192) that are positioned in a hemispherical array. Tungsten collimators of di↵erent
sizes can be positioned between the sources and the patient to shape each “shot”
delivered. The patient is fitted and imaged, usually in a Magnetic Resonance Imaging
(MRI) scanner, with a stereotactic frame that defines the stereotactic space within
which the treatment target is located. For the treatment delivery, the patient is localised
by attaching the fitted stereotactic frame onto the GK robotic couch. The couch then
moves the patient with respect to the beam isocentre and multiple shots can be used
to achieve conformal dose coverage to irregular shaped targets. Previous models did
not have any on-board imaging. However, the latest model (GK Icon) has a kV X-ray
gantry with Cone-Beam CT (CBCT) capabilities.
Figure 1.1: Illustration of a Gamma knife unit [37].
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CKs (Figure 1.2) are comprised of a compact 6MV linac attached to a robotic arm
that allows movement in six degrees of freedom. The beam is shaped using circular
collimators, but an MLC attachment is also available. The patient is typically scanned
and imaged in a thermoplastic mask. Two X-ray imaging sources on the ceiling and two
detectors on the floor provide stereoscopic imaging before and throughout a treatment.
These images are compared to the reference Computed Tomography (CT) scan and if
a deviation is detected the robotic couch moves and repositions the patient.
Figure 1.2: Illustration of a CyberKnife unit [38].
The Novalis system by Brainlab (Figure 1.3), is the most prominent linac-based SRS
system. It is equipped with a micro-MLC that can also have circular collimators at-
tached to it. It comes with the ExacTrac positioning system which employs the princi-
ples of stereo-photogrammetry to monitor reflective markers on the patient’s skin using
cameras. It also has the capability of performing stereoscopic imaging, before or after
1.2. Contemporary stereotactic radiosurgery 9
each treatment field, with two X-ray sources in the floor and two imaging detectors on
the ceiling, opposite to the CK. It is also equipped with a robotic couch that can move
in six degrees of freedom to correct any deviations from the reference CT scan.
Figure 1.3: Illustration of a Novalis unit [39].
There are other linac platforms, such as the Varian TrueBeam linac, that can be fitted
with the ExacTrac positioning system and therefore utilise favourable features available
of other linac platforms, such as CBCT or di↵erent beam energies. To be inclusive of
all the possible variations of equipment in linac-based SRS, Table 1.1 includes a column
for linac-based systems in general.
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Features Gamma Knife Perfexion CyberKnife v.10.5 Linac-based systems
Source
192 60Co sources -
Gamma rays (⇡1.25MeV)
Xrays (6 MV) X-rays (6 MV/10 MV)
Flattening filter N/A No Yes/No
Image guidance Yes (latest version) - CBCT Yes - Planar X-rays Yes - Planar X-rays & CBCT
Output ⇡3.5 Gy/min at installation up to 1000 MU/min Up to 2400 MU/min
Treatment time Longest Longer Shortest
Daily capacity Low Medium High
Collimation Circular Circular, IRIS & MLC Circular & MLC
Delivery Technique “Spherical” shots Static fields Dynamic & Modulated fields
Target dose homogeneity Lowest Higher Highest
Dose fall o↵ Highest High Lowest
Extracranial No Yes Yes
Immobilisation
Fixed-frame or
frameless (latest model)
Frameless Fixed-frame or frameless
Fractionation Yes (on the latest model) Yes Yes
Functional SRS Ideal Not ideal Not ideal
Versatility Least More Most
Quality Assurance Simple Complex Complex
Maintenance Simple Rigorous Rigorous
Reliability Good Variable Variable
Source reload Every 5 years N/A N/A
Table 1.1: Comparison of the radiosurgery systems.
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1.2.2 Immobilisation devices
Alongside the evolution of delivery units discussed in sections 1.1.4 and 1.1.5, pa-
tient immobilisation systems also evolved. Initially, fixed stereotactic head frames were
adapted to become more robust, allow access from more treatment angles but also to
improve patient comfort. Moreover, they became compatible with CT and MR imag-
ing in order to allow more precise delineation of the targeted tissue [40]. Nowadays,
all major manufacturers provide frameless solutions but some still provide fixed-frame
solutions as they may be preferred over frameless system for certain indications. Frame-
less systems are most commonly employing thermoplastic masks with or without the
use of a mouth-bite immobilisation device. Up until recently, GK treatments were only
performed with a fixed-frame until Elekta released the “Icon” model in 2015 and ther-
moplastic masks also became available [41]. The CK robotic radiosurgery system was
developed with frameless SRS as its main purpose and although originally a stereotac-
tic frame was used [30], it is now a truly frameless radiosurgery technique. The Novalis
system is also compatible with both frameless and a fixed-frame solutions.
1.2.3 Prescription protocols
In recent years, it was observed that fractionating a radiosurgical procedure might be
beneficial for improving radiation induced side e↵ects [42]. Typically, some centres
prefer to fractionate when the target is in close proximity to an organ at risk or when
the target volume is larger than usual. These practices expanded the field of SRS, from
only single fraction deliveries, to include treatments that are delivered within two to
five fractions. This is sometimes referred to as Stereotactic Radiotherapy (SRT) and
when it is delivered extracranially it is called Stereotactic Body Radiotherapy (SBRT)
or Stereotactic Ablative Body Radiotherapy (SABR). Although these treatments are
similar and they even produce similar results for some pathologies [43], the theory
that underpins them is di↵erent. On one hand, SRS is used to ablate the target and
obliterate it whilst sparing nearby healthy structures. On the other hand, SRT is based
on the principles of radiobiology and utilises the di↵erences in radiosensitivity of the
target and healthy tissue [44] whilst allowing for repair, redistribution, repopulation
and reoxygenation [45]. The two regimes complement each other as certain indications
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produced good outcomes with SRS but not SRT and vice versa [43]. Ongoing trials
will be able to provide more evidence on the merits and drawbacks of each modality
for specific patient groups.
The pathologies treated with the stereotactic techniques in oncology nowadays include
acoustic neuromas, arteriovenous malformations in the brain, primary brain tumours
and brain metastases, lung cancer, spinal metastases, metastatic liver disease, prostate
cancer and others [46–54]. Moreover, apart from malignant and benign lesions, a num-
ber of functional disorders may also be treated to produce a desired radiobiological
response. These include trigeminal neuralgia, glossopharyngeal neuralgia, epilepsy, es-
sential tremor and Parkinson’s tremor or rigidity and others [46–49,55–57]. The clinical
decision making process before prescribing SRS takes into account a number of factors.
The lesion has to be of a compatible size, location and type but also the patients’ gen-
eral health and age are taken into account. Very often it takes months for the e↵ect
of treatment to be evident due to the fact that the tumour is not removed but biolog-
ically deactivated. SRS is used worldwide to treat large numbers of patients with the
aforementioned pathologies each year.
It can be argued that neurosurgeons have been the most influential group of profes-
sionals in the development and evolution of radiosurgery. From the moment of the
conception of the idea until at least three decades after that, GK SRS was a tool
exclusively available to neurosurgeons as it was a treatment option available for most
indications previously treated with neurosurgery. The prescription regime followed dur-
ing this time was focused on ablation of the target, with good target coverage and steep
dose fall o↵, with no interest regarding the homogeneity of dose inside the target. This
practice is still existent in present times predominantly in GK centres. Due to the fact
that the desired outcome of the treatment is biological deactivation of the target and
local control, a steep dose gradient is preferred and dose inhomogeneity is encouraged.
Despite this standardised approach and universal approach within the GK community,
there are examples of other aspects of prescription practices where consensus has not
been achieved. Two of the most influential institutions for GK radiosurgery follow dif-
ferent planning approaches. At the Karolinska Institute, target volumes are outlined
and the prescribed dose is delivered to 95% of the target volume. The remaining 5%
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of the volume will receive a slightly lower dose than the target. This ideology supports
the theory that it is not necessary to treat 100% of the target to the full prescription
dose to achieve local control. A di↵erent approach is followed at Pittsburgh where
target volumes are not outlined at all. The lesion to be treated is covered completely
by the prescription isodose and target coverage is inspected visually. Reported results
of retrospective outlining of the target volume showed that in most cases 100% of the
target was covered [58].
During the 1980’s, when linac-SRS was proving feasible, linacs were ubiquitous in
radiotherapy centres. This is also the case today and it is therefore not surprising that
linac-based SRS programs are predominantly run by oncologists. In e↵ect, this group
of professionals has traditionally followed alternative methods in the use of radiation,
which in turn has influenced the way linac-SRS is delivered today. The target volume is
always outlined and it is then enlarged by a margin to account for various uncertainties
in the delivery. The prescribed isodose typically covers 100% of the enlarged target
volume as opposed to GK practice where a lower percentage of the target volume is
covered (95%) which has not been enlarged by a margin. Moreover, the prescription
isodose chosen is much higher than the prescription isodoses used in GK practices.
Whilst GK clinicians prescribe to the 40-60% isodose, linac clinicians prescribe to the
80-100% isodose. Another source of variation is that prescribed isodose is normalised to
the maximum dose in GK practices, whereas in linac-SRS it can be a percentage of the
dose to the isocentre, which is rarely the maximum dose. Moreover, dose homogeneity
within the target volume is always sought after in oncology but as mentioned previously
it considered irrelevant in neurological radiosurgery. CK practices tend to be the middle
ground between GK and linac-based radiosurgery practices.
In summary, the di↵erences in SRS practices described above show variations in dose
prescription, target coverage and homogeneity of dose. This is mainly equipment and
clinician dependent, although there are examples of di↵erent practices followed in dif-
ferent countries of the world. The practices outlined in the reports of International
Commission of Radiation Units and Measurements (ICRU) are hardly followed, espe-
cially when it comes to reporting dose to a delivery reference point [59]. This can cause
confusion and misunderstanding in communication between SRS practitioners. More-
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over, when prescription doses are included in publications they do not convey the detail
of the treatments delivered unless additional information is included. It is important to
establish ground rules for this communication that will facilitate better understanding
and direct comparisons of outcomes. This can in turn open new avenues for research
and clinical trials. A strong mechanism in facilitating this process within the UK SRS
community could be the initiation of a national, inter-departmental and cross-platform
comparison of radiosurgery services.
1.3 Quality assurance in stereotactic radiosurgery
1.3.1 Local quality assurance
SRS demands extraordinary attention to Quality Assurance (QA) issues. This is related
to the high geometric and dosimetric accuracy needed to perform a successful procedure,
the accuracy demanded by the proximity of the target lesion to organs at risk and the
high dose delivered in one or a few sessions. A geographical miss in SRS is not only
sparing the problematic target volume but also ablating healthy tissue with a lethal
dose of radiation.
The first steps for producing guidelines for radiosurgery were taken in the early 1990’s
when many of the pioneers of radiosurgery from both the neurosurgical and oncology
communities in the US published a consensus statement manuscript [60]. The major
purpose of this paper was to emphasise the necessity for quality improvement, which
was deemed achievable by enhancing QA procedures. During the same period, more
documents with guidelines were published in an attempt to standardise the quality of
SRS worldwide [61, 62]. These e↵orts mainly focused on the details of how commis-
sioning of a new SRS units should be undertaken giving advice for both linac-based
systems and the GK. The reports also highlighted the multi-disciplinary team compo-
nent that should be apparent in a radiosurgical setting and the need for double-checking
all parameters before delivery. There was wide agreement in the fact that apart from
the initial testing of the unit, routine testing procedures need to be performed daily,
monthly and annually [55]. Apart from these guideline documents, there were a num-
ber of studies published outlining QA procedures performed for both GK [63, 64] and
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linac-SRS [65,66]. The recommended accuracy for the beam delivery system alone was
recently reported to be below 1mm [55]. As technology developed and computer capa-
bilities increased, QA procedures necessarily became more rigorous. In particular, the
emergence of high-resolution CT and MR has enabled targeting lesions with an overall
accuracy of 2.5 - 2.7 mm [67]. QA e↵orts are now capable of allowing for such accu-
racy to be assessed and attained routinely in practice. According to the Radiological
Physics Centre, “the clinically applicable 95% confidence level of positional uncertainty
is 1.8 mm” and 1.6% for the dose delivered. The uncertainty in the dose prescription
line is around 1mm [68]. In comparison to a non-stereotactic radiation treatment of a
brain lesion, one study found this uncertainty to be up to 7 mm [69]. These figures
are indicative of the positional certainty required for SRS delivery. For a radiosurgery
program to run confidently it is essential to have good knowledge of the characteristics
of all the systems in place. The overall positional accuracy relies on the following [68]:
a) The rigidity of the stereotactic frame system or frameless localisation equipment
b) The pixel and slice separation dimensions of the pre-treatment images
c) The spatial accuracy of the treatment unit; this may be subdivided to the mechanical
and geometric accuracy of the unit, the dose delivered to the tumour and surrounding
healthy tissue but also the treatment planning system (TPS) that is used
d) The motion of internal anatomy between the imaging and treatment steps.
Patient immobilisation is sometimes dependent on the indication treated. As explained
in section 1.2.2, there are a few devices available for stereotactic delivery including re-
movable frames and frameless approaches to enhance fractionated treatments. What-
ever the system used, it is recommended that it thoroughly assessed in order to quantify
the uncertainty it may contribute to the delivery of SRS [67].
It is important to highlight point b) because tolerances applicable in radiosurgical
procedures are such that the slice thickness and resolution chosen for pre-treatment
images, if inadequate, can have a significant impact on treatment accuracy. A study
showed that target localisation is highly dependent on imaging resolution [40]. In
this study a scan of 3 mm slice separation typically contributed to 4.5 mm of target
position uncertainty, irrespective of other issues. The overall uncertainty of linac-based
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procedures using images of 1 mm slice separation was estimated to be 2.4 mm [68].
Therefore, high resolution pre-treatment imaging is imperative for SRS.
The spatial accuracy of all SRS treatment units should be assessed routinely using
established methods [26,70] to maintain the high degree of accuracy required. Moreover,
all radiosurgery delivery systems have to be routinely assessed for their radiation output
and where possible these measurements should test the ability of the planning system
to predict them. If this is not the case, additional tests for the planning system should
be undertaken.
Finally, to account for internal motion, approaches vary in a number of ways. Some
consider negligible internal motion and proceed to treatment; some utilise imaging
technologies only once before the treatment delivery whilst others acquire a number
of images throughout the treatment or use tracking systems to continuously adjust
treatment delivery. Regardless of the practices used, a thorough understanding of all
the factors that can contribute to inaccuracies is of utmost importance. QA checks
may then be tailored accordingly and performed routinely to address the consistency
of the procedure in order to identify any problems that may contribute negatively.
1.3.2 External audit
Even with rigorous local QA practices, undetected errors may still occur. External
audit is a useful mechanism to reveal such errors. Apart from the fact that the word
“audit” connotes a performance test that is done by an independent mechanism, the
di↵erences between QA and audit are minor. Stamatis defines audit as: “a planned
and documented activity to determine by investigation, examination, or evaluation
of objective evidence, the adequacy and compliance with established procedures and
the e↵ectiveness of an implementation” [71]. In healthcare, the audit process has been
associated with procedures that aim to assess patient care against the quality expected.
Clinical audit procedures are therefore mechanisms used for reviewing the performance
of clinical services. In the instances where the performance status is not satisfactory, the
identification of errors acts as constructive feedback to the service providers, followed-up
by improvements to the service in order to avoid errors in the future. These procedures
were o cially introduced in the National Health Service (NHS) in 1993 as a means of
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improving the standard of patient care [72].
The field of radiotherapy in the UK was one of the early adopters of independent clinical
audit with multi-departmental dosimetric comparisons initiated in 1987 [73], six years
before the formalisation of audit by the NHS. As radiotherapy was developing and
becoming more advanced, dosimetric audit in the UK was also evolving. Firstly taking
on electron radiotherapy [74], then a series of more complex audits performed as part of
clinical trials for lung [75], prostate [76] and breast cancer [77], and recently assessing
the services o↵ered with the advents of IMRT [78] and rotational radiotherapy [79].
Despite the presence of SRS in the UK since 1985, radiosurgery services have not yet
been subjected to an independent, cross-platform dosimetry audit at a national level.
Dosimetry audits in radiotherapy can be categorised into three main areas: basic
dosimetry audits, “plan and treat” audits and end-to-end audits. In basic dosime-
try audits the auditor performs a series of measurements to compare their results with
the local centre. The parameters compared are usually basic beam characteristics such
as the output in reference conditions, Percentage Depth-Dose (PDD) curves, field sizes,
the quality index of a beam (defined as the Tissue Phantom Ratio (TPR) of measure-
ments at di↵erent depths, i.e: TPR20cm10cm), etc. In “plan and treat” audits, the centre
prepares a treatment plan, typically calculated on a phantom, and then the auditor
performs measurements and compares the measured doses with TPS-predicted doses.
The findings give an indication of the overall accuracy of the treatment planning and
delivery chain. This type of audit can be combined with some basic dosimetry measure-
ments to perform a more comprehensive test. End-to-end audits are designed to test
every step that can contribute to uncertainties in the treatment delivery. This includes
patient immobilisation devices, pre-treatment imaging, contouring, image fusion etc.
In comparison to other tests, it may be more di cult to evaluate the level of contri-
bution to errors of each step tested, but they are the only types of audit that provide
an assessment of the overall accuracy of the pathway assessed. With the addition of
more measurements during an end-to-end audit, some sources of uncertainty can be
accounted for independently. For example, a basic measurement can evaluate the dif-
ferences in output at the time of the measurement from the reference conditions which
are defined on the TPS for dose calculations. The ratio of the measured over expected
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output can then be used as a correction factor. As radiotherapy practices are becoming
more complex and the sources contributing to errors are increasing, end-to-end audits
are becoming more valuable as they are inclusive of all steps in the patient pathway.
Therefore, this type of audit should be the preferred method for a national SRS audit.
With regards to the specific aspects of treatment planning as part of an audit, there
are two common approaches. The most common, which is typically used in clinical
trials, involves a set of dose constraints fixed by the auditor to be delivered by the
service provider to a target volume that contains one or more radiation detectors.
This approach was followed for the UK rotational radiotherapy audit as it also served
to credential the centres for clinical trials [79]. The other approach does not impose
dose constraints and the service provider is asked to deliver the treatment of interest
in the same way that it is routinely performed in their centre. This approach was
used for the IMRT audit as it was a postal audit designed to give a snapshot of the
practice of IMRT in the UK at the time [78]. For both approaches, the target volume
tends to be a pre-defined area within a phantom device or a delineated volume in an
anonymised patient scan. This exercise is adapted to represent a clinical treatment
procedure as much as possible and the audited centre is assessed upon the quality of
the treatment delivered. Comparative assessments between all the service providers
audited may contribute valuable information as to how each centre compares to the
rest of the population.
It would be inappropriate to set up an audit with dose constraints, where the goal is to
assess the local practice with di↵erent modalities used for SRS, due to the di↵erences
in treatment protocols used within the SRS community. As explained in section 1.2.3,
there is a multitude of variables in the field of SRS and it would not be representative
of clinical practice if centres were asked conform to a prescribed treatment delivery.
Considering these discrepancies, the second and more flexible approach is more appro-
priate; where centres are asked to deliver a treatment following to the local protocol for
a known indication. The methodology chosen for an SRS audit has to take into account
the idiosyncrasies of the service. It is therefore crucial to understand the nature and
complexity of small radiation fields before choosing appropriate methods for measuring
them.
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1.4 Scope of this work
SRS is field of medicine without standardised practice as over the years it has been
subject to influences from neurosurgery and radiation oncology. It is essential to un-
derstand the variations existing in SRS practices in order to facilitate a level of stan-
dardisation. This will produce a cohesive national approach which would encourage
scientific communication and development of the field, facilitate research studies and
enable clinical trials to take place. Audit is a strong intervention that supports new
clinical implementations whilst identifying errors and providing constructive feedback
for eliminating them. The development of a national SRS audit, inclusive of GK, CK
and linac-based SRS services is a novel approach that can be the driving force behind
this e↵ort. Within the framework of an audit, a number of important research questions
can also be tackled. The dosimetric and geometric accuracy of each modality used in
SRS can uncover important findings and areas of potential improvement. The same
applies to treatment plan quality and TPS calculation algorithm accuracies. Finally, a
national audit presents a unique opportunity to access a large number of facilities and
test novel instrumentation for the purposes of radiation dosimetry.
1.5 Summary of thesis
• Chapter 2: This chapter briefly describes the properties of the small radiation
fields used in radiosurgery and the implications apparent in small-field dosimetry.
This is followed by a review of existing detection technology to identify good
candidates for SRS dosimetry. The theory of three detection systems is then
briefly summarised.
• Chapter 3: This chapter presents the results of a national survey conducted to
investigate the current status and practices of radiosurgery in the UK.
• Chapter 4: This chapter presents the characterisation of a new radiochromic film
and the development of a protocol suitable for audit purposes.
• Chapter 5: This chapter presents the characterisation of a new plastic scintillation
detector and the development of a methodology suitable for audit purposes.
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• Chapter 6: In this chapter the detectors characterised are utilised in an adapted
phantom to develop a procedure for conducting an end-to-end test for stereotactic
radiosurgery. The system is validated for this purpose.
• Chapter 7: This chapter describes all steps of the methodology developed for
performing an end-to-end assessment of all SRS systems active in the UK.
• Chapter 8: This chapter presents and discusses the results of the national UK
audit for stereotactic radiosurgery.
• Chapter 9: The final chapter summarises the findings of this thesis and proposes
future directions for dosimetry, audit and standardisation in SRS.
1.6 Research Objectives
a) To conduct a survey in order to investigate current SRS practices in the UK
b) To understand the complexities of performing accurate dosimetry in clinical SRS
deliveries and characterise suitable detectors for SRS audit
c) To test novel detector systems for suitability in dosimetry audits
d) To develop and test an end-to-end phantom methodology for SRS audit, compatible
with all SRS platforms in the UK
e) To conduct a national UK SRS audit in order to assess the dosimetric and geometric
accuracies of SRS practices
f) To identify areas of SRS practices that may benefit from standardisation
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Chapter 2
Theory
2.1 Small radiation fields
Radiosurgery targets are typically small in volume. In order to tightly conform a high
dose around these targets whilst sparing surrounding healthy tissue, small (smaller
than 3 x 3 cm) photon fields are used in all mainstream SRS practises and delivery
platforms. GKs and CKs use small static fields, whereas linacs may use static or com-
posite (modulated/dynamic) fields. In all cases, the characteristics of these fields are
far removed from reference measurement conditions and are considered non-standard
due to the di culty in measuring or calculating them accurately [80]. For the accurate
calculation of dose distributions in a patient, TPSs require a number of accurate mea-
surements in the small fields that will be used clinically. These include output factors,
dose profile measurements and percentage depth dose plots. Hence, special consider-
ations are required in these measurements in order produce an accurate beam model
on the TPS that can predict resulting dose distributions within the patient with high
accuracy.
There are many factors contributing to inaccuracies in small photon field measurements,
which have been previously described in great detail [81–83]. For the purposes of this
chapter, a brief review of the major contributing factors is included, leading to their
relevance and impact in a dosimetry audit for SRS. Finally, a review of current detector
technologies has been conducted to identify the best candidates.
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2.1.1 Lack of charged particle equilibrium
Charged particle equilibrium (CPE) can be defined in simple terms as the state where
the energy carried by the charged particles entering into a region of interest is equal to
the energy carried by the particles exiting from that region. For instance, when charged
particles that are leaving the volume of interest are replaced by particles entering of the
same mean energy, a state of CPE is assumed. When particles leaving the volume are
not replaced by particles carrying the same mean energy, charged particle equilibrium
cannot be assumed. In photon beams, charged particles refers predominantly to scat-
tered electrons. The lack of lateral electronic equilibrium, which is apparent in small
photon fields, is demonstrated in Figure 2.1.
Figure 2.1: Illustration of the lack of charged particle equilibrium in small photon fields.
As illustrated in Figure 2.1, the forward range of electrons does not have an impact
on CPE within the volume of interest, as exiting electrons are replaced by entering
electrons moving in the direction of the photon beam. Where the lateral range of the
electrons is concerned, if the range exceeds the boundaries of the field edge (from the
point of measurement), the field is considered as small. Das et al demonstrate that
one of the problems caused by the lack of CPE in small fields is the overestimation of
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field sizes [81]. This is also dependent on source occlusion which is discussed further
in Section 2.1.2. In large photon beams, where lateral CPE is present, cavity theory
assumes that when a detector is inserted into these fields, which have a uniform flux
of particles, the measurements performed are accurate as any perturbations caused by
the detector are negligible [84]. On the contrary, in small photon fields where there
is no lateral CPE, cavity theory is no longer applicable. Moreover, the lateral range
of electrons varies with the density of the medium traversed and therefore prolonged
electron tracks are produced in areas of low-density, whereas the opposite e↵ect occurs
in areas of high-density [83]. Therefore, unless the detector has the same density as the
surrounding medium, it will contribute further to the level of disequilibrium. This is
an important consideration as detectors with near water-equivalent densities are ideal
for SRS dose verification.
On a similar note, density inhomogeneities are often met in SRS where scattered elec-
trons are crossing through dense skull bone and air-filled sinuses in the cranium. As
density e↵ects are not always taken into account by TPS algorithms, the use of an
anthropomorphic phantom with realistic densities is re-emphasised and the question as
to how accurate such algorithms are is raised.
2.1.2 Source occlusion & detector size
With modern radiosurgery collimation systems, occlusion of the direct photon radia-
tion source as seen from the point of measurement is common practice. This results
in errors when calculating the field size as the full width half maximum (FWHM) is
overestimating the field size. The same problem arises when the detector size, relative
to the field size, is bigger than desired causing partial view of the field. Figure 2.2
adapted from IPEM report 103 [82] demonstrates these conditions. These two condi-
tions contribute to what is known as “volume averaging e↵ects” of the detector and
lead to underestimation of the dose within the field and overestimation of the penum-
bra. Consequently, inaccuracies in small field dosimetry can lead to both geometric and
dosimetric uncertainties in SRS delivery if inappropriate methodologies are utilised in
creating the beam model of the TPS. Therefore, another important consideration for
accurate dosimetry in SRS is the size of the detector, or the resolution of the detector
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if a 2D dosimetry technique is employed.
Figure 2.2: Illustration of source occlusion e↵ect and the impact of detector size.
2.1.3 Considerations for accurate dosimetry in radiosurgery audit
The e↵ects discussed in Sections 2.1.1 and 2.1.2 are the defining factors of small field
dosimetry and big contributors to uncertainty in the characterisation of small fields.
Despite these, one can still produce accurate beam models on a TPS if suitable steps
are taken to account for these e↵ects. However, there are more considerations to be
taken when selecting detectors for dose verification in SRS treatments.
SRS plans are usually delivered in a non-coplanar fashion to achieve high levels of
conformity around the target and steep dose fall o↵ from diseased tissue to healthy tissue
[85,86]. Therefore a detector whose response is dependent on the angle of irradiation will
yield significant errors in the measurement of an SRS plan, which may mask mistakes
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in the beam model or the delivery.
SRS plans, particularly those delivered on linacs, utilise variable dose rates to achieve
better dose distributions. Therefore, even detectors with dose rate dependence may gen-
erate erroneous measurements. Furthermore, the detectors utilised in a multi-platform
audit should be compatible with all delivery methods to enable direct comparisons.
Inherently, across the population of SRS centres in the UK dose rates will vary due to
di↵erences in source activity (GK) or dose-per-pulse (linac & CK).
In recent years, it was noticed that the flattening filter present in linacs, used to flatten
the central section of the beam, did not have a significant contribution in small fields
and stereotactic applications as the central region of the field is still relatively flat even
in the absence of a flattening filter [87]. However, the removal of the flattening filter
results in substantially higher dose rates. Flattening Filter Free (FFF) beams were
therefore adopted in clinical practise to achieve faster treatments. This requires extra
attention in dosimetry as FFF beams have di↵erent characteristics to flattened beams.
The use of FFF beams by some SRS centres in the UK re-emphasises the need for a
detector that is dose rate independent, due to the higher dose rates. The removal of the
flattening filter also causes a spectral change in the beam as low energy contributions
are not filtered causing the beam to have a lower average energy and be less penetrating.
The performance of the detectors chosen should therefore be evaluated in FFF beams.
The energy dependence of the detector must also be considered due to the large energy
range across the population, as shown previously in Table 1.1 ( 1.25MeV - 10MV).
Detectors that are highly energy sensitive over this range of beam energies should be
avoided.
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2.2 Small field detectors
Section 1.3 highlighted the need for accurate dosimetry in SRS and section 2.1 outlined
how inappropriate dosimeters may yield erroneous measurements and result to patient
overdose or underdose. Hence, the ideal dosimeter for an SRS audit should have the
following characteristics:
a) High spatial resolution (especially lateral) - small size
b) Soft tissue (or water) equivalence
c) Low field size dependence
d) Low photon beam energy dependence
e) Low angle of incidence dependence
f) Low dose rate dependence
g) Linear response in the dose range of interest
h) Perform stable and reproducible measurements
The detectors for which there is documented evidence of their use in SRS include:
ionisation chambers, Thermo-Luminescent Dosimeters (TLDs), micro-TLDs, metal ox-
ide semiconductor field-e↵ect transistor (MOSFET) detectors, diamond detectors, sil-
icon diodes, alanine pellets, radiochromic film, polymer gels and plastic scintillators
[59, 88–97]. Most of these detectors, approach the ideal only to an extent and only
over a limited range of conditions. Many of these dosimeters are dependent on pho-
ton energy and beam angle, and the spatial resolution varies. Multi-dimensional high
spatial resolution detectors are appealing for SRS measurements as they provide a bet-
ter assessment of the treatment accuracy and they should be preferred when they are
able to achieve low uncertainties. Unfortunately, some dosimeters which may give high
spatial resolution (eg: detector arrays) are hard or impossible to use for measurements
in anthropomorphic phantoms due to di culties in accurate positioning and handling.
Other detectors with high spatial resolution (eg: TLDs, gels) have significant energy
dependence and may require strenuous preparation or calibration [59,98].
The most reliable and well-documented detector in dosimetry is the ion chamber. There
are many studies that have assessed the e cacy of small ion chambers in small fields
[99–101]. Many inaccuracies were found attributed to volume averaging e↵ects and
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their non-tissue equivalence. A comparative study measuring various small field char-
acteristics with radiochromic film, a TLD and a gel dosimeter demonstrated that the
three dosimeters were in good agreement with each other and that an ionisation cham-
ber underestimated the absorbed dose [102]. It is widely recognised that ion-chambers,
regardless of how small they are or whether they are gas or liquid filled, are not ideal
for SRS dosimetry.
Semiconductor diode detectors may have a role to play in SRS dosimetry. Their small
size, real-time measurements and superiority to ion chambers are key advantages. On
the other hand, their high Z value, temperature-dependence, dose rate dependence and
in some cases their finite lifetime are considered major flaws that make them unsuitable
for an SRS audit [103].
There are numerous publications investigating the performance of polymer gel dosime-
try in stereotactic applications [88, 93, 99, 104–106]. The attention that this field is
receiving is indicative of the promising nature of gel dosimetry and its acceptance from
the research community as an e cient 3D dosimeter. Unfortunately, there are some
serious drawbacks and barriers that are di cult to overcome and it is therefore un-
likely that this technique will become main stream in the near future. The limitations
are mostly related with the di culties in producing gel (consistently), handling and
scanning the material for readout after radiation exposure. Considering these factors,
it is apparent that despite the many benefits exhibited by gel dosimeters, they will be
highly impractical for dosimetry audits.
Diamond detectors are appealing for small field dosimetry due to their near tissue
equivalence and small size. It was shown that natural diamonds can be dose rate
dependent, but if this dependence is corrected, they produce more accurate measure-
ments than film and diodes [90]. Synthetic diamonds showed very good performance
in small field measurements, IMRT and VMAT plans [52,96,107,108]. There are some
disadvantages such as the need for pre-irradiation to maintain stability and a degree
of angular dependence along the polar axis of the detector [52]. Diamond detectors
may have a role to play in SRS dosimetry but high dose rates, treatment angles and
the need for pre-irradiation need to be taking into consideration. Bearing in mind the
variations in dose rates and angles of irradiation in SRS delivery systems, it may not be
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possible to directly compare measurements performed with a diamond detector within
the framework of an audit.
Electron paramagnetic resonance (EPR) dosimeters, such as alanine and lithium for-
mate, are promising methods in SRS dosimetry. Lithium formate custom shaped
dosimeters were used in an anthropomorphic head phantom and proved the feasibil-
ity of this technique for SRS dose verification [109]. As far as alanine is concerned,
there is a growing body of evidence for its use in small fields and in dosimetry audit
[79, 95, 107, 110–112]. The drawbacks of EPR dosimetry is mainly the non-automatic
and expensive readout process, and the compromise between detector size and sensi-
tivity. On the other hand, it is well-established, allows for small size detectors to be
manufactured and it is a near water-equivalent detection system with little dependence
to any other factors [113]. Another key benefit of alanine is that it can be independent
of the ionisation chamber traceability chain.
Some common and practical methods for SRS dosimetry utilise TLDs and radiochromic
films to acquire 2D measurements [114], with film being more popular [97, 115, 116]
and also used in stacks for acquiring 3D dose distribution measurements [117]. In
the USA, there are at least three dosimetry services that o↵er mailed dosimetry for
SRS by evaluating the absorbed dose and/or dose distribution using radiochromic film
and TLDs [55]. However, there are limitations with these techniques mostly due to
the calibration and post-exposure processing [59]. On the other hand, there are some
very attractive advantages to be gained if a good system for handling and processing
radiochromic film is established. Film has a high resolution, very little dependence to
other factors and has the ability to measure complex geometries, which are attributes
that are close to ideal for SRS. Moreover, it is a practical audit dosimeter which is easy
to cut and position in phantoms [97,110,114,118,119], although it is essential that this
is done accurately.
Another appealing approach adopts plastic scintillators attached to fibre-optic cables
[120–122]. There are a number of advantages in the use of plastic scintillation dosime-
ters (PSDs), for example the fact that corrections for pressure and humidity are not
necessary [123]. They can be very small, they are tissue equivalent and capable of tak-
ing real-time measurements. There is currently only one commercially available PSD
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(Exradin W1 by Standard Imaging, Middleton, WI, USA), which could present a very
good option to be used in a dosimetry audit. Initial characterisations of the detector
showed mainly a good behaviour [124, 125] but raised some concerns about the long
term stability of the detector, the stem e↵ect and its energy dependence [126, 127].
Nevertheless, any dependence shown appears to be correctable, making the detector
able to produce low uncertainty measurements. The Exradin W1 has also been tested
for the measurement of small field output factors producing good agreement with other
suitable small field detectors and Monte Carlo calculated output factors [128–130]. The
detector was also used in an Italian multi-centre study for the measurement of output
factors, which confirmed its suitability for small field measurements [131]. There is
little evidence of PSDs being used for dose verification purposes [132,133] but the evi-
dence available suggests that the Exradin W1 is a good candidate for an SRS dosimetry
audit.
To summarise, there is currently no ideal detector for SRS plan dose verification. De-
spite the fact that ionisation chambers are the gold standard in radiation detection, it
has been shown that they are inadequate for measurements in small fields. There is
promise shown by diamond detectors but their dose rate and angular dependence are
not ideal for an SRS audit. Likewise, gel dosimeters have distinct advantages but the
labour-intensive task of handling and scanning is impractical for an audit. A detec-
tor with a good combination of characteristics for an audit is the Exradin W1 PSD.
However, as it is not a well-established product yet, if used in an audit its performance
should be assessed against a well-established, well-characterised detector. Radiochromic
film and alanine require significant attention to the methodologies used and the analysis
can be labour intensive. However, there is a large body of evidence which shows that
they are suitable detectors for SRS and for dosimetry audits.
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2.3 Alanine dosimetry
Alanine is one of the most abundant amino acids in the human body used in the
synthesis of proteins. It can also be chemically synthesised and used in radiation
dosimetry as it has favourable properties. When alanine is irradiated, it goes through
a deamination process and forms stable free radicals as by-products [134]. This e↵ect
occurs in both solid and aqueous solutions and has been used for radiotherapy dosimetry
for at least two decades [135]. The NPL alanine service, produces pellets made of 90%
L-↵-alanine and 10% para n wax. They are manufactured in a cylindrical shape with
5 mm diameter and 2.5 mm height. They have a density of 1.2 g/cm3 and weight
approximately 55 mg [113]. They can be used in stacks and placed in a number of
holders for irradiation in plastic or water phantoms. In order to achieve reasonable
signal-to-noise ratios (SNR) the service operates a therapy level threshold of doses
above 10 Gy only. This poses an implication for routine radiotherapy doses that are
normally 2 Gy per fraction. In order to overcome this issue, centres are commonly
asked to deliver multiple fractions in order to scale to higher doses and achieve a high
SNR with lower uncertainty in the measurement. This does not pose an issue for SRS
doses in the target, as prescriptions are usually above 15 Gy, which makes alanine
ideal for this application. However, measurements performed outside the target may
still su↵er from low SNRs. For the purposes of this work, the NPL alanine dosimetry
service produced the uncertainty budget shown in Table 2.1, which also accounts for
doses in the region of 5 Gy.
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Source Standard uncertainty (%)
Type A Type B
Dose delivery during
calibration in 60Co
±0.65
Energy dependence
for MV range
±0.35
Correction for dose
received during
transport
±0.4 at 5 Gy, ±0.2 at 10 Gy
Correction for fading ±0.2
Temperature
dependence
±0.3
Statistical
uncertainty in
calibration line
±0.4 at 5 Gy, ±0.2 at 10 Gy
Pellet-to-pellet
reproducibility
±1.0 at 5 Gy, ±0.5 at 10 Gy
Combined
For 60Co: ±1.9 at 5 Gy, ±1.6 at 10 Gy
For MV X-rays: ±2.0 at 5 Gy, ±1.7 at 10 Gy
Table 2.1: Uncertainty budget calculated for the purposes of this work by the alanine
dosimetry service operated at NPL.
2.3.1 Electron paramagnetic resonance
A signal from irradiated alanine pellets can be acquired using Electron Paramagnetic
Resonance (EPR) spectroscopy. This method uses a magnetic field to detect free elec-
trons within a sample by exciting their electronic spin. The signal from post-irradiation
free radicals in the alanine sample is detected by EPR spectroscopy. The most abun-
dant free radical species produced in alanine after irradiation is CH3-C*H-COOH, which
upon scanning with an EPR spectrometer produces characteristic peaks. The method
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used at NPL for the analysis of the signal is based on a peak-to-peak evaluation method,
which has been proven to be superior to more sophisticated analysis methods [136]. A
pellet-specific calibration function can be developed from pellet measurements in a
60Co irradiator. This function is then used for converting the signal to dose-to-water.
The dose response is linear for low doses and saturates above approximately 100 kGy
where free radicals start to recombine and the pellets also start to su↵er radiation dam-
age. Pellets are typically scanned 48 hours post-irradiation to reduce changes in the
EPR spectra to negligible levels. EPR spectroscopy is a non-destructive technique and
theoretically pellets could be rescanned if necessary.
2.4. Radiochromic film dosimetry 36
2.4 Radiochromic film dosimetry
The term “radiochromic” is reserved for materials that exhibit a change in colour after
exposure to radiation. These materials are passive dosimeters and require a readout
process. Despite that, the e↵ect of energy absorption from radiation is immediate
and therefore additional development processes are not required. Various radiochromic
materials have been investigated over the last three decades for their application in
medical dosimetry [137]. These e↵orts led to the development of a number of com-
mercial radiochromic films that were successfully implemented for QA purposes [138].
Their advantages include water-equivalent density, energy independence over the clin-
ical range of MV beams and high-resolution two-dimensional (2D) spatial information
[139]. The most widely used radiochromic films for radiotherapy dosimetry are com-
mercially available under the name Gafchromic (Ashland ISP, NJ, USA) and the last
two generations were EBT3 and EBT-XD. These films are di↵erent to their predecessor
EBT2 in that they are symmetric when viewed in cross section, which eliminates the
need for a specific orientation in use. Moreover, whilst EBT2 was susceptible to scan-
ning artifacts (Newton’s rings) these have been eliminated with EBT3 and EBT-XD
due to their matte finish [140]. The latest films are comprised of an active layer of
lithium-10,12-pentacosdiynoate (LiPCDA) micro-crystalline monomers laminated be-
tween flexible, clear polyester sheets. When irradiated, these crystal monomers undergo
topochemical photo-polymerisation and form rod-shaped micro-polymers that are vis-
ible and stable on the polyester base [141]. The level of polymerisation increases with
absorbed dose, which also increases colouration of the film. This detection method
enables the measurement of complex and inhomogeneous dose distributions with very
high spatial resolution. Due to many potential sources of uncertainty in film dosime-
try, many studies using radiochromic film only report relative dosimetry measurements
[142–145]. This approach assumes that systematic errors occur throughout the film and
the measured dose planes are used qualitatively. In this approach, another dosimeter
is used to verify the dosimetric accuracy of the delivery. However, many studies have
demonstrated that by using advanced practices, absolute film dosimetry is possible
[118,146,147].
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2.4.1 Triple-channel film dosimetry
It is now common practice to scan films using conventional (high-end) flat-bed docu-
ment scanners to acquire digitised images for calibration and analysis. Various math-
ematical models have been developed in attempts to better explain the relationship
between film colouration and dose [139,143,148–152].
Most well-established methods involve scanning films in Red-Green-Blue (RGB) format
and acquiring 48bit images. Each pixel of the image contains three values, one for each
colour channel. These values are then used to calibrate film response to dose. Many
studies have demonstrated that multi-channel methods are superior to single-channel
methods as they minimise many sources of uncertainty [139, 144, 149–152]. Therefore,
the use of multi-channel methods is recommended and should be utilised where possible.
2.4.2 Scanner-related uncertainties
In order to perform accurate film dosimetry, it is essential to appreciate that the film
only comprises half of the dosimetry system. Many errors can occur if a poor scanning
protocol is adopted. The post-exposure time allowed before scanning films should be
considered carefully. Due to post-irradiation darkening of the film, it is recommended
to wait for up to 48 hours after exposure before scanning it [140, 148]. However, some
methods have been proposed to correct for this e↵ect and allow scanning sooner [153].
A well-known problem with flat-bed scanners is the reduction of light output laterally
to the central axis of the scanner [154]. Two recent studies identified the cause of this
e↵ect and described additional e↵ects that can contribute to errors [155, 156]. Careful
considerations of the scanning resolution, film size (or region of interest), orientation
and position on the scanner can diminish these e↵ects to acceptable levels. The e↵ect
of film curvature on the scanner bed has been shown to contribute to errors of up to 4%
in the dose measured therefore the use of a glass compression plate to keep films flat is
recommended [157]. Other sources of error include scanner warm-up times and dirty
scanner surfaces [148]. Therefore in order to perform accurate film dosimetry special
attention is required for appropriate scanning practices.
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2.5 Plastic scintillator dosimetry
The use of PSDs for radiation dosimetry applications has been investigated for over
two decades [158]. Their characteristics are very appealing for small field dosimetry
due to their near water equivalence (negligible perturbation e↵ects) and high spatial
resolution. Early recommendations for SRS dosimetry recognised the ability of these
detectors in small fields even at a time when the technology was still developing [32].
The basis of their operation lies in the sensitive volume, which is typically an organic
material, doped with scintillating elements. Upon irradiation by a photon beam, scat-
tered electrons interact with the sensitive volume of the detector, depositing energy
which excites the electrons in the scintillator material. These excited orbital electrons
are then returning to ground state emitting a fast component of light (fluorescence) in
the visible spectrum, within a few nanoseconds. There is a slow component of light
emitted, phosphorescence, a process that takes place tenths of milliseconds after irra-
diation [121]. A number of approaches have been used in the detection of light from
PSDs. A common approach couples optical fibres to the sensitive volume, which act as
the light guide from the scintillator to a photo-detector. The photo-detector could be
a photomultiplier tube [159] a photodiode [160] or a Charged-Coupled Device (CCD)
camera [161].
2.5.1 The Cherenkov noise
The instrumentation used for light detection in PSDs su↵ers from Cherenkov radiation
emissions “noise” produced in the optic fibre. The light emitted from the scintillator
travels through the coupled optic fibre significantly slower than light in vacuum (c).
The speed of light in the fibre (v) is governed by the refractive index (n) of the material
as v = c/n. As the refractive index of the fibre material n ⇡ 1.5, v ⇡ 2/3 c. Electrons
travelling through the fibre with an energy above ⇡150 keV, are travelling faster than v.
When these conditions are met in a dielectric medium, Cherenkov radiation is released
by interaction between the charged particle and the medium. Cherenkov light peaks
at a wavelength ( ) near the violet region of the visible spectrum and its intensity in
other regions of the spectrum varies as   3. This light is also transmitted through the
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optical fibre and overlaps with scintillation. The optical fibre also produces delayed
fluorescence (phosphorescence) like the scintillator. The amount of Cherenkov in the
wavelength region of interest is usually relatively low, but can be up to 20% of the signal
if a large amount of fibre is irradiated. Therefore, steps need to be taken to remove
the Cherenkov contributions from the signal in order to perform accurate dosimetry.
Various approaches have been taken in decomposing the signal: the use of another fibre
to measure the Cherenkov noise only [158], the optical filtering method to remove the
majority of Cherenkov from the signal [162, 163], a time-resolved approach to discern
between scintillation and Cherenkov by their time-stamp [164] and the “chromatic
removal” method [165–168]. The fast nanosecond components of the detected signal
are graphically represented in Figure 2.3.
Figure 2.3: The light signal from a plastic scintillation detector.
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2.5.2 The chromatic removal method
The chromatic removal method is the most widely used method for calibrating PSDs.
This is largely attributed to the fact that currently there is only one commercial system
available (Exradin W1, Standard Imaging, Middleton, WI, USA) and the manufacturer
recommends this method for its calibration [169]. The calibration method was formu-
lated and validated by Guillot et al for a PSD system that was very similar to the
Exradin W1 [168]. The basis of this method is that the amount of Cherenkov produced
is proportional to the amount of fibre irradiated. By using dichroic colour filters to split
the spectrum into two wavelength bands, it is then possible to perform simultaneous
measurements in both bands. These two regions of the spectrum (Figure 2.3) are:
1) a region dominated by light from the scintillator
2) a region dominated by Cherenkov and fluorescence produced from the fibre
The detector is then irradiated in two setup conditions where the only parameter
changed is the amount of fibre irradiated. In one setup condition a small amount
of fibre is irradiated (min) and in the other a large amount (max). The two simulta-
neous measurements, in regions 1 and 2, taken in the two setup conditions, max and
min, enable the determination of a correction factor that accounts for the removal of
the Cherenkov component from the total signal. This correction factor is annotated as
the Cherenkov Light Ratio (CLR) and is acquired using equation 2.1.
CLR =
(R1max  R1min)
(R2max  R2min) (2.1)
Where R1 and R2 correspond to readings in regions 1 and 2,
R1max and R2max are measured simultaneously in the max fibre setup condition,
R1min and R2min are measured simultaneously in the min fibre setup condition.
A cross-calibration factor is also required to convert the signal measured to dose to
water. This requires a measurement in reference conditions, with an ionisation chamber
traceable to a primary standard. A measurement with the PSD is then taken in the
same conditions and the “Gain” factor is then defined using Equation 2.2:
Gain =
Doseref
(R1 R2 ⇤ CLR) (2.2)
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Where Doseref is the dose measured by the ionisation chamber in reference conditions.
Following the determination of these two factors, any subsequent measurements can be
used to derive dose using Equation 2.3:
Dose = Gain ⇤ (R1 R2 ⇤ CLR) (2.3)
Note that in Equation 2.2 and 2.3 the product of CLR and R2 is the Cherenkov over-
response. This is then subtracted from the total signal measured in R1, and the result
is the signal from the scintillator only. In this work, the above method was used for
measuring dose with the Exradin W1 PSD.
Chapter 3
Current status of stereotactic
radiosurgery in the United
Kingdom
3.1 Rationale for conducting a survey
The rapid evolution of SRS has been described in Section 1.1. It is a treatment under-
going constant development that is now established as the preferred route for a large
number of indications [170–173]. The UK was one of the early adopters of SRS, as the
first GK unit to be installed in the UK (Weston Park Hospital, She eld) in 1985 was
only the second commercial unit in the world [19]. The first Linac-Based (LB) service
in the UK was initiated in 1989 by St. Bartholomew’s Hospital in London [57] and in
2009 CK radiosurgery was introduced for the first time in the UK by the Harley Street
clinic [174].
As outlined in Section 1.2, there is a variety of SRS practices which makes it di cult
to perform comparisons for assessing the e cacy of this technique, but also causes
confusion in science communications. Recently, there have been e↵orts put into im-
proving standardisation in SRS. The ICRU has proposed a new report on “Prescribing,
Recording, and Reporting Stereotactic Treatments with Small Photon Beams” that is
in preparation [175]. Also, the International Leksell Gamma Knife Society (ILGKS)
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has recently published a report that attempts to standardise the terminology used in
radiosurgery. This report deals with the variations in nomenclature and aims to stan-
dardise them, not only for GK users but across the field, to facilitate collaborations
between radiosurgical technologies [176]. Alongside these international initiatives it is
an appropriate time to facilitate collaborations and communication nationally. More-
over, NHS England recently published a consultation for SRS and stated that due to
the inability to determine whether one type of SRS machine produces better outcomes
there is a need for more robust reviews and technology appraisals on SRS in the UK
[177]. The development of a national audit inclusive of all SRS platforms can contribute
significantly in facilitating collaborations and communication nationally. Furthermore,
it will constitute a robust appraisal to the technologies available for SRS.
The aim of this chapter was to investigate the current status of clinical and dosimetric
practice for SRS. It is planned to employ the results to help develop the methodology
for an SRS audit, an approach which was previously successfully implemented in a
national audit setting [178]. The findings will also provide a useful reference as a basis
for benchmarking and future comparisons, but also in assisting new centres to launch
their SRS programs. Moreover, a better understanding of the current practices would
facilitate better communication in the UK community and support the standardisation
of practices between users of di↵erent equipment. The results may also provide relevant
information for protocol design in clinical trials. The findigs of the survey presented
below were published in the British Journal of Radiology [179].
3.2 SRS Survey - Methods
An online questionnaire (Appendix A) was sent to the Heads of Radiotherapy Physics
at 70 UK radiotherapy centres (63 NHS and 7 private) in June 2014. The survey
defined “cranial radiosurgery” as “a single high dose of photon radiotherapy in a small
volume within the cranium” and requested that participants only submit replies for
intracranial radiosurgery. For respondents who did not have plans to implement SRS
in the near future only a few questions were required to be answered.
The aim was to identify the centres with active SRS programs and those working to-
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wards implementation, in order to account for the logistical implications of undertaking
a national audit. The survey also aimed to obtain details of the current issues and vari-
ations in clinical practices to ensure compatibility of the methods chosen for the audit
with all current practices. The questions were divided into five sections:
1. Generic information and experience
2. Pathologies treated
3. Treatment planning practices
4. QA and verification
5. Immobilisation and imaging
The results reported are presented as fractions/percentages of the centres that re-
sponded to each question due to the fact that some partial replies were submitted.
3.3 SRS Survey - Results
3.3.1 Generic Information, Equipment and Experience
68/70 centres responded by December 2014, six months after the launch of the survey.
21/68 centres were performing SRS clinically, 5/68 were in the process of implementing
and planning to be clinical within one year. 7/68 were planning to implement within
two years and the remaining 35/68 centres did not have active programs nor did they
plan to have one in the next two years. Centres were also asked for how long they
have been delivering SRS: 13/21 indicated that they have been clinical for more than
5 years, 4/21 for 3-5 years, 3/21 for 1-3 years and 1/21 began treating in the last year.
Figure 3.1 shows the diversity and numbers of vendors used in the 21 centres that were
treating with SRS in the UK at the end of the survey.
According to the responses, there are 31 radiotherapy treatment machines in total used
clinically for SRS in the UK: 16/31 are linacs, 6/31 are CKs, 7/31 are GKs and 2/31
are TomoTherapy (TT).
2/21 centres (both GK) indicated that they have treated over 1000 cases, 5/21 (2 GK,
2 LB and 1 CK) had treated 500-1000 cases, 10/21 (2 GK, 5 LB and 3 CK) had treated
100-500 with the remaining 4/21 (2 CK, 1 LB and 1 TT) having treated less than 100
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Figure 3.1: The number of SRS centres in the UK using equipment from each manu-
facturer indicated.
cases. GK centres have the highest patient throughput per month followed by LB and
CK centres as shown on Figure 3.2.
The centres were asked if they wished to expand their current SRS programs; this
expansion was di↵erentiated between increasing the indications which they already
treat (60% of centres said “Yes”) and the numbers of cases per week (75% of centres
said “Yes”). 40% of centres wanted to expand on both areas and 5% had no expansion
plans. 11/21 centres did not limit the number of cases treated with the remaining 10
limiting them. The reasons indicated as the limiting factors for limiting/not expanding
SRS programs were: resources for delivery (5/10), planning resources (4/10), contouring
resources (3/10) and NHS funding (2/10).
All GK centres (6/21) use the GK Perfexion beam array as a collimation system and
4/6 CK centres use circular collimators whereas the remaining 2/6 CK use both circular
collimators and the CK IRIS system. 6 LB and 1 TT centre use only MLCs (7/21), 1
LB centre uses only circular collimators (1/21) and 1 LB centre uses both (1/21). The
majority of the centres that use MLCs adopt micro-MLCs (2.5 mm) although there are
two centres that use wider MLCs (5 mm and 6.25 mm ). The CK and LB centres that
use more than one collimation systems stated that the collimation system of choice is
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Figure 3.2: The average number of patients treated with SRS per month in the UK
grouped under three frequencies. The equipment used in each group is also indicated
on the chart.
dependent on the pathology, its size, its location and its proximity to organs at risk
(OARs).
The nominal photon energies used for SRS delivery are 60Co ( 1.25 MeV) used by the
6 GK centres, 6 MV used by 14/21 centres and 10 MV used by 1 centre. Of the 8 LB
centres, 1/8 indicated that they use FFF mode (10MV FFF). 3/8 said that they do not
use FFF but they plan to within two years whilst 4/8 stated that they have no plans
to use FFF within the next two years. GK, CK and TT do not use flattening filters by
default. The most common delivery technique is the use of non-coplanar static fields
(89% of respondents use it), however modulated fields or arcs with MLCs or cones are
also being used, but less often (5-21% of respondents).
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3.3.2 Pathologies
The majority of centres are treating solitary and multiple brain metastases but many
other sites are also being treated. The centres were asked to state the number of
patients treated for each indication per month. They were also asked about their
expansion plans in terms of numbers of patients treated and indications treated. It is
anticipated that there will be an increase for both as shown in Figure 3.3 and Table 3.1.
Figure 3.3: The number of centres treating the indicated pathologies and expected
increase by the end of 2016.
There are di↵erences in the indications treated between equipment groups. GK centres
treat the largest variety of clinical indications (mean: 9.2, range: 6-13), followed by
CK (mean: 6.5, range: 2-10) and LB (mean: 4.9, range: 1-10). LB is mostly focused
on brain metastatic diseases, acoustic neuromas and arteriovenous malformations. The
number of indications treated was also found to increase with the experience of the
centre, as more experienced centres treat more indications than less experienced centres.
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Indications
Not
within 2
years (%)
Start
within 2
years (%)
Currently
4/month
(%)
Currently
5-8/month
(%)
Currently
 9/month
(%)
Solitary
brain metastasis
4.8 - 57.1 33.3 4.8
Multiple
brain metastases
4.8 4.8 61.9 28.6 -
Acoustic
neuromas
23.8 4.8 52.4 9.5 9.5
Meningiomas 28.6 - 61.9 4.8 4.8
Pituitary
adenomas
28.6 4.8 66.7 - -
Arteriovenous
malformations
33.3 14.3 47.6 - -
Trigeminal
Neuralgia
57.1 - 38.1 4.8 -
Primary
CNS tumours
52.4 4.8 42.9 - -
Glomus
jugulare tumours
52.4 9.5 42.9 - -
Cranio-
pharyngiomas
52.4 9.5 38.1 - -
Table 3.1: The percentage of centres that treat the indicated anatomical sites. The
results are categorised in three frequency groups. The percentage of centres that are
and are not planning to to treat within the next 2 years are also presented. The
indications have been sorted with the most common indications at the top and least
common indications at the top and least common indications at the bottom.
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3.3.3 Treatment Planning Practices
Participants were asked to state the imaging modalities they use for SRS target and
OAR visualisation and outlining. Multiple answers were allowed as centres often decide
to use a di↵erent modality depending on the availability of modalities, the equipment
used and the pathology to be treated. The results show that there is a wide range of
imaging-modalities used with fused CT-MR being the most common (Figure 3.4).
Figure 3.4: The percentage of centres using the indicated imaging modalities for SRS
target and OAR definition (multiple answers were allowed)
The structures outlined are dependent on the location of the target volume as only
proximal OARs are usually delineated. The target volume is delineated by all centres
at all times. The respondents indicated the following structures as those that are most
often delineated: optic chiasm (90%), optic nerves (90%), brainstem (86%), eyes (76%),
lenses (71%), cochlea (24%), trigeminal nerve (19%), whole brain (14%), hippocampus
(10%), lacrimal gland (5%), pituitary (5%), scalp (5%) and temporal lobe (5%). One
centre reported that OAR contouring is only performed retrospectively to the plan and
is dependent on the clinician’s judgement which OARs are to be contoured after review-
ing the dose distribution. Figure 3.5 shows the range of TPSs used. 6/21 respondents
reported that they may not use their TPS for delineation and use di↵erent software
instead.
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Figure 3.5: The percentage of centres using each Treatment Planning System and
Algorithms (multiple answers were allowed).
All GK centres use an MRI data set in the TPS for defining the target and OARs as
well as the stereotactic space and were using a tissue maximum ratio (TMR) algorithm,
which assumes that everything inside the patient has water density, in order to calculate
dose distributions. 2 GK centres indicated that they may use CT for certain pathologies
or when the MR distortion is significant. The remaining centres use a CT data set for
dose calculation.
GK and CK centres only use non-coplanar static fields and the TT centre only uses
coplanar IMRT. There is a variety of techniques used in the 8 linac centres but 7 centres
employ non-coplanar techniques only and one centre may also use coplanar techniques.
The most common techniques used by linac centres are non-coplanar static fields (5/8)
and non-coplanar dynamic conformal arcs (4/8). 2 centres use non-coplanar circular
collimator arcs and only one centre uses VMAT.
The centres were asked to indicate the most commonly used prescription isodose (Fig-
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ure 3.6). The reported values range from 45-50% to 95-100% indicating that there are
di↵erent prescription practices employed by each equipment group. GKs prescribe in
the range of 45-55%, CKs within 55-80% and LB with TT within 80-100%.
Figure 3.6: The most common prescription isodoses used in each centre.
3.3.4 Quality assurance and verification
Participants were asked to state the quantity of patient-specific QA (plan dose verifica-
tion) performed. 6/21 reported that they do not perform such measurements routinely
(5 GK, 1 CK) and 7/21 perform measurements on every plan (3 LB, 3 CK and 1 TT).
4/21 perform QA measurements for new techniques/sites only (2 LB and 2 CK) and
3/21 perform it as part of a regular QA program (2 LB and 1 GK). 1 LB centre per-
forms QA for less than 10% of all plans. For the centres that had reduced the amount
of patient-specific QA measurements made, 87.5% stated that they reduced it after
10-25 plans. 70% these of centres reduced the amount of patient-specific QA following
an experience-based decision and the remaining stated that main reason for reducing
them was insu cient time (15%) and the lack of a suitable phantom/detector (15%).
There is a large range of phantoms and detectors used for QA measurements. These
are illustrated in Figure 3.7.
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Figure 3.7: Phantoms(a) and detectors(b) used for Quality Assurance measurements.
The majority of respondents (13/18) reported that they measure both point doses and
dose distributions (4 CK, 5 LB, 3 GK and 1 TT). 4/18 stated that they only measure
point doses (2 LB and 2 CK) and one centre only dose distributions (1 LB).
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3.3.5 Immobilisation and Imaging
The majority of centres (12/21) use thermoplastic masks for the immobilisation of
patients (6 LB and 6 CK). All GKs always use invasive fixed frames (Leksell) to im-
mobilise the patient and 2 LB may use masks or frames depending on the indication
treated (one centre stated that frames are always used for AVMs).
Due to the GK Perfexion design, the centres that have this system do not perform any
imaging guidance for localisation before or during treatment. The 6 CK centres perform
orthogonal kV X-rays before and throughout the treatment. The TT centre performs
a pre-treatment MV CT scan and no further imaging during treatment. Between LB
practitioners, 3/8 centres acquire a CBCT scan before treatment and do not perform
any other imaging during treatment. 4/8 centres, all of which use the Novalis Exac-
Trac system, start by taking a set of orthogonal kV X-rays to ensure precise patient
positioning and repeat these images after each couch movement and before each beam
delivery. Only one LB centre does not perform any image guidance before or during
treatment but it was reported that they are intending to use CBCT in the near future.
Figure 3.8 shows the action level below which setup accuracy is considered acceptable
by each centre.
Figure 3.8: The reported values of setup accuracy below which treatment is considered
acceptable. The di↵erent equipment groups are indicated.
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3.4 SRS Survey - Discussion
3.4.1 Generic Information, Equipment and Experience
The use of SRS has been steadily increasing since its introduction in the UK in 1985.
By 2009, at least 13 centres were active and in the last five years the number has
increased to 21. The results also suggest that this growth will continue as almost half
the UK’s centres stated that they were planning to o↵er cranial radiosurgery services
by the end of 2016. The rapid increase over the last few years is mostly attributed to
CK and LB radiosurgery, as well as the growing interest in hypofractionated treatment
schemes. The survey responses suggest that this expansion will continue to occur both
for the pathologies treated and the number of cases per month. In order to support
this development and maintain high quality in clinical delivery, a national audit for
SRS services is essential.
Since GK units are dedicated to cranial radiosurgery it is not surprising that the results
showed them having higher patient throughput. The disadvantage in having a versatile
SRS unit that can be used for other techniques is that it is unable to match a dedicated
unit in the number of cases treated per month. This is also reflected in the responses
from the 5 centres who limit the numbers of patients they treat due to resources for
SRS delivery who are all LB.
The only LB centre that currently uses an FFF beam is also the only centre that uses 10
MV. This is perhaps less striking when considering the fact that an FFF beam is softer
(has a lower average energy) than a filtered beam of the same nominal energy. As more
LB centres switch to FFF beams (4 centres are intending to do so), in order to benefit
from faster delivery times, it will be interesting to see if 10 MV beams are adopted
by more of these centres. The results indicate that the advent of FFF beam delivery
is slowly becoming prominent in the clinic. It is therefore essential that rigorous QA
monitors and tests the systems in place. A national radiosurgery audit can contribute
significantly in ensuring that FFF dosimetry is accurate, at least in the centres that
use such beams for SRS.
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3.4.2 Pathologies
The results suggest that the most commonly treated pathologies are brain metastases
and acoustic neuromas, with a single brain metastasis being the most common. The
treatment of these pathologies is likely to increase, as new centres launching their pro-
grams in the near future will probably take on these indications first. A realistic and
patient-like audit scenario that allows for all centres to participate should therefore
be based on single brain metastasis. This way, even centres that have not yet started
performing SRS clinically can participate in the audit to practise on a plausible clinical
case and have their SRS pathway assessed in an end-to-end test. Simple geometric
phantoms are considered inadequate for performing end-to-end audits as they are not
representative of patient-like conditions [97]. Considering the above, an anthropomor-
phic head phantom should be adopted for the purposes of an audit, with a solitary
brain metastasis as a target.
As shown in Section 3.3.2, there is a general intention by centres to increase the number
of pathologies treated and the number of patients treated for each pathology. This
highlights further the importance of an SRS audit, as this is additional evidence of the
growth of SRS and the potential for detriment if rigorous QA is not undertaken.
3.4.3 Treatment Planning
The majority of centres use fused CT and MRI for the purposes of contouring and
planning, except GK centres that tend to use MRI only. It would be beneficial to
incorporate both CT and MR in an end-to-end audit as any errors that may occur in
image fusion can be factored in to the final results. However, the limited visibility of
phantoms on MR-scans and the restricted availability of MR-scanning time in most
NHS hospitals may prove to be impractical for an end-to-end audit, in which case a
CT only methodology may need to be adopted even for GK centres.
A number of studies have looked at the inter-observer variations in target contouring
on patient cases and reported large disagreements in the contoured volumes [180,181].
It is widely accepted that delineation may be the weakest link in radiotherapy and
radiosurgery practices due to these large variations. The survey results indicate that
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there is a multitude of contouring practices currently in place for SRS. This may cause
some smaller but significant variations in volume size that are inherent to the scan slice
thickness, voxel size and delineation software used. The collection of audit plans will
allow for these variations to be quantified.
As shown in Figure 3.5 there are at least 9 di↵erent combinations of planning systems
and calculation algorithms used for SRS. Some of these perform heterogeneity correc-
tions whereas others do not, and some perform convolution, pencil beam or Monte
Carlo (MC) type calculations to predict dose distributions. A dosimetric comparison
between measured doses and expected doses can provide valuable information as to
which algorithms perform better in SRS. The use of a head phantom with tissue-like
electron densities and e↵ective atomic numbers is crucial in revealing any di↵erences
between calculation algorithms that may be clinically significant.
The survey responses show a large number of techniques used for SRS with non-coplanar
static fields and non-coplanar arcs (including dynamic conformal arcs, VMAT and
circular collimator arcs) to be the most common. A few centres reported the use of
coplanar VMAT and IMRT. It would be of interest and clinical benefit to establish
whether certain techniques produce superior results in a dosimetry comparison. The
survey findings could be indicative that some techniques, such as coplanar IMRT or
coplanar VMAT, are less common because they produce inferior plans. A retrospective
analysis of the plans produced during the audit may provide valuable evidence for
recommendations to the use of only certain techniques for SRS. This will create a more
cohesive approach to SRS but will also prevent upcoming centres from undertaking
timely investigations in assessing the suitability of a range of techniques.
Figure 3.6 illustrates that the most commonly used prescription isodoses di↵er between
equipment groups. The survey replies have not been reported with a percentage of tar-
get coverage. Also, the centres were not asked to indicate whether any target margins
are being used in these prescriptions. If target coverage and margins are taken into
account this distribution may change as these parameters influence the prescription
isodose. The variation presented is a demonstration of the di↵erences in prescription
practices. In addition to this, it should be mentioned that the level of dose homo-
geneity in the target volume is also variable. Typically, LB radiosurgery adheres to
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ICRU practices and aims for more homogeneous dose distributions within the target
volume. On the other hand, some dose inhomogeneity in the target volume is accept-
able for CK users and it is actively sought in GK radiosurgery. The large variation
in prescription practices requires discussion and perhaps indicates that it will benefit
from regulation/standardisation. The proposed end-to-end audit will present the same
patient-like scenario to all centres, which will retrospectively invite the opportunity for
the variations in prescription practices to be studied. The survey findings are support-
ive of the argument hypothesised in Section 1.3.2 that performing an audit with dose
constrains would be inappropriate and a more flexible approach should be preferred.
3.4.4 Quality assurance and verification
The number of patient-specific QA measurements performed by each centre suggests
that some centres have more confidence in their method of treatment delivery than
others. The predominant reason for reducing the amount of QA was an experience
based decision and the reduction was mostly introduced after 10-25 treatment plans.
Interestingly, some experienced centres continue to perform QA on every plan whereas
some less experienced centres have reduced their QA. Also, the majority of GK centres
do not perform measurements routinely, which indicates higher confidence, possibly
due to the simpler design of the system with fewer moving parts and the well-known
activity related output of the sources.
The detectors and phantoms in use are diverse with the exception of GK users who
follow similar practices. Solid water blocks are used by the majority of centres and
ionisation chambers are the most commonly used detectors despite their limitations in
small field dosimetry capabilities discussed previously (Section 2.2). Some evidence of
recognition that these limitations exist is seen as some centres are using other detectors
such as Gafchromic film, diodes, diamond and thermoluminescence detectors in their
practices. Additional comments provided with the survey submission as well as personal
communications with SRS practitioners, stressed the need for the verification of multi-
dimensional dose distributions as opposed to point doses. Modern TPSs allow for
heavily modulated and highly conformal plans to be simulated on the computer screen
at the expense of time and resources. Even though plans of high complexity are often
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verified during local QA measurements, there is still lack of confidence in the results
as 2D or 3D dosimeters are not always available in the clinic. It is therefore suggested
that the audit methodology introduces a target of irregular shape in close proximity to
OARs in an attempt to produce a challenging but realistic case. This, in combination
with suitable 2D/3D dosimeters can provide valuable findings for SRS centres.
3.4.5 Immobilisation and imaging
The results illustrate the wide range of immobilisation devices and image guidance
protocols used by the SRS community. It is essential that the audit methodology is
compatible with all immobilisation devices used. It should also allow validation of the
accuracy of all image guidance systems in place. This re-enforces the significance of an
anthropomorphic phantom with realistic tissue densities as it will provide the closest
representation possible to patient-like conditions.
As a result of the di↵erent immobilisation and imaging systems in place, a range of
acceptable set-up accuracy levels are in use, as shown in Figure 3.8. LB and TT centres
assess acceptable positional accuracies via the integrated imaging systems but this is
not possible for GK centres due to the lack of an imaging system. The answers reported
by GK centres on their acceptable positional accuracy are reflections of the accuracy
believed to be achievable by their units based on their QA measurements and empirical
knowledge. This raises concerns regarding the accuracy of delivery due to the lack of on-
board imaging for positional verification and the reduced levels of routine QA discussed
in Section 3.4.4. Arguably, the use of a fixed frame in GK SRS eliminates the need for
imaging verification, but it is essential to test this in an independent audit. CK centres
are also able to assess the setup accuracy via the integrated imaging system; however,
there was no consensus on the reported setup accuracy levels. It should be noted that 4
out of 6 CK centres submitted their replies to this question with additional commentary
that allows some insights into the reasons behind the large spread of the levels reported.
These 4 submissions commented on the nature of the CK system that automatically
repositions the patient after each pair of kV images is acquired. The machine therefore
“corrects” misalignments above an action level set by the user. However, there are
still some inherent positioning errors that need to be taken into account which can be
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assessed in the audit.
LB centres generally agree and report a level of 1 mm with the exception of one centre,
reporting a level of 2 mm. Responses from GK users range between 0.2 – 1 mm. The
largest range is seen in CK responses which vary from 0.1 mm to 1.5 mm. The spread
of the reported acceptable setup accuracies also indicates benefit from standardisation.
With only two centres reporting a setup accuracy above 1 mm, this suggests that a
reasonable national level for SRS setup accuracy would be less than 1 mm. Quantitative
evidence to support this proposal for standardisation can be acquired in the national
SRS audit.
3.5 SRS Survey - Conclusions
SRS in the UK has undergone a rapid increase since its introduction in 1985. This
is particularly the case with LB radiosurgery which is now overtaking GK and CK
in terms of number of units and patients treated. This increasing trend will probably
continue in the coming years, not only for the number of centres delivering SRS but also
the number of patients treated and the range of pathologies treated. There is variation
in the practices followed between di↵erent centres for most aspects of radiosurgery. It is
proposed that a national end-to-end audit, compatible with all practices, is conducted to
evaluate the dosimetric and geometric accuracy of SRS in the UK. Such an audit should
adopt an anthropomorphic phantom with realistic tissue densities and capabilities for
multi-dimensional dose verification. The target should be modelled on a single brain
metastasis of irregular shape which is in close proximity to an OAR.
Chapter 4
Characterisation of a new
commercial radiochromic film
4.1 Gafchromic EBT-XD film
EBT-XD became commercially available to the UK in the Spring of 2015. This film
has a slightly di↵erent structure to its well-established predecessor EBT3. Both films
are composed of two identical polyester surfaces that are 125 µm thick, with a density
of 1.35 g/cm3. In their sensitive layers, between the two polyester sheets, they have
di↵erent atomic compositions with the new film featuring the addition of 4 new elements
and higher density. Figure 4.1 illustrates a schematic representation of the two films
showing their atomic compositions and densities. EBT-XD (XD stands for eXtended
Dose) was marketed as the film of choice for high-dose radiotherapy applications, such
as SRS and SABR. Whereas EBT3’s optimum dose range is 0.1 Gy - 10 Gy, according
to the manufacturer EBT-XD can measure doses up to 100 Gy. The size of LiPCDA
crystals in the active layer has also been changed. These crystals are needle-shaped
particles, which in EBT3 measure 15 µm - 20 µm in length and 1 µm - 2 µm in
diameter. In EBT-XD they have the same diameter but are a lot shorter in length,
measuring 2 µm - 4 µm [182]. This is a substantial change in aspect ratio, going
from approximately 10:1 to 2:1. The re-sized crystals are expected to improve the
homogeneity of the active layer distribution, as preferential alignment will be decreased
and the particles will be more prone to random Brownian movement before lamination
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Figure 4.1: Structural comparison between EBT3 and EBT-XD.
[182]. As a result, film thickness is expected to show improved uniformity and therefore
improved response to dose. Moreover, scanning orientation e↵ects are expected to be
minimised. It is also speculated that the lateral scanner response artifact will be less
pronounced on EBT-XD due to reduced polarisation. This film therefore is a very
appealing dosimeter for use in high dose applications, like SRS. The higher dose range,
near water-equivalent structure and ability to perform high-resolution measurements,
with potentially improved response to EBT3 are favourable characteristics.
The purpose of this chapter was to evaluate EBT-XD by comparison to EBT3 and assess
its performance in SRS dose verification. Another objective was the development of a
suitable film dosimetry protocol for the purposes of an SRS audit. The work in this
chapter was partly published in the Journal of Physics and Medicine in Biology [183].1
1Initial investigations described in Section 4.2 were carried out in collaboration with Antony Palmer
at Queen Alexandra Hospital, Portsmouth. Subsequent investigations (Section 4.5) were performed at
NPL.
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4.2 Initial characterisation of EBT-XD - Methods
4.2.1 Film structure
The information on the atomic composition of the films shown in Figure 4.1 was col-
lected via communication with the manufacturer. E↵ective atomic numbers (Zeff) for
the two films were calculated using a power-law method which uses the atomic number
of each element in the compound and the proportion of electrons associated with it
[184]. Although, it is acknowledged that this method is simplistic, it was considered
suitable for comparison of the two dosimeters and for comparing them to water.
4.2.2 Calibration
All measurements were performed with EBT-XD batch no.0108501 and EBT3 batch
no.12171303. Ten pieces of film from each batch were used for calibration purposes.
Each film was placed in a WT1 phantom at 95 cm SSD, 5 cm deep and irradiated in a
10 cm2 field with a 6 MV linac beam. The range of doses used for irradiation were from
0 Gy - 40 Gy and the absolute dose was measured using an ionisation chamber with a
traceable calibration to NPL. The recommendations of AAPM TG-55 for film handling
were followed [138]: latex gloves were worn, films were always kept at a clean and
controlled with minimum exposure to ambient light. The scanning methods adopted,
were previously evaluated and implemented for brachytherapy dosimetry audit [152].
Films were scanned in consistent orientation, 48 hours after exposure on an Epson
Expression 11000XL flat-bed scanner. The scanning resolution used was 72 dots-per-
inch (dpi) and a 3 mm thick piece of glass was used to press film flat on the scanner.
The scanner was switched on for several minutes and a number of warm-up scans were
performed before any film was scanned. The digitised film images were acquired in
RGB 48bit TIFF format (16bit per colour channel) using transmission mode without
colour or sharpness corrections. The software package FilmQAPro version 5 (Ashland
ISP Advanced Materials, NJ, USA) was used for generating calibrations curves. This
was done for both films using a conventional single (red) channel method and also using
the red channel with triple-channel correction (TCC) [149].
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4.2.3 Lateral scanner response artifact
The Lateral Scanner Response Artifact (LSRA) is attributed to a number of e↵ects,
but the dominating source is the scanner light polarisation as it passes through the film
[156]. This results to a non-uniform lateral (perpendicular) response to the direction of
the scan. In order to avoid or minimise errors caused by this e↵ect, films must be placed
on the central axis of the scanner. This e↵ect is also known to vary with dose and to be
di↵erent for each colour channel. Depending on the methods used, large errors could be
caused even for small pieces of films that do not extend very far from the central axis
of the scanner [185]. To evaluate the LSRA, four strips of film were exposed to doses
of 0 Gy, 13 Gy, 20 Gy and 40 Gy. Each strip was then cut into three pieces to create
identical samples. One piece was placed on the central axis of the scanner while the
other two identical pieces were placed 3 cm laterally to the central piece. Eight scans
were acquired with the o↵-axis films moved successively further away from the central
axis until they reached the boundaries of the scanner at 15 cm o↵-axis. The artifact is
quantified in the ratio of the pixel values between the o↵-axis and on-axis films. This
was calculated for all colour channels.
4.2.4 Dose verification for SRS
In order to compare the two types of film in SRS-type measurements, with minimum
influence from other factors, a simple 30 cm cubical WT1 phantom was used for this
test. 6 cm x 9 cm pieces from each film (test films) were placed in the frontal plane of the
phantom at 5 cm deep. The phantom was CT-scanned using 1 mm slice thickness and
the images were imported in the Eclipse TPS version 13 (Varian, Palo Alto, CA, USA).
A single-arc VMAT plan for a 2.5 cm diameter spherical target was re-calculated on the
phantom using the anisotropic analytical algorithm (AAA). The plan was positioned
so that the test film bisected the sphere of the high-dose region. Output measurements
were performed before and after the film measurements to account for any variations
in the delivery. The plan was delivered three times for each film and a 1 mm resolution
coronal plane was exported from the TPS for comparison. Film scanning and analysis
were performed following the methods described in Section 4.2.2. The film dose-linear
scaling method [153] was used to recalibrate the film. This method requires two pieces of
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film, one un-irradiated and one irradiated at a known dose, to be scanned together with
the test film. The two reference films act as a additional calibration and are used to re-
scale the test film response map to mitigate any variations caused by post-irradiation
darkening and/or scanner light-source variations. For the purposes of this test, the
reference films used had doses of 0 Gy and 20 Gy (prescription isodose). Test-films
were auto-aligned with the TPS dose map in FilmQAPro to eliminate any positional
errors that may have occurred. Gamma analysis [186] was used to evaluate the level
of agreement between the two dose distributions. This method is used for comparing
two dose distributions and quantifying the percentage of pixels in agreement within
predefined criteria for distance-to-agreement (DTA) and dose di↵erence (DD). Such
tests can be performed to compare pixels to the local value (local gamma) or to a
normalisation value (global gamma), which is typically the maximum dose.
4.3 Initial characterisation of EBT-XD - Results and Dis-
cussion
4.3.1 Film structure
In examining the structure of the films, it was noted that the smaller EBT-XD sam-
ples had a substantially larger natural curl than EBT3 samples. This emphasised the
importance of using a glass plate during scanning. The e↵ective atomic number of the
sensitive layers of the two films are 7.26 for EBT3 and 7.37 for EBT-XD. These are
both comparable to the e↵ective atomic number of water. The two films are almost
identical in structure as they both measure approximately 275 µm, and the bulk of
them is composed of the same polyester sheets. Small di↵erences are seen in the ef-
fective atomic number of their sensitive layers, and therefore both films are considered
water-equivalent the MV energy range clinically used for SRS. These findings are sup-
ported by experimental evidence from Grams et al who showed that measurements at
the same dose levels with 6 MV and 18 MV gave the same values of OD [185].
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4.3.2 Calibration
As expected, EBT3 was darker than EBT-XD at all dose levels. This is translated
to lower pixel values on all colour channels of the calibration curve. Figure 4.2 shows
the calibration curves for the three colour channels of each film over the dose range
of 0 Gy - 40 Gy. The curves have similar appearances but they are o↵set in the y-
axis (pixel value). EBT3 has a steeper gradient on all three colour channel curves for
doses approximately up to 10 Gy. Above 10 Gy, EBT-XD curves have steeper gradients
whereas EBT3 curves become almost flat as the film response comes close to saturation.
EBT-XD colour channels appear to have not reached plateaux regions at 40 Gy, the
end of the dose range investigated. SRS prescription isodoses tend to be above 15 Gy.
Hence, for the doses of interest in SRS dosimetry EBT-XD is expected to be superior.
Figure 4.2: Calibration curves for EBT3 and EBT-XD.
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The model used in FilmQAPro for fitting calibration curves is based on the rational
function shown in Equation 4.1 [149].
R(D) =
a+ bD
c+D
(4.1)
Where R(D) is the scanner response, in the range of 0 to 1, at dose D,
and a, b and c are the constant equation parameters that are fitted.
Rational functions, like the one in Equation 4.1, are considered to be better represen-
tations of film-dose response. This is due to Optical Density (OD) not showing a linear
relationship with dose and therefore showing no benefit in converting transmittance
to OD [187]. On the other hand, a corrected transmittance value, using a rational
function, shows a linear relationship with dose [188]. A uniformity correction is also
used in FilmQAPro based on the paper by Micke et al [149]. This method is capa-
ble of separating dose-dependent and dose-independent parts of the signal using the
values acquired from the three colour channels. This way any perturbations, such as
film thickness variations or noise, can be reduced. The method is more e↵ective when
the slopes of each colour channel are su ciently di↵erent to each other. The steeper
gradients seen by EBT-XD in this high dose range, are therefore essential in better
measurement accuracy. It also benefits from larger di↵erentials between colour chan-
nel values to determine the correction. The triple-channel uniformity correction can
be applied on any colour channel but the red channel is most commonly used. Since
EBT-XD colour channels show bigger separations, it is expected that the uncertainty
of the measurement will be lower than that of EBT3.
4.3.3 Lateral scanner response artifact
The LSRA of an Epson Expression 11000XL scanner was evaluated for both films, in
all three colour channels and at di↵erent dose levels. The relative change in pixel value
for di↵erent o↵-axis displacements is shown in Figure 4.3. An additional dose level of
13 Gy was chosen for the evaluation of EBT3, as it had the same optical density with
EBT-XD at the 40 Gy level.
As shown in Figure 4.3, the artifact is more pronounced at higher dose levels. It is
expressed as a decrease in the pixel value and therefore an increase in the reported
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dose. At the extreme case where a 40 Gy film was placed 15 cm o↵ axis, the pixel
value was decreased by 35% for EBT3 and 16% for EBT-XD. The results highlight
the importance of film position on the scanner bed and are indicative of the error
contributed depending on the o↵-axis extend of the film used. If for example, a 6
cm wide film is irradiated at 40 Gy, the LSRA would be up to 0.5% for EBT-XD.
In comparison, this is four times larger for EBT3 reaching up to 2%. The LSRA is
generally smaller for EBT-XD due to lower optical densities in comparison to EBT3.
However, the e↵ect is still smaller for the 40 Gy EBT-XD film when compared to the
13 Gy EBT3 that has the same optical density. This must be related to the re-sized
crystals in the sensitive layer of EBT-XD [155]. The findings of this section are in
agreement with other published studies [182,185,189].
Figure 4.3: Lateral scanner response artifact for EBT3 and EBT-XD.
4.3.4 Dose verification for SRS
The average output of the linac, evaluated by two sets of ionisation chamber measure-
ments in reference conditions, before and after film measurements, was 0.997 cGy/MU.
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This suggested a deviation of only 0.3% from TPS reference conditions and therefore
no corrections were applied.
The film sizes used were small enough to assume negligible errors from the LSRA
considering the findings of Section 4.3.3. The maximum o↵-axis displacement of the
6 cm wide film was 3 cm, where the edges of the film were exposed to dose levels well
below 20 Gy. Therefore, the measurement uncertainty attributed to the LSRA was
estimated to be up to 0.2%.
Three independent measurements were performed with each type of film in an SRS
dose distribution. Each set of three films was assessed to evaluate the repeatability of
the measurement. Both types of film showed a high degree of repeatability. All isodose
levels between 2 Gy and 24 Gy were found to be repeatable within 1 mm distance. This
value is indicative of the reproducibility of film measurements performed in this work, as
they were carried out under controlled conditions with little impact from other sources
of uncertainty. These sub-millimetre di↵erences seen were therefore accounted in the
uncertainty budget. Figure 4.4 shows the three repeated measurements performed with
EBT-XD film, overlayed with the TPS-calculated isodose map.
Figure 4.4: Repeated measurements with EBT-XD film in SRS-type dose distributions.
(Thin lines are film-measured isodoses, thick lines are TPS-calculated isodoses).
When triple-channel corrected EBT-XD films were compared to the TPS-calculated
isodoses, they agreed within 2 mm in the range of 5 Gy - 15 Gy and 1.5 mm in the
range between 15 Gy - 22 Gy. In comparison, triple-channel corrected EBT3 was
inferior as agreements were found to be within 2 mm and 6 mm respectively for the
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Film type and method
Local Gamma (%) Global Gamma (%)
3%
2 mm
3%
1.5 mm
2%
1 mm
3%
2 mm
3%
1.5 mm
2%
1 mm
EBT-XD, triple-channel 98.5 97.0 78.0 100 99.8 95.5
EBT-XD, single channel 94.9 91.3 63.4 99.6 98.2 89.7
EBT3, triple channel 55.6 45.0 30.4 71.0 63.7 38.9
EBT3, single channel 94.2 90.5 59.9 98.0 96.9 89.1
Table 4.1: Gamma analysis passing rates for EBT3 and EBT-XD in an SRS dose
verification test.
two ranges.
The agreement between films and TPS was also evaluated using gamma analysis for a
number of criteria. Both local gamma (normalised to the local pixel dose) and global
gamma (normalised to the film pixel with the maximum dose) criteria were tested.
For local gamma (LG) criteria, a 20% threshold was applied. The di↵erence in passing
rates was also investigated between single (red channel) and red channel with TCC. The
results from this analysis are shown in Table 4.1. For all criteria investigated, EBT-XD
using triple-channel correction had the highest gamma passing rates. EBT-XD film at
3% DD and 1.5 mm DTA global gamma (GG) had an average passing rate of 99.8%,
and for the same criterion but LG the average passing rate was 97.0%. Single-channel
corrected EBT-XD film also showed high passing rates but these were, on average, 5.3%
lower than triple-channel passing rates. Higher percentage passing rate losses, when
switching from triple to single correction, were seen for the strictest criteria used.
EBT3 unexpectedly showed higher passing rates with single rather than with TCC.
The lower passing rates seen with TCC may be caused by the lack of separation in
calibration curves at high doses, increasing the uncertainty of the corrections applied.
Single-channel EBT3 improved passing rates by an average of 37.3%. Despite this
improvement, when comparing the highest EBT3 (single) passing rates to the highest
EBT-XD (triple) passing rates, EBT-XD rates were (consistently) higher by an average
of 6.7%. At the most challenging criteria, significantly better agreement was seen with
EBT-XD reaching up to 18.1% passing rate increase. The improved agreement with the
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TPS shown by EBT-XD and the high degree of repeatability shown are complimentary
to the characteristics of this dosimeter and supportive of its use for SRS audit.
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4.4 Initial characterisation of EBT-XD film - Conclusions
Initial characterisations demonstrated the di↵erences between the two films in terms of
their structure, water equivalence and response to dose. Both films are considered to be
water-equivalent and structurally very similar. The extended dose range and improved
response shown by EBT-XD at high doses are valuable features for SRS dosimetry,
where the maximum doses measured can be up to 40 Gy.
The susceptibility of both films to the lateral artifact of a Epson Expression 11000XL
scanner has been quantified. This was assessed for all colour channels and di↵erent
dose levels. Based on these findings, a suitable scanning protocol can be adopted to
minimise any perturbations to the measurement caused by the scanner.
The findings demonstrated the feasibility of achieving good agreement between film
dosimeters and TPS, for a complex SRS dose distribution in a simple geometric phan-
tom. High levels of repeatability were seen for both films. EBT-XD showed better
agreement with the TPS, whilst allowing for TCC to be applied, whereas TCC was not
e↵ective for EBT3, but single-channel EBT3 measurements yielded high passing rates.
There are however many advantages in applying TCC, mainly in compensating for
film thickness variations, scanner noise and inter-scanning variations and resilience to
contamination.Considering these, EBT-XD with TCC should be the preferred method.
On a final note, the levels of agreement shown are also attributed to good film handling
practices such as using a glass compression plate to compensate for film curvature,
wearing latex gloves, thoroughly cleaning the scanner and film, minimising exposure
to ambient light and maintaining film in controlled conditions without exposure to
extreme temperature, pressure or moisture.
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4.5 Development of a film dosimetry protocol
Following on from the initial film characterisation, a film protocol was developed for
the purposes of radiosurgery audit and using the advocated film type, EBT-XD. It
was decided that for practical reasons this would be based at NPL. The facilities at
NPL would allow for controlled film handling, irradiations when they were needed and
scanning on an Epson Expression 10000XL scanner. Due to the fact that a di↵erent
scanner would be used, a new calibration curve was generated. Seven pieces of EBT-
XD film were irradiated in the dose range of 0 Gy - 40 Gy and scanned 72 hours after
irradiation to generate new scanner-specific calibration curves. The response observed
was identical to that shown previously in Figure 4.2 with a small expected shift on the
y-axis, due to di↵erences in pixel values obtained from two di↵erent scanners.
The subsections that follow outline some additional tests that were carried out to quan-
tify the uncertainties associated with the film scanning process. The energy dependence
was measured experimentally and additional considerations for accurate film dosimetry
are described.
4.5.1 Scanner response
The Epson 10000XL and 11000XL are successive scanner models with the same ge-
ometry. They have some di↵erences in their instrumentation, with the newer scanner
allowing for higher scanning resolutions, but it is anticipated that these di↵erences are
irrelevant for the studied application. In order to assess the LSRA of the NPL scanner,
a similar test to that described in Section 4.2.3 was performed. Figure 4.5a shows a
comparison of the o↵ axis response between the two scanners. As the response was
symmetric on the central axis, only one lateral displacement is shown. The di↵erences
observed are negligible and confirm the reliability of the scanner with regards to the
LSRA. As with the previous scanner assessed, if the films used are up to 6 cm wide
(maximum o↵-axis distance of 3 cm), the uncertainty contributed in within 0.2%.
The response of the scanner was also tested along the scanning axis to investigate its
variations. This was also performed using a method similar to the previous test, by
placing three films irradiated with known dose along the scanning axis and recording
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Figure 4.5: a)The lateral scanner response artifact of an Epson Expression 10000XL
compared to the 11000XL model. b)The on-axis response of the Epson Expression
10000XL scanner.
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the di↵erences seen with respect to the central point of the scanner. The results shown
in Figure 4.5b, demonstrate a more uniform response along the axis in comparison with
o↵-axis measurements. The edges of the scanner show a tendency towards higher pixel
values in comparison to the centre. A possible explanation for this is that ambient light
entering at the edges of the scanner is responsible for this e↵ect. This is consistent with
the findings and explanation of another study [154]. In the central region of the scanner
the e↵ect is within 0.5%.
4.5.2 Positioning jig
In order to minimise the impact of the lateral and longitudinal e↵ects, a rectangular
frame was constructed to exclude regions at the edges of the scanner where the e↵ects
shown are larger. This is also used as a positioning jig allowing repeatable placement
of films on the scanner bed, in a region where the scanner response is as uniform as
possible. Figure 4.6 shows a photograph of the positioning jig (made of black non-
reflective paper) securing the calibration films in a central position on the scanner,
pressed against the scanner-bed with the use of a glass plate. The longitudinal and
lateral scanner directions are indicated.
Two scans were performed to assess any perturbations caused by the presence of the
positioning jig. Pixel values with and without the jig were compared for all colour chan-
nels throughout the calibration dose range (0 Gy - 40 Gy). The di↵erences seen were
within 0.5%, equal to the level of inter-scanner variations and therefore not indicative
of any additional disturbances caused by the presence of the jig.
4.5.3 Scanner resolution
A scanning resolution of 96 dpi was considered reasonable for the purposes of the audit
as it corresponds to 3.8 pixels per mm, an adequate resolution for comparison to a
typical high-resolution 1 mm TPS dose grid. Moreover, it allows for quick scanning
times and manageable image sizes. The noise contributed at this scanning resolution
was assessed by calculating the standard deviation from the mean pixel value for con-
sistent 4 cm2 central regions of interest in the homogeneously irradiated calibration
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Figure 4.6: Photograph of the scanner setup used for film calibration: Calibration films,
glass compression plate and positioning jig are shown on the scanner bed.
films. This assessment was performed for all three colour channels and the level of
noise was found to increase with dose, reaching a maximum of 0.8% at 40 Gy. It should
be noted that these levels of noise were seen on the raw images using on a open-access
image processing software (ImageJ), without any corrections applied. Non-uniformity
corrections applied in triple-channel dosimetry have been demonstrated to lower this
noise significantly [149].
4.5.4 Scanner stability
Following recommendations and suggestions from other film studies [138,152,154,190],
the scanner was switched on, allowed several minutes to stabilise and 5 full length
scans were performed to warm-up the scanner. The response of the scanner to three
pieces of films irradiated at di↵erent dose levels was recorded in 11 scans acquired at
3 minute intervals over a total period of 30 minutes. The results for films of 0 Gy,
20 Gy and 40 Gy are shown in Figure 4.7. The scanner response at all dose levels
tested did not exceed di↵erences above 0.9%, after appropriate steps were taken to
warm-up the scanner. As with the previous test, raw images were analysed to assess
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the scanner response and no corrections were applied. Film-dose linear scaling has been
demonstrated to decrease inter-scanning variations [153].
Figure 4.7: Consistency of the Espon 10000XL scanner response over 30 minutes of
activity.
4.5.5 Film Energy dependence
The energy dependence of the film was measured experimentally in a method similar
to another study but for a di↵erent energy range to reflect the clinical energy range
used for SRS [185]. This was done by comparing the mean pixel values in central 4 cm2
regions of three film samples irradiated with a dose of 18 Gy: one in a 60Co beam and
the other two in nominal 6 MV and 10 MV linac beams. The three films were scanned
together in the central region of the scanner, and their pixel value di↵erences for all
three colour channels were within 0.5%. This is comparable to the findings of Grams
et al who showed di↵erences within 0.8%.
4.5.6 Post-irradiation darkening
Previous studies have shown or suggested that post-irradiation darkening of radiochromic
films occurs mostly in the first 48 hours after irradiation [140, 148, 152]. Due to this
e↵ect, it is recommended that films are scanned after this initial period of rapid changes
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in optical density. Regardless of this, for the purposes of a multi-centre audit, scanning
films before 48 hours would be impractical. It was therefore decided to allow 72 hours
post-irradiation for scanning test films, consistent with the practice followed for film
calibration.
4.5.7 Film orientation
According to the manufacturer the re-sized crystals in EBT-XD should minimise any
scanning orientation e↵ects. For the practical reasons and for the purposes of this work,
a consistent film orientation was used for all films. Orientation e↵ects were therefore not
evaluated as they did not constitute a source of uncertainty in the method presented.
4.5.8 Protocol
Taking into account the findings of the initial film characterisation and the subsequent
tests performed, a step-by-step protocol was developed for the purposes of handling and
scanning film for radiosurgery audit. This protocol outlines the steps and precautions
to be undertaken when preparing, irradiating and scanning film samples (Appendix B).
4.5.9 Uncertainty budget
The findings presented in this chapter allow for the calculation of an uncertainty budget
for dose measurements performed with EBT-XD film. The analysis of uncertainty
follows the Joint Commitee for Guides in Metrology (JCGM) Guide to the Expression
of Uncertainty in Measurement [191]. Uncertainties evaluated by statistical analysis are
grouped as type A and the rest are grouped as type B. These are added in quadrature
to give a combined standard uncertainty with coverage factor k = 1. Table 4.2 shows
the calculated film uncertainty.
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Source Standard uncertainty (%)
Type A Type B
Film position (±0.5mm) ±2⇤
Inter-scanning variations ±0.9
Ion chamber measurement uncertainty ±0.8
Calibration fit ±0.5
Film repeatability ±0.5
Energy dependence ±0.5
Intra-scanning variations ±0.5
Lateral scanner e↵ect ±0.2
Combined ±2.5
Table 4.2: Uncertainty budget for Gafchromic EBT-XD film.
⇤ Estimated film positional uncertainty in phantom of 0.5 mm - Dose value of 4%
estimated for a typical maximum dose gradient of 8% per mm for k = 2
4.6 Development of a film dosimetry protocol - Conclu-
sions
Scanner related uncertainties and the energy dependence of the film were quantified.
The findings of this section, along with considerations from recommended good film
practices were taken into account for the development of an appropriate protocol that
aims to minimise uncertainties in film dosimetry. This protocol is suitable for the
purposes of radiosurgery dosimetry audit.
Chapter 5
Characterisation of a new
commercial plastic scintillator
5.1 The Exradin W1 plastic scintillation detector
The Exradin W1 became commercially available in the UK in the summer of 2014. The
sensitive volume of the detector is a 3 mm (length) by 1 mm (diameter) polystyrene
cylinder doped with scintillating agents. It is encased within an opaque enclosure
made of epoxy and acrylonitrile butadiene styrene (ABS). The scintillator is coupled
to an optical fibre with a 1 mm diameter polymethyl methacrylate (PMMA) core and
a 2.2 mm diameter polyethylene jacket. The scintillator-fibre coupling is externally
protected with a polyimide sheath. The fibre is 3 metres long and is attached to a
metal photodiode box. Although the manufacturer does not provide a detailed account
of the contents of the photodiode box, it is likely to include instrumentation for the
chromatic separation of light (dichroic filters and photodiodes). The other end of the
photodiode box has two connectors for transmitting the electrical charges collected by
a dual channel electrometer. Two individual electrometers could also be used, as long
as they are able to detect the small charges produced by the PSD which are in the
pico-Coulomb range. The company also provides a 30 x 30 cm polystyrene calibration
slab that allows placement of the detector in the min and max fibre orientations. The
instrumentation described above is shown in Figure 5.1.
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Figure 5.1: Photographs of the components of the Exradin W1 plastic scintillation
detector, SuperMAX electrometer and calibration slab.
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A study that performed MC simulations of di↵erent detectors in small fields reported
that the Exradin W1 showed the best behaviour and its response was accurate within
1% [192]. Similar findings were experimentally validated by another study in the mea-
surement of small field output factors [130]. The PSD was subsequently used to deter-
mine correction factors for other small field detectors. The available evidence supports
the use of this detector in small fields. However, all characteristics of the detector need
to be investigated to assess its suitability for SRS dose verification.
The Exradin W1 has been recently characterised by two independent and almost simul-
taneously published studies [124,125]. Some aspects were investigated by both studies
and some were only presented in one of the two. The findings show good character-
istics and minimal dependence to most factors evaluated. Slightly di↵erent findings
were seen for the energy dependence and long term stability of the detector which
were highlighted and discussed in a letter to the editor [126]. A response to the letter
commented on the possibility that such di↵erences may be observed between di↵erent
detectors and highlighted the need for more studies investigating the Exradin W1 [127].
There are also some crucial investigations that will determine whether the detector is
suitable for SRS dose verification which have not been within the scope of these two
studies. The angular dependence of the detector along its polar axis and the manual
collection mode for high dose measurements need to be investigated.
The purpose of this chapter was to conduct a characterisation of the Exradin W1,
to verify published findings and investigate further, with the aim of adopting it in
the methodology of a national SRS audit. The contents of this chapter were partly
presented as an oral presentation at the 2nd International Conference in Dosimetry
Applications in Guildford, UK and submitted to the Journal of radiation physics and
chemistry for publication in a special edition volume of the conference proceedings.
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5.2 Characterisation of the Exradin W1 - Methods
The detector was connected to a SuperMAX dual channel electrometer that is commer-
cially available from the same manufacturer. The readings from both channels were
acquired in the low range (pC), using both triggered and manual collection modes.
All factors and dose measurements were calculated manually using the methods and
equations shown in Section 2.5.2. Channel 1 of the electrometer collected the signal
produced mainly from the scintillator (shown previously as Region 1), and channel 2
collected signal mainly produced from Cherenkov in the stem (Region 2). When trig-
ger mode collection was used, channel 1 was automatically initiating and ending the
measurement using the default threshold values of 0.4 pA (start) and 0.2 pA (stop).
Manual collections were acquired by starting the collection right before the beam went
on and stopping the collection after the beam went o↵ and the dose rate indications for
both channels of the electrometer returned to zero. Substantial leakage currents were
occasionally noticed during the experiments. In order to minimise them, the detector
was left to acclimatise for at least 10 minutes, pre-irradiated with a dose of approxi-
mately 10 Gy and the electrometer was subsequently corrected for background. The
photodiode box was kept as far away from the beam as possible and shielded from
scatter, as there is evidence to suggest that similar instrumentation is susceptible to
noise from scatter radiation [193,194]. The irradiations were performed with an Elekta
Versa HD linac and a Theratron (60Co) unit at NPL, and a Varian Trilogy linac and
Varian TrueBeam STx linac at Royal Surrey County Hospital (RSCH).
The work presented was undertaken with the PSD positioned in both perpendicular
and parallel orientations to the beam. For perpendicular irradiations, the detector was
calibrated in its calibration slab (Figure 5.1), using 30 x 30 cm blocks of WT1 (water-
equivalent plastic material) for buildup and backscatter. The detector was placed at the
isocentre with 5 cm buildup, 95 cm Source-to-Surface Distance (SSD), and at least 15
cm for backscatter, in a 40 x 40 cm field. Absolute dose measurements were performed
in the same setup conditions but in a 10 x 10 cm field, using ionisation chambers
with a calibration traceable to the NPL primary standard. For parallel irradiations,
the PSD was placed in water, in a Blue Phantom plotting tank (IBA, Belgium). The
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PSD manufacturer recommends a di↵erent calibration procedure for this orientation
[122] as the perpendicular calibration method using the calibration slab is not valid for
these conditions. An alternative method was also proposed by Underwood et al and
both of these methods were used for di↵erent tests in this work [130]. Di↵erent setup
conditions than those stated above were used for some tests, which are described below
in their respective sections. All uncertainties presented were calculated as one standard
deviation of repeated measurements.
5.2.1 Dose response, collection mode and short-term repeatability
The response of the PSD to dose was checked in 60Co, 6 MV, 10 MV and 15 MV
with respective TPR20cm10cm Quality Indices (QI) of 0.682, 0.733 and 0.758 for the latter
three beam qualities. For the linac beams, a PTW Semiflex ionisation chamber was
placed 5 cm below the PSD to account for any variations in output. Measurements
were performed using both triggered and manual collection modes to investigate their
di↵erences. The dose range investigated was from 0.1 Gy up to 40 Gy. The short-term
repeatability of the detector was also assessed by performing repeated measurements
in the same conditions in a 60Co beam.
5.2.2 Dose rate and dose-per-pulse
The dose rate dependence was investigated in air using a wooden clamp to ensure
low scatter conditions and to position the detector parallel to the beam at the desired
Source-to-Detector Distance (SDD). A cylindrical brass mini-phantom was fitted to the
PSD to allow measurements beyond the depth of maximum dose (dmax). Irradiations
were performed in a 3 x 3 cm field using the maximum dose rate available on the linac
of 580 Monitor Units (MU) per minute. The SDD was varied from 70 to 130 cm and
any deviation seen from the inverse square law was recorded as dose rate dependence.
The 100 cm SDD setup was performed three times throughout the experiment to assess
the uncertainty associated with the positional accuracy.
The dose-per-pulse dependence of the detector was also evaluated by varying the linac
setting for dose rate from 100 MU/min up to 580 MU/min. For this test the detector
was set up in a WT1 phantom and irradiated with a 10 x 10 cm beam at SSD 95 cm
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and 5 cm deep.
5.2.3 Angular dependence
The purpose of the tests described below was to check for dependence in the angle of
irradiation along both the symmetry and polar axis of the PSD. The gantry angle was
kept at 0  for all tests. The irradiations were performed in a 3 x 3 cm field in order to
minimise Cherenkov emissions from the stem.
For the symmetry axis angular dependence test, a cylindrical plastic sleeve was drilled
for the PSD and marked along its circumference for 0 , 30 , 90  and 150  rotations
in the clockwise and anticlockwise direction. The detector was fixed inside the sleeve,
which was placed in a plastic phantom. The sleeve was rotated using the indicated
angle marks. The signal collected at each rotation was normalised to the one at the
reference angle 0  and the deviations were recorded as angular dependence along the
symmetry axis.
For the polar axis angular dependence test, the PSD was initially positioned with its
stem parallel to the beam in a water tank (reference detector angle 0 ). The align-
ment cap provided by the manufacturer was used to align the sensitive volume of the
detector with the water surface and the central axis of the beam (SSD = 95 cm). In
order to evaluate the e↵ect of the beam profile shape on the long axis of the detector,
measurements were performed at three di↵erent depths: 1.5 cm, 5 cm and 10 cm. The
PSD was rotated by 30  steps from 0  to 90 , where the PSD’s stem becomes perpen-
dicular to the beam axis. Measurements were performed in clockwise and anticlockwise
directions. A goniometer was used to visually verify the angle of rotation. The signal
collected at each angle was compared to the one at the reference angle (0 ) and the
deviations were recorded as angular dependence along the polar axis. The reference
irradiation was repeated three times throughout the experiment to determine positional
uncertainty.
An additional test was performed to evaluate the e↵ect of the detector orientation on
dose measurements. For this tests, the detector was irradiated at a depth of 5 cm
(95 cm SSD) in a 10 x 10 cm field with a 6 MV beam. The calibration was performed
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following the manufacturer-recommended method for irradiations in a water tank with
the PSD’s stem parallel to the beam axis [122]. This calibration procedure requires
measurements with approximately 10 cm of the fibre exposed for the minimum setup
condition and 20 cm - 30 cm for the maximum fibre setup condition. As recommended,
the fibre bend radius was kept approximately the same for both conditions. The Gain
and CLR factors from this calibration were then applied to measurements performed
with the PSD’s stem perpendicular to the beam axis. Additionally, calibration factors
were acquired with the PSD’s stem perpendicular to the beam axis, following the stan-
dard calibration procedure [168, 169]. Similarly, these calibration factors were applied
to measurements performed with the PSD’s stem parallel to the beam axis. Five in-
dependent measurements were performed with both approaches and the averages were
compared to the absolute dose measured with an NPL 2611 ionisation chamber. The
deviation seen from absolute dose was recorded as dependence to orientation-specific
calibration factor determination.
5.2.4 Temperature dependence
A water bath with a temperature calibration certificate traceable to NPL was used to
maintain a temperature-controlled environment for the PSD. The detector was secured
in the water bath held by a perspex stand, parallel to the beam at 5 cm deep (95 cm
SSD). After allowing for a few minutes for the bath to achieve a homogeneous temper-
ature, measurements with a thermistor placed close to the PSD were performed. To
account for the temperature variations likely to be met in di↵erent linac bunkers, during
a multi-centre audit, the range investigated was from 18  C to 24  C. Standard room
temperature (20  C) was used as a reference for comparison of the detector response.
5.2.5 Energy dependence
It is known that PSD CLR factors are energy dependent [124, 125]. The energy de-
pendence was therefore investigated by calibrating the detector through a wide energy
range (60Co, 6 MV, 10 MV and 15 MV). Subsequently, measurements in all beams were
performed and converted to dose, using calibration factors determined for all beam en-
ergies. The average of five measurements was recorded for each combination of beam
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and calibration factors. Each of these combinations produced a dose measurement. The
measured doses were compared to the absolute dose measured using a calibrated PTW
Semiflex ionisation chamber. Any deviations from the absolute dose were recorded as
energy dependence. The whole procedure was repeated a second time and the average
values from both sets of measurements were calculated.
As the CLR factor shows energy dependence, the accuracy of the measurement could
be compromised by the spectral change between large fields (calibration fields) and
small fields (SRS fields). In order to investigate this e↵ect, a MATLAB (MathWorks,
Inc) model was developed. The model was based on the theoretical Cherenkov electron
energy cut-o↵ and refractive index of the fibre. A theoretical CLR was then analytically
formalised using the Cherenkov emission spectrum and the detection e ciency functions
for channels 1 and 2 of the detector. MC simulations of several photon energies were
performed, and the spectra were then used to generate theoretical CLRs. These were
compared with the previously experimentally measured CLRs to validate the model.
The results shown in Section 5.3.5 were presented at ESTRO 35 in Turin, Italy [195].1
5.2.6 Long-term stability
The degradation of the scintillator over its irradiation history needs to be evaluated. It
is expressed as the loss of scintillation signal and is evident in the CLR factor change
over accumulated dose. Studies with other PSDs suggest large losses of signal due to this
e↵ect [59]. However, recently it has been shown that acceptable levels of degradation
can be achieved [121]. The manufacturer suggests that the detector should be re-
calibrated every 1 kGy of exposures to account for this e↵ect [169]. The long term
stability of the detector was evaluated by periodically repeating the CLR calibration
process in the same 6 MV beam over approximately 25 kGy of irradiation history. The
decrease of CLR in relation to the initial measured value was recorded as the loss of
sensitivity due to fibre degradation from accumulated dose.
1This work was performed at NPL in collaboration with Hugo Bouchard who developed the MAT-
LAB model
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5.2.7 Evaluation of detector response in small fields
The performance of the PSD was evaluated in the determination of small field output
factors. Following the same approach as Underwood et al [130] the Exradin W1 was
used as a class detector to determine detector-specific correction factors for an IBA SFD
diode, a PTW E diode 60012 and an Exradin A26 micro-chamber. Measurements were
performed in water for beam energies of 6 MV, 10 MV, 6 MV FFF, and 10 MV FFF
and field sizes from 4 cm2 down to 0.5 cm2 at a depth of 10 cm and SSD 90 cm. Care
was taken to determine the central axis (CAX) positions by measuring beam profiles in
the inline and crossline directions through the various field sizes with all detectors. This
work was presented at the 7th Latin-American medical physics congress in Cordoba,
Argentina [196].1
5.2.8 SuperMAX electrometer characterisation
As the manufacturer issued certificate for the SuperMAX electrometer did not fully
cover the range of interest, tests were performed at NPL in the pC range for both
channels. A calibrated current source was applied to each channel and 15 second
collections for di↵erent currents ranging from 10 pA to 500 pA were acquired. Any
deviations observed in range and linearity were included into the uncertainty budget.
1This work was performed at NPL in collaboration with Ileana Silvestre Patallo who performed
the analysis of the measurements.
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5.3 Characterisation of the Exradin W1 - Results
5.3.1 Dose response, collection mode and short-term repeatability
The measurements showed linear response (R2 = 1.000) in both pulsed and continuous
radiation throughout the dose range investigated. There were no significant di↵erences
between triggered and manual collections for doses above 1 Gy, where variations of up
to ±0.1% were observed. For doses between 0.1 Gy to 1 Gy, manual collection readings
were noticeably higher than triggered collection readings, with the di↵erences reaching
up to 2.5% for 0.1 Gy. The detector’s short-term stability was found to be within
±0.3%.
5.3.2 Dose rate and dose-per-pulse
The deviation from the inverse square law in the dose rate measurements was found
to be within ±0.5%. Repeated measurements of the 100 cm SDD setup showed re-
peatability within ±0.3% and therefore indicating reasonable levels of setup accuracy.
The dose-per-pulse dependency was found to be slightly larger, reaching a maximum
relative di↵erence of 0.8% from the reference dose rate.
5.3.3 Angular response
The angular dependence along both axes of rotation of the PSD is shown in Figure 5.2.
The dependence around the symmetry axis is very small as expected, and does not
exceed 0.3% from the response at the reference angle of 0 . Along the polar axis, larger
di↵erences were expected as the sensitive volume is cylindrical and its length is three
times the size of its diameter. The largest di↵erences are seen when the detector was
at a depth of 5 cm and at 60  - 90  rotations. The detector is showing over-response
when rotated from the parallel orientation (0 ) towards the perpendicular orientation
(90 ). The dependence shown is close to 1% of the reference irradiation at angle 0 .
Repeated measurements at angle 0  showed a setup uncertainty of ±0.3%, similar to
the detector’s short-term stability, and therefore not indicative of additional sources of
uncertainty.
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Figure 5.2: Angular dependence of the Exradin W1 plastic scintillation detector.
When parallel-specific calibration factors were applied to perpendicular measurements,
the detector over-responded by 0.5%. When perpendicular-specific calibration factors
were applied to parallel measurements, the detector under-responded by 0.7%. This
e↵ect appears to be greater than the detector reproducibility and indicates that a large
amount of the dependence seen in the polar axis test may be attributed to calibration
factor determination.
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5.3.4 Temperature dependence
The temperature dependence of the PSD is shown in Figure 5.3. The signal produced
decreases at a rate of approximately 0.25% per  C throughout the range investigated.
Using the results presented, it is possible to apply temperature corrections to the mea-
surements performed during an audit, in cases where a change in environmental con-
ditions takes place.
Figure 5.3: Temperature dependence of the Exradin W1 plastic scintillation detector.
5.3.5 Energy dependence
The results of the measurements performed with all calibration factors are shown in
Table 5.1. The deviations from absolute dose become noticeable when the calibration
factors from a di↵erent beam are applied. These deviations become bigger for bigger
energy di↵erences between correction factors and beams. The maximum di↵erence is
seen when 15 MV correction factors are used in a 60Co beam (1.99%) and when 60Co
correction factors are used in a 15MV beam (-1.62%). Reasonable agreement is seen
with smaller di↵erence in beam quality: 15 MV factors used in a 10 MV beam yield dose
di↵erences of 0.22%. When the correct factors were used for all energies the di↵erence
in absolute dose between the two detectors becomes negligible.
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Beam Energy 60Co 6MV 10MV 15MV
Quality Index 0.568 0.682 0.733 0.788
Calibration factors
60Co 0.04% -0.83% -1.37% -1.62%
6MV 1.22% 0.02% -0.58% -0.99%
10MV 1.70% 0.42% -0.01% -0.55%
15MV 1.99% 0.64% 0.22% -0.04%
Table 5.1: Deviations from absolute dose for each factor-energy combination with the
Exradin W1. Underlined results show where the correct factors were used.
The theoretical model-generated CLR factors are compared against experimentally
measured CLR factors in Figure 5.4. They are plotted against the beam quality index of
the di↵erent beams used. The comparison between experiments and the model, shows
that the model reproduces the behaviour of the CLR energy dependence. However,
the model under predicts the magnitude of the e↵ect. For the energy range of 60Co
to 18MV, CLR variation was measured to be about 1.8% whereas the model predicts
variations around 0.5%.
Figure 5.4: Experimentally measured and simulated energy dependence of the
Cherenkov light ratio.
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5.3.6 Long-term stability
The loss of sensitivity of the PSD over 25 kGy of exposures is plotted in Figure 5.5. A
rapid drop of about 8% was observed in the first 5 kGy we recorded (1.6% per kGy).
In the following 20 kGy of exposures, the rate of loss of sensitivity decreased to about
0.2% per kGy.
Figure 5.5: Long term stability of the Exradin W1 plastic scintillation detector.
5.3.7 Evaluation of detector response in small fields
The small field output factors measured by all detectors in a 10 MV FFF beam are
shown in Figure 5.6. In the larger fields measured, where the micro-ionisation chamber
is considered a class detector, very good agreement was seen with the PSD for fields
above 2 cm2. In the two smaller fields, it is expected that the ionisation chamber
will under-respond and the diode will over-respond due to the e↵ects described in
Section 2.1. In these fields the PSD is considered a class detector [130] and was used
to determine detector specific correction factors for the other detectors used.
5.4. Characterisation of the Exradin W1 - Discussion 93
Figure 5.6: Small field output factors measured for a 10 MV FFF beam using various
detectors including the Exradin W1 plastic scintillator.
5.3.8 SuperMAX electrometer characterisation
The linearity and range correction of the electrometer were found to be accurate within
±0.1% in the range of interest.
5.4 Characterisation of the Exradin W1 - Discussion
The detector showed good levels of reproducibility in measurements, similar to the
levels reported by the other two studies [124, 125]. In order to achieve these levels of
stability, the detector requires careful handling to ensure low leakage currents. Leakage
appeared to become negligible when the photodiode box was shielded from scatter
radiation and the optical fibre and cables were positioned with minimal strain applied
to them. Since this system comprises of sensitive electronics and produces signals that
are many orders of magnitude smaller than other dosimetry systems, leakage currents
can produce large errors in measurement. However, it was possible to achieve high
levels of reproducibility using the methodology described.
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Manual and triggered modes did not show significant di↵erences in the collected read-
ings for doses above 1 Gy but the di↵erences increased by an order of magnitude for
doses below 1 Gy. The di↵erences seen must be related to the amount of phosphores-
cence (delayed luminescence) collected at the end of a reading. Triggered mode stops
the collection as soon as the signal passes the predefined threshold whereas manual
collection, at least using the method described, always had a longer acquisition time.
As the dose becomes larger, the contribution from phosphorescence is proportionally
smaller and becomes negligible above 1 Gy. Carrasco et al reported similar di↵erences
when using manual collection mode at low doses but they did not investigate doses
above 1 Gy [125]. Also, the authors do not describe how the manual collection was
acquired so it is possible that a di↵erent methodology was used. Using the method
described in this study, it was possible to achieve agreement within ±0.1% between
two collection modes. In SRS plan verification measurements, the detector will be ex-
posed to multiple beams and/or heavily modulated beams where a large amount of the
dose collected will be delivered from penumbrae. The triggered mode is unreliable in
ensuring appropriate start and stop time points for this collection, whereas the manual
mode allows for this to be controlled by the user. The findings demonstrated that using
manual mode and the consistent collection method described, accurate measurements
are acquired in the dose range of interest, making this method suitable for the proposed
audit.
The detector exhibits negligible angular dependence along the symmetry axis. Along
its polar axis, a dependence of about 1% was observed, which is relatively small in
comparison to diamond detectors that exhibit dependencies of up to 3% [52]. This
dependency has not been previously reported and is important to include within the
uncertainty budget for non-coplanar deliveries, like SRS. The determination of calibra-
tion factors, to be applied to SRS dose measurements, can only be performed using
one of the two orientations. The standard perpendicular method is more reliable and
practical for the purposes of an audit. As shown in the results, a dose di↵erence of up
to 0.7% was observed when calibration factors were acquired at a di↵erent orientation
from the measurement. It should be noted, that the scenarios and uncertainties calcu-
lated from these tests are generous as the conditions simulated are unlikely to be met in
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a clinical delivery. The tests accounted for situations where all of the dose is delivered
from a single plane but in reality the delivery will be occur over multiple planes and
the e↵ects shown should be significantly smaller.
The results show a spread of 1.8% in the CLR factor determination over the range
of energies investigated. This was expressed as a maximum di↵erence of 2% in the
dose measured. This di↵erence diminishes when the factors are from a similar beam
quality and disappear when the factors are acquired at the same beam energy. As
demonstrated, the detector has an energy dependence which can be eliminated by
performing the calibration in the same beam where the measurements are going to be
performed. It should be mentioned that the calibration process most practical for an
audit, requires irradiations in a 40 x 40 cm field. These conditions are not possible
for all SRS delivery machines. However, by acquiring calibration factors in a beam
with a quality index as close as possible to the measurement beam, the dose di↵erence
observed becomes very small.
The MATLABmodel presented assumes isotropic Cherenkov emission while the angular
distribution of the light varies with the electron kinetic energy and the optical fibre
only guides light emitted at a specific angular range. Further improvements modelling
Cherenkov light transport explicitly should confirm this. A potential application for
the model would be to quantify the e↵ect of small field spectral changes on the CLR.
The results shown for the long term stability of the detector are comparable with
published studies. Beierholm et al show a rate of decrease in sensitivity of 2% per
kGy over 1.5 kGy of exposures, comparable to the initial loss seen in this study (1.6%
per kGy) [126]. Carrasco et al show the same trend in sensitivity loss but at di↵erent
rates. However, the initial rate of loss seen in that study is similar to the latter rate
seen in this study [125]. The results presented are supportive to the speculations that
such di↵erences in detector characteristics could be related to di↵erent pre-irradiation
exposures by the manufacturer to overcome the need for frequent calibration [127]. The
results suggest that the detector’s long term stability is su cient for use in an audit.
If a calibration is performed per kGy of exposures, the uncertainty contributed will be
of the range of 0.2%.
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The output factor measurements performed confirm that the PSD is a reliable detector
for fields as small as 2 x 2 cm as the agreement with micro-ionisation chamber is very
good. The detector-specific correction factors determined by the PSD are in good
agreement with published correction factors, confirming the reliability of the detector
in small fields [130].
5.4.1 Uncertainty budget
The findings presented in this chapter allow for the calculation of an uncertainty budget
for any measurements performed for dose verification in SRS. The analysis of uncer-
tainty follows the JCGM Guide to the Expression of Uncertainty in Measurement [191].
Uncertainties evaluated by statistical analysis are grouped as type A and the rest are
grouped as type B. These are added in quadrature to give a combined standard uncer-
tainty with coverage factor k = 1. Table 5.2 shows the calculated uncertainty budget
using the manual collection mode for doses above 1 Gy, ranked from biggest to smallest.
Source Standard uncertainty (%)
Type A Type B
Gain determination ±1.2
Angular dependence ±1.0
Dose rate dependence ±0.8
Ion chamber measurement uncertainty ±0.8
CLR determination ±0.7
Setup accuracy ±0.5
Long-term stability ±0.2
Manual collection mode ±0.1
Electrometer ±0.1
Combined ±2.1
Table 5.2: Uncertainty budget for the Exradin W1 plastic scintillation detector.
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5.5 Characterisation of the Exradin W1 - Conclusions
The Exradin W1 plastic scintillation detector was tested in various conditions to char-
acterise its behaviour. The results show good agreement with published data and the
dependencies to all factors investigated are relatively small. The PSD used in the
manual collection method, with careful calibration and handling constitutes a suitable
dosimeter which can be employed in a multi-centre dosimetry audit. The measurement
uncertainty calculated is generous and accounts for the worst case scenario for measured
doses above 1 Gy.
Chapter 6
Adaptation and validation of a
phantom for radiosurgery audit
6.1 Phantom adaptation - Introduction
This chapter presents the adaptation of a commercial anthropomorphic phantom for the
novel use of three simultaneous detectors, with the purpose of employing it for a radio-
surgery dosimetry audit. The methodology utilised was guided by the current practice
for cranial SRS in the UK presented in Chapter 3 [179]. This indicated that single brain
metastatic lesions of volumes ranging from 1 to 20 cm3 are the most commonly treated
indications. The survey also highlighted that quality assurance programs should pro-
vide confidence not only in the dose delivered, but also the location and shape of the
dose distribution delivered, as SRS is often prescribed to irregularly shaped targets.
The goal of the adaptation was to combine a close representation of a typical radiosur-
gical patient case, with a design capable of simultaneous measurements with a number
of previously characterised detectors, suitable for SRS dose measurement. These were
the new commercially available radiochromic film EBT-XD presented in Chapter 4,
the new commercially available Exradin W1 PSD presented in Chapter 5 and alanine
pellets from the NPL chemical dosimetry service [113]. The validation of this phan-
tom and detectors combination included verification that the di↵erent systems did not
adversely a↵ect one another when making simultaneous measurements.
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The work presented in this chapter has been submitted to Biomedical Physics and
Engineering Express (under review at the time of submission of the thesis).
6.2 Phantom adaptation - Methods
STE2EV is a commercially available anthropomorphic phantom (CIRS, Norfolk VI,
USA) which has been designed with a range of materials to simulate tissue electron
densities. The phantom contains bone and soft tissue structures, as well as teeth
and air gaps to reflect realistic anatomy. The phantom design allows the insertion of
interchangeable cuboid inserts in the centre of the brain and the insertion of radiation
detectors through two parallel cylindrical access cavities that run superior to inferior
through the phantom connecting the neck to the brain. The two cylindrical access
cavities are 3 cm apart, centre to centre. The anterior cavity is aligned with the
trachea and the posterior cavity is aligned with the spinal cord.
Figure 6.1: The STE2EV anthropomorphic phantom, bespoke inserts and detector
sleeves developed.
6.2. Phantom adaptation - Methods 100
Two interchangeable bespoke cuboid inserts were developed for the brain cavity of the
phantom. The first, the target insert, was modelled on real anatomical structures from
clinical CT to simulate a patient as closely as possible. The insert is a 3D-printed cube
made of proprietary resin that contains two liquid-fillable structures; one irregularly
shaped “target” structure (Planning Target Volume – PTV) designed to simulate a
centrally located brain metastasis of typical size (⇡8 cm3) and another “organ at risk”
(OAR) structure in the shape and size of the brainstem and thalamus of the brain
(Figure 6.2a). The two structures are aligned and centred with the cylindrical access
cavities. The posterior surface of the PTV structure is approximately 1 cm away from
the anterior surface of the OAR.
Figure 6.2: CT scan sections of the STE2EV phantom through axial, coronal and
sagittal planes with the target insert (a) and dosimetry insert (b) placed inside the
cavity.
The second, the dosimetry insert, is made of the same material as the surrounding brain
equivalent material, obtained from the manufacturer, and was designed for multiple
simultaneous dose measurements (Figure 6.2b). It is comprised of three cubes which,
when joined together, have the same dimensions as the target insert (Figure 6.2a). The
dosimetry insert was engineered to have two planar indentations of 280 microns depth
to be loaded with film, one in the sagittal and one in the axial plane. Sections through
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these are shown in Figure 6.2b. The axial film is positioned such that it bisects the
target structure in the superior to inferior direction. The sagittal film is positioned
superior and perpendicular to the axial film, such that it bisects the superior half of
the target structure.
Figure 6.3: Successive pictures of the di↵erent parts of the dosimetry insert being put
together. The last two images show the dosimetry insert fitted into the phantom and
the film in the insert after irradiation.
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Three small asymmetric fiducial markers (1 mm diameter) have been built into each
film plane to allow accurate registration of the film when doing the analysis.
The lower part of the insert, which sits under the axial film, allows access from the
inferior direction through the cylindrical cavities of the phantom, for the placement of
other radiation detectors. Two bespoke detector holders have also been manufactured
to hold the PSD and a stack of four alanine pellets. They are interchangeable so
that they can be used to make measurements in both cylindrical cavities. The holders
were designed so that the geometric centres of the top alanine pellet and the PSD are
aligned as shown in Figure 6.4. The goal was to have the two measurement systems
placed in the same position and enable two di↵erent geometries to produce comparable
measurements for the mean dose absorbed in their volume.
Figure 6.4: Schematic representation of the sagittal plane through the middle of the
STE2EV phantom showing all detectors on the Planning Target Volume (PTV) and
Organ at Risk (OAR). The scintillator positions are superimposed on the interchange-
able alanine pellet positions. Both are cylindrical detectors - dimensions of scintillator:
3 mm length x 1 mm diameter, dimensions of pellets: 2.5 mm length x 5 mm diameter).
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The methodology was designed to enable accurate point measurements as well as ac-
curate dose distribution measurements. Alanine [111] and radiochromic film [118, 119]
have been chosen due to their good performance in dose measurement and successful
use in other previous radiotherapy dosimetry audits. EBT-XD film was preferred to
the most commonly used EBT-3 film as it was previously demonstrated (Chapter 4)
that it is more suitable for small field high dose applications, mainly due to its ex-
tended dose range and reduced lateral scanner e↵ects. Both alanine and Gafchromic
film are near-water equivalent detectors with small sensitive volumes (high spatial res-
olution), characteristics considered ideal for SRS dosimetry. The Exradin W1 PSD is a
novel detector with attractive characteristics that are suitable for SRS-type small field
measurements. The chosen methodology enables us to assess the performance of this
detector in SRS against the TPS calculated dose but also against alanine which is an
established dosimeter. All detectors chosen, have small sensitive volumes compared to
the PTV and field sizes typically used for radiosurgery. Assuming a relatively homoge-
neous dose distribution in the target, these detectors are expected to generate reliable
measurements. For measurements in the OAR, larger deviations are expected due to
lower absolute doses and steeper dose gradients.
The Exradin W1 PSD was calibrated for its stem e↵ect (Cherenkov Light Ratio – CLR)
and dose-to-water (GAIN) correction factors following the manufacturer’s recommen-
dations [168] in a 40 x 40 cm and 10 x 10 cm field respectively, with the later done
against a PTW Semiflex chamber with a traceable calibration to the National Physical
Laboratory, Teddington, Middlesex, UK.
6.2.1 Positioning accuracy of inserts
Multiple CT scans of 0.625 mm slice thickness were performed with each insert inside
the phantom cavity. The inserts were removed and replaced between each scan to assess
the reproducibility of positioning the inserts. The CT-origin was centred for all scans
using the phantom’s built-in fiducials and the CT coordinates of two opposite corners of
the cube insert were recorded for each scan. The maximum vector distance between the
coordinates of the corners was calculated and defined as the positional reproducibility of
the insert. CT scans were also taken with the PSD and alanine pellets in both cavities
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to assess that their superimposed positions were as intended (Figure 6.4). This was
assessed by contouring the detector in each position and fusing the two scans together
on iPlan Image Fusion (BrainLAB, AG, Feldkirchen, Germany).
6.2.2 Basic plan dose verification with ionisation chamber
A basic treatment plan was generated on the phantom, to be tested for plan dose
verification, in order to establish a baseline of the dosimetric accuracy of the phantom.
The treatment plan was a 3-field conformal radiotherapy plan with one anterior beam
at gantry angle 0  and two lateral beams at 90  and 270 . All three fields had primary
jaw collimation fixed at 3 x 3 cm and MLC collimation in their four corners to produce
approximately circular 3 cm fields. The plan isocentre was placed in the middle of the
anterior phantom cavity, to match the position of a calibrated PTW Semiflex ionisation
chamber. The plan was delivered to the phantom and the measured dose for each beam
was compared to the TPS predicted mean dose for a contour structure created to match
the ionisation chamber sensitive volume.
6.2.3 Radiochromic film measurements
Film measurements were performed three times to assess the repeatability of the mea-
surements. A measurement was conducted with the film only inside the phantom and
it was repeated twice with the other detectors present, in order to assess the e↵ect of
any perturbations caused by the presence of the alanine and PSD on the film. In the
absence of the film and alanine pellets, water equivalent rods were used to fill the cylin-
drical cavities. The methodology used for the film analysis in this chapter was similar
to the one previously presented in Chapter 4. The films were scanned on an EPSON
Expression 10000XL scanner at 96 dpi (0.265 mm resolution) in transmission mode with
no corrections applied, and analysed on FilmQA Pro software (Ashland ISP Advanced
Materials, NJ, USA). They were scanned consistently in the landscape orientation, 3
days after exposure to allow for post-irradiation darkening to occur. The films were
always kept together in a controlled environment and were handled with latex gloves.
A glass compression plate was used during the scans to keep the films flat on the scan-
ner. High resolution (1 mm grid) predicted dose planes were exported from the TPS
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for comparison with the 48bit images of digitised films. A selection of gamma passing
rates [186] suitable for SRS plan analysis were chosen. These include both local gamma
(LG) and global gamma (GG) criteria to highlight the impact of agreement in the low
dose regions of the dose map distributions. The distance-to-agreement (DTA) param-
eter of the gamma criteria used was always kept below 2 mm as distances above that
are considered unacceptable tolerances for SRS delivery. Similarly the dose-di↵erence
(DD) parameter was varied between 2-5% to be representative of acceptable tolerances
in SRS whilst accounting for the steep dose gradients present. The gamma passing
rates used were collected using the red colour channel with triple channel dosimetry
correction (TCC) [149] for the regions shown in Figure 6.5 (50 x 60 mm axial and 70 x
40 mm for sagittal), with a cut-o↵ threshold for doses below 2 Gy to remove areas of
low signal and high noise from the analysis.
6.2.4 End-to-end validation test
The phantom, inserts and detectors were tested for their suitability in performing an
end-to-end dosimetry test for SRS. The phantom was immobilised in a thermoplastic
mask used for radiotherapy treatment and CT scanned with both inserts in the cavity.
The two scans were then imported into iPlan (BrainLAB AG, Feldkirchen, Germany)
where they were fused, the target and detectors were contoured and a 7-field IMRT plan
was generated using the local protocol’s prescription practice. The plan was delivered
on a TrueBeam STx Linac (Varian, Palo Alto, CA, USA) with ExacTrac (BrainLAB
AG, Feldkirchen, Germany). Measured point doses and dose planes were compared to
Treatment Planning System (TPS) predicted doses and planes.
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6.3 Phantom adaptation - Results
6.3.1 Positioning accuracy of inserts
The vector distances from the origin for the two points of the dosimetry insert were
found to range from 53.51 - 53.79 mm for point 1 and from 74.18 - 74.61 mm for point
2. For the target insert the two distances ranged from 53.47 - 53.87 mm and 74.06
– 74.46 mm respectively. The maximum deviation in position was less than 0.5 mm
for both inserts and the positional agreement between the two inserts was found to be
better than 0.6 mm. The detector holders showed reproducible placement of the PSD
and alanine detectors and confirmed the intended relative positions were as designed
and shown in Figure 6.4. This analysis was limited to a qualitative assessment as
any quantification of the PSD position was not possible due to the small and water
equivalent sensitive volume of the detector that was di cult to visualise on the CT
scans.
6.3.2 Basic plan dose verification with ionisation chamber
Table 6.1 shows the ionisation chamber measurements for the plan dose verification of
the basic 3-field plan. The percentage di↵erence for each beam and the overall di↵erence
were within 0.5%, suggesting an acceptable phantom accuracy.
Beam Name Measured dose
(in cGy)
Predicted dose
(in cGy)
Percentage
Di↵erence
Left Lateral 50.7 50.5 0.4%
Anterior 101.2 100.7 0.5%
Right Lateral 49.8 49.6 0.5%
Total 201.7 200.8 0.5%
Table 6.1: Measurements of a basic 3-field plan dose verification using the STE2EV
phantom and a Semiflex ionisation chamber. The calculated k=1 uncertainty of the
chamber is ±0.7%.
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6.3.3 Radiochromic film measurements
High levels of agreement were found between the film and TPS, whether the alanine or
PSD were in place or not. All GG criteria used (Table 6.2) were in all cases agreeing
with more than 93.2% of pixels passing. Any di↵erences seen between LG and GG had
the disagreements mainly in the low dose areas. However, these disagreements are not
significant as the results for 5%-2mm LG were always above 96.1%.
The variation in gamma passing rates between the three pieces of film was very similar
for all the criteria investigated. The maximum percentage di↵erence was seen with
the strictest criteria of 5%-1mm LG and 5%-1mm GG, which was 3.8% and 3.7%
respectively.
Detectors used
Local Gamma Global Gamma
5%-
2mm
3%-
2mm
2%-
2mm
5%-
1mm
5%-
2mm
3%-
2mm
2%-
2mm
5%-
1mm
Film only 97.1 87.1 73.3 73.6 99.8 96.4 95.9 93.2
Film & PSD 96.1 88.0 76.0 70.4 100 99.8 98.0 96.9
Film & alanine 96.9 87.9 75.1 69.8 100 97.4 96.2 95.4
Table 6.2: Gamma passing rates for EBT-XD axial film measurements with and without
the PSD/alanine abutting the film plane.
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6.3.4 End-to-end validation test
Table 6.3 shows results for the PSD and alanine measurements. The di↵erence between
measured and TPS dose was within 0.4% for the PTV and the agreement between the
PSD and pellet 1 was also within 0.4%. For the OAR the di↵erence between the PSD
and pellet 1 was 1.2%. The film dose plane measurements are shown in Figure 6.5.
Detector
location
Detector
used
Measured dose
(in cGy)
Predicted dose
(in cGy)
Percentage
Di↵erence
PTV
PSD 2605.7 2598.0 0.3%
Pellet 1 2595.6 2598.0 -0.1%
Pellet 2 2598.4 2595.0 0.1%
Pellet 3 2604.4 2595.0 0.4%
Pellet 4 2613.6 2604.0 0.4%
OAR
PSD 51.5 43.0 19.8%
Pellet 1 51.0 43.0 18.6%
Table 6.3: Dose measurements in the target and OAR compared to TPS predicted
doses. The calculated k=1 uncertainties of the PSD and alanine pellets are ±2.1% and
±2.0% respectively.
6.3. Phantom adaptation - Results 109
Figure 6.5: Dose distribution comparisons between the film-measured doses (thin lines)
and the TPS-calculated doses (thick lines) for the axial and the sagittal films used in
the end-to-end test.
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6.4 Phantom adaptation - Discussion
As the phantom and inserts are intended for performing end-to-end tests in SRS it
is imperative that the positional uncertainty of the inserts is as low as possible. In
the survey conducted in Chapter 3 it was found that the majority of SRS centres in
the UK reported positional accuracies less than 1 mm for SRS delivery. Considering
the engineering tolerances allowed to facilitate insertion and removal of the two inserts
inside the phantom, the sub-millimetre variations found are considered acceptable.
The agreement between film and TPS for the three films used in this study showed
mean passing rates of 96.7% for 2%-2mm global gamma. This shows equivalent agree-
ment with the measurements previously performed in a simple homogeneous phantom
in Chapter 4. The results presented in this study also demonstrate similar levels of
agreement with the TPS to other studies that also used anthropomorphic phantoms
[97, 119]. Most importantly, the film measurements show a high degree of repeatabil-
ity which is essential if the methodology is to be employed for audit purposes. The
high agreement to the TPS and repeatability in measurement suggest that this is an
appropriate phantom design and film methodology to be used for an end-to-end audit.
The PSD showed very good agreement with the TPS and the first alanine pellet. The
agreement between the two detectors in the target was within 0.4% demonstrating
the potential of positioning two detectors of di↵erent geometries in the same area to
compare their measurements. The results also suggest that the Exradin W1 PSD could
be a suitable detector for end-to-end audits.
The measurements performed in the brainstem show larger di↵erences from TPS calcu-
lated doses than the measurements in the target. This is due to the measurement being
performed in a region with a high dose gradient, where a small positional deviation re-
sults in a large dose di↵erence. The detector signal measured is also much lower than
the detector signal measured in the target which hence produces larger uncertainties
in the relative measurement. Despite the above, the absolute di↵erence between the
measured and predicted doses is at low levels of 8-9 cGy. Also, the di↵erence between
the alanine pellet in the brainstem and the PSD is within 1% giving more confidence
to the measurement. Moreover, the two film measurements performed that sit immedi-
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ately superior to the two detectors also show that the dose measured in the brainstem
is slightly higher than the TPS predicted dose and therefore confirms that the mea-
surements of the three independent systems provide consistent results, even in regions
where the TPS calculation algorithm may be less accurate.
The perturbation of the alanine and PSD on the sagittal film plane was expected to
be very low due to the near-water equivalent density of the two detectors. Also, the
small volume of the two detectors, relative to the large area of the film, would only
potentially a↵ect a small number of pixels, which would be reflected in a small change in
gamma passing rates. The gamma passing rate di↵erences observed between the three
exposures, are mostly attributed to dose di↵erences in the low dose regions. These must
therefore be related to film measurement variations or treatment delivery variations,
but not detector perturbation. The results confirm that the di↵erences seen are very
low as hypothesised.
The phantom and inserts used enabled a thorough test of all aspects of the treatment
protocol in place for SRS. The immobilisation system, CT scan and scanning protocol,
import of images into TPS, fusion of two sets of scans, TPS accuracy, export of images
on the treatment platform, pre-treatment imaging for precise positioning and finally
dosimetric and geometric accuracy of the treatment delivery were all tested.
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6.5 Phantom adaptation - Conclusions
This chapter presented the adaptation of a commercial anthropomorphic phantom with
suitably designed inserts to image and irradiate in order to be suitable for an end-
to-end dosimetry audit of SRS. It was demonstrated that the inserts produced have
reproducible positioning inside the phantom and they can be utilised for end-to-end
tests to provide accurate and repeatable measurements. The adopted methodology was
tested for dose verification and it is possible to achieve high agreement and repeatability
between TPS and the three detectors used in the phantom (EBT-XD film, alanine
pellets and the Exradin W1 PSD). The use of all detectors simultaneously inside the
phantom does not produce any significant perturbations and is therefore a suitable and
time-saving methodology. The work presented has demonstrated a novel combination of
three detectors for simultaneous measurement in an anthropomorphic phantom which
create a suitable phantom-detector system and methodology for an end-to-end SRS
dosimetry audit.
Chapter 7
Methodology of the national
audit for stereotactic
radiosurgery
7.1 National SRS Audit - Introduction
Chapters 4 and 5 presented the characterisation of appropriate detectors for SRS dose
verification and showed the development of suitable measurement methods. Chapter 6
presented the use of these detectors and alanine in an anthropomorphic phantom,
demonstrating their suitability for end-to-end radiosurgery audit. In this chapter, the
methods developed were incorporated into the procedure used for conducting an end-
to-end audit for SRS.
The work presented in this chapter was endorsed by the RadioTherapy Trials and
Quality Assurance (RTTQA) team, and was used as the credentialing QA exercise that
was completed by centres participating in two clinical trials. Additionally, NHS England
procured the commissioning of SRS services in early 2016 and used the results of this
audit as the part of the credentialing exercises completed by centres that competed in
the selection process [197].
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7.1.1 Initial investigations of a pilot audit study
Initial investigations for compatibility of the end-to-end audit methodology presented
in Section 6.2.4 with all treatment delivery platforms were performed. As shown previ-
ously in Section 3.3.3 most centres use MRI scans for treatment planning. Therefore,
the initial tests incorporated MR imaging of the phantom. This confirmed the lim-
ited visibility of the phantom on MRI scans and the di culty of booking MR time for
non-clinical work. As a pragmatic approach, it was therefore decided that the audit
procedure would require centres to only perform CT scans of the phantom, due to the
good visibility of the phantom and detectors and the availability of scanning slots.
During these initial tests it was also noticed that inserting and removing the water-
filled target insert could be problematic. It could lead to damaging both the phantom
and the insert, but also had the potential to compromise the measurements performed
with the (hygroscopic) alanine pellets, due to water drops left in the phantom after
removal of the insert. Moreover, it was noticed that during the filling process, small
air bubbles were left in the insert. If dose calculations were performed on this insert,
algorithms with inhomogeneity corrections would be taking into consideration the lower
density regions and predicting slightly di↵erent dose distributions. Due to the above
reasons, it was decided not to scan the phantom with this insert during the audits but
rather to provide participating centres with a CT image set of the phantom with the
insert in place. This image set was then used only for outlining the target and OAR,
but not for dose calculations. After contouring, the provided image set could be fused
with a scan taken on the day, with the dosimetry insert placed inside the phantom.
The centre then proceeded to treatment planning and dose calculations. This process
avoided dosimetric inaccuracies contributed from density di↵erences between the two
inserts. It also streamlined the audit as the CT image set was sent to the centre in
advance and by the day of the visit the centre had the opportunity to prepare a suitable
plan.
The film analysis methodology presented previously in Section 6.2 was used in these
initial investigations to assess its compatibility with all SRS platforms. Some of the
exported dose planes from the TPSs tested were incompatible with the film analysis
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software, but it was possible to overcome these by editing the files using third party
software prior to the analysis. It was also noticed that the coordinate systems used
by the TPSs tested were di↵erent. Due to these di↵erences, in some cases it was
impossible to use the fiducial markers for co-registering the film with the exported dose
plane. Where the use of fiducial markers was possible, it added significant time to the
analysis and proved to be an impractical method for use in a national audit. In order
to overcome these problems, it was decided not to use the fiducial markers registration
function, but instead utilise the optimisation function of FilmQA Pro. This function
attempts multiple registrations between the two dose distributions to find a best fit,
where the gamma passing rate is as high as possible. The film was initially positioned
manually and one optimisation cycle was subsequently applied. The positional shifts
applied by the optimiser to the initial position were monitored to ensure that they were
within reasonable limits (±1 mm and ±1  rotations).
7.2 National SRS Audit - Methods
7.2.1 Schedule of audits
Audit visits were performed between January 2016 and July 2016 in 26 participating
centres. During these visits, 28 treatment plans were assessed as two centres partici-
pated with two di↵erent treatment modalities. Two auditors were always present during
each audit, where at least one was a registered clinical scientist from NPL and/or RT-
TQA. The author was present in 27 audits, Russell Thomas of NPL in 11, Jonathan
Lee of RTTQA in 6, David Eaton of RTTQA in 5, Rushil Patel of RTTQA in 4, Ileana
Silvestre Patallo of NPL in 2 and Rada Zotova of RTTQA in 1. The geographical loca-
tions and equipment groups of the UK centres visited are shown in Figure 7.1. Sixteen
treatment plans were delivered by Linacs, seven by GKs, four by CKs and one by TT.
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Figure 7.1: Map of the UK showing the geographical locations and equipment groups
of the centres visited.
7.2.2 Audit image set
A high resolution CT scan (1 mm slice thickness) of the phantom was performed with
the target insert in place (see Figure 6.2a). The insert was carefully filled with water
following the manufacturer’s recommendations for minimising air bubbles to improve
image quality. The image set was saved in Digital Imaging and Communications in
Medicine (DICOM) format and sent to participating centres along with instructions
on how to outline the target and OAR. This scan was the secondary data set and was
used instead of the MRI scan most commonly used in SRS patient pathways. After
outlining the two structures, the centres were able to use the scenario presented to
them in deciding on an appropriate treatment plan.
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7.2.3 Immobilisation and CT scan
On the day of the audit, centres were asked to “immobilise” the phantom following
the local protocol for a patient with a single brain metastasis. The phantom was
loaded with the dosimetry insert, axial and sagittal films, four alanine pellets in the
posterior cavity and the PSD in the anterior cavity. A laser alignment system was
used to position the phantom parallel to the couch. Where a laser system was not
available, handheld levelling devices were used instead. Figure 7.2 shows some of the
immobilisation systems used by di↵erent centres.
Figure 7.2: Immobilisation systems used by di↵erent participating centres in the au-
dit: a) BrainLab thermoplastic mask, b) U-frame thermoplastic mask, c) White orfit
thermoplastic mask, d) Leksell Gamma Knife stereotactic frame.
To ensure a reliable setup with the Leksell stereotactic frame without damaging the
phantom, hard rubber caps were placed on the stereotactic pins. The frame was firmly
attached so that the pins were pushing the rubber caps against the surface of the
phantom. Initial tests showed reliable fixation with this method and it was considered
suitable for use in the audit.
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After immobilisation, a CT scan (primary data set) was performed following the centre’s
protocol for the scenario presented. Figure 7.3 shows an example of a CT scan acquired
during an audit visit, with the phantom immobilised and all detectors in place.
Figure 7.3: Example of a primary data set CT scan acquired during an audit visit with
the dosimetry insert and all detectors placed inside the phantom.
7.2.4 Image fusion and contouring
The primary data set was then imported into the TPS and co-registered (fused) with
the secondary data set, which was provided prior to the visit. The local planner verified
that the fusion between the two scans was correct and proceeded to outline all structures
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required, following the instructions provided by the auditors (Appendix C).
As shown in Figure 7.3, the primary data set was acquired with the PSD in the target
and alanine pellets in the OAR. As these structures were visible on the scan, the
planners were able to contour them directly. In order to allow dose comparisons with
both detector systems in both phantom cavities, the contoured structures were copied
and positioned concentrically to the other cavity. As both detectors are near water-
equivalent, density perturbations were considered negligible. The copied contours are
shown in Figure 7.4. The four alanine pellet structures were copied and centred into
the anterior cavity position, and the PSD structure was copied and centred into the
posterior cavity position.
Figure 7.4: Sagittal section through the middle of the phantom showing copied and
repositioned contours.
Figures 7.5a and 7.5b, show sagittal sections of the two data sets fused together. The
blue-framed pane tool shown, displays the primary data set position relative to the
secondary data set during the fusion procedure. Figure 7.5c, shows an example of the
primary data set with all required contours displayed.
Up to this stage, the procedure described tested the patient pathway for immobilisation,
CT scanning, image export, image registration, image fusion and contouring.
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Figure 7.5: Sagittal sections of the phantom showing fusion of the primary and sec-
ondary CT data sets (a & b) and contours for all structures (c).
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7.2.5 Treatment planning
Following contour delineation, audited centres proceeded to treatment planning. They
were asked to follow their local prescription protocol and tolerance doses. Treatment
plans acceptable to local practice were generated, checked and exported to the deliv-
ery platform. Plan exports were collected by the auditors for retrospective analysis.
Sagittal and axial dose planes calculated with a 1 mm grid were also collected by the
auditors for comparison to film planes. The maximum, minimum and mean doses as
calculated by the TPS were recorded for all contoured structures. Figure 7.6 shows an
example of a treatment plan generated on iPlan (BrainLab AG, Feldkirchen, Germany)
that was planned with four non-coplanar dynamic conformal arcs.
Figure 7.6: Example of a audit treatment plan: a) beam orientation, b) axial view
through film plane, c) sagittal view through film plane, d) frontal view through anterior
phantom cavity.
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7.2.6 Treatment delivery
After completion of the treatment plan, the auditors continued with a measurement
session on the delivery platform. Output measurements were performed, followed by
calibration of the scintillation detector and a reference film measurement. Subsequently,
the anthropomorphic phantom was setup with all detectors in place. The phantom
position was verified using on-board imaging, where available, and the phantom was
repositioned if necessary following the local protocol. When on-board imaging was
used, a small imaging dose was inevitably delivered to the film and alanine pellets.
This is, however, negligible in comparison to the treatment dose. Following phantom
positioning and verification imaging, the treatment plan was delivered twice. Between
the two treatment deliveries, films and alanine pellets were replaced. The position of the
PSD was also swapped with the new set of alanine pellets for the second measurement.
7.2.7 Output measurement
A PTW Semiflex ionisation chamber, traceable to the graphite calorimeter primary
standard at NPL, was used in all centres to perform output measurements. The cham-
ber was placed in WT1, using the centre’s reference conditions, to measure the output
in the machine specific reference field [80, 198]. For linacs, CKs and Tomotherapy the
beam quality index (TPR20cm10cm) was measured to derive a beam-specific dose-to-water
correction factor for the chamber. Ion recombination correction factors were measured
using a two-voltage method [199]. For GKs, output measurements were performed in
spherical phantoms provided by the centre. A TPR20cm10cm of 0.568 for
60Co was assumed
and ion recombination was considered negligible. All measurements were corrected for
temperature and pressure. The measurements were analysed with respect to the TPSs
reference conditions and the deviations from agreement were expressed as percentage
di↵erences.
7.2.8 EBT-XD film measurements
Reference film irradiations were performed in WT1 blocks at the centre, using the local
reference conditions. Where this was not possible, the measurement was performed
at NPL on the same day. Alternatively a film reference measurement from another
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centre was used, ensuring always appropriate post-exposure scanning times following
the manufacturer’s recommendations [153]. The film was irradiated with a dose as
close as possible to the prescription dose level. The output measurement in the same
conditions was used to calculate the exact dose delivered to the film.
During treatment plan deliveries, four test films (two sagittal and two axial) were
irradiated at each centre. All films were returned to NPL and scanned at least 72
hours after exposure following the protocol (Appendix B) developed in Chapter 4 and
using the scanner setup shown in Figure 7.7.
Figure 7.7: Setup used for scanning audit test films.
All films were handled following the methods described in Chapter 4. The film analysis
was performed collectively on FilmQAPro at Queen Alexandra Hospital in Portsmouth
after all audit visits were completed. One axial and one sagittal film was analysed
from each centre using the methods described in Section 6.2 with the modifications
described in Section 7.1.1. The regions of interest used for the analysis were a 6 x 5 cm
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rectangle for the axial films and a 7 x 4 cm rectangle for the sagittal films. Passing rates
were collected for the same criteria used in Section 6.2 for both red and green channels
with TCC. The passing rates were also recorded with and without the film-dose linear
scaling corrections applied.
7.2.9 Exradin W1 measurements
The Exradin W1 was positioned in its calibration slab and WT1 was used for build-up
and back-scatter. Measurements were performed after the Semiflex output measure-
ment, using the same setup conditions. The PSD was initially irradiated with approx-
imately 10 Gy to encourage stability. Where a 40 x 40 cm beam was achievable by the
delivery machine, the PSD was calibrated for CLR using the method described in Sec-
tion 2.5.2. For CKs, GKs and TT where these conditions were not possible, the CLR
factor was acquired in a beam of similar quality index either at NPL or another audited
centre. The CLR factor was then applied to PSD measurements in reference conditions,
in order to calibrate the detector for absolute dose. Equation 2.2 and the ionisation
chamber dose measurement were used for defining the cross-calibration (Gain) factor.
As di↵erent spherical phantoms were used in GK centres, it was not possible to per-
form measurements with the PSD in the reference conditions due to the lack of detector
holders compatible with all phantoms. The PSD was therefore calibrated in the NPL
Theratron 60Co beam to acquire suitable calibration factors, which were then applied
to the dose verification measurements performed during the audits.
Two dose verification measurements were performed with the PSD in each audit: one
in the brainstem and one in the target. The raw readings from the two electrometer
channels were converted to dose using the calibration factors and Equation 2.3. Tem-
perature corrections were applied when di↵erences of more than 1  C from calibration
temperatures were observed. The dose measured by the PSD was compared to the
mean dose calculated by the TPS in the PSD contour. The dose measured with the
PSD was also compared to the first alanine pellet that was placed in the same relative
position.
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7.2.10 Alanine measurements
Two sets of four alanine pellets were irradiated in each centre: one in the target and
one in the brainstem. The pellets were kept in their holders at all times during the
audits. The pellets were only handled by the Chemical Dosimetry group at NPL during
preparation and processing of the samples. The phantom temperature before and after
each measurement was recorded and the mean temperature was used to apply the
correction factors. All pellets were returned to NPL and were scanned within 1 month of
the audit visit, ensuring negligible fading as the recommended time frame for scanning
is less than three months post-irradiation. The measured doses were compared to the
mean dose calculated by the TPS for each pellet structure. Alanine was considered
the class detector for the audit measurements, as it is a reliable dosimeter which has
proven its e cacy in small fields, provided by an established dosimetry service based
at NPL.
Chapter 8
Results of the national audit for
stereotactic radiosurgery
8.1 National SRS Audit - Results
The sixteen linac plans assessed adopted di↵erent methods for planning and delivery.
With regards to the beam energy chosen, eight plans used 6 MV, three used 6 MV-SRS
mode, three used 10 MV FFF and two used 6 MV FFF. A range of delivery techniques
was also used: six centres used 3 Non-Coplanar Dynamic Conformal Arcs (NC-DCA),
three centres used 8-9 Non-Coplanar Static Conformal Fields (NC-SCF), three centres
used 3-5 Non-Coplanar VMAT (NC-VMAT), three centres used 1-2 Coplanar VMAT
(C-VMAT) and one centre used 4 Non-Coplanar Circular Collimator Arcs (NC-CCA).
Four di↵erent TPSs with six di↵erent calculation algorithms were used, all of which
employed density heterogeneity corrections. Pencil Beam was the most commonly used
algorithm followed by Collapsed Cone Convolution, Analytical Anisotropy and Monte
Carlo.
In the GK group, five centres were equipped with a Perfexion model and two with
an Icon, all of which use 192 60Co sources. All centres used GammaPlan Version 10
or 11 with the TMR10 algorithm for dose calculation that does not apply density
inhomogeneity corrections. Four centres used CT to generate skin contours and three
used depth helmet measurements. The shot diameters used were comparable for all
centres with the number of isocentres ranging from 16 to 22.
All CK centres were equipped with variations of the CK model 5. They all used the Ray
Tracing dose calculation algorithm with heterogeneity corrections. The same nominal
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beam energy was used by all CKs (6 MV FFF).
The TT centre used a HiART unit to deliver a helical treatment plan. The nominal
beam energy used was 6 MV FFF and the dose was calculated using a Non-Voxel Broad
Beam algorithm.
The prescription doses used across all delivery platforms ranged significantly, from 16
to 21 Gy. The same trend was also observed with the prescription isodose used. Pre-
scription isodoses can be di cult to compare as some TPSs normalise to the isocentre
whereas others normalise to the maximum dose, or the prescription dose. In order to
enable comparisons between all treatment plans, the prescription isodoses described
below are relative to the plan maximum dose. Prescription isodoses ranged from 43-
90%, translated to a range of maximum doses inside the target of 19.9 - 41.7 Gy. The
prescription isodoses used by the di↵erent equipment groups were: for GKs 43-50%,
for 3 out of 4 CKs 65-70% (1 centre prescribed at 53%), for 15 out of 16 linacs 76-90%
(1 centre prescribed at 52%), and for the one TT plan at 87%.
As there was only one centre that used TT in the audit, the findings may not be
representative of a typical TT delivery. Therefore, in order to avoid misrepresentation
of the modality but also to avoid identification of the centre, the TT plan was included
in the linac group for the results that follow and for the rest of this thesis.
Table 8.1 summarises the equipment, techniques and prescription practices of the audit
participants. The centres were grouped by platform in random order, di↵erent to the
order shown in the results.
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No. Platform Energy Technique Coplanar/
Non-Coplanar
Algorithm Heterogeneity
Corr.
Prescription
Dose (Gy)
Prescription
Isodose rel.
to Dmax
(%)
Dmax
(Gy)
1 LB Varian 10 MV FFF Four DCA NC Pencil Beam Yes 21 80 26.4
2 LB Novalis 6 MV Nine SCF NC Pencil Beam Yes 17.5 77 22.7
3 LB Varian 6 MV Four CCA NC Circular Cone Yes 18 76 23.6
4 LB Elekta 6 MV Five VMAT NC Convolution Yes 18 79 22.9
5 LB Novalis 6 MV SRS Eight SCF NC Convolution Yes 18 80 22.4
6 LB Elekta 6 MV Three DCA NC Monte Carlo Yes 18 90 19.9
7 LB Novalis 6 MV SRS Four DCA NC Pencil Beam Yes 18 78 23.1
8 LB Varian 6 MV Four DCA NC Pencil Beam Yes 18 79 22.8
9 LB Elekta 6 MV Five VMAT NC Monte Carlo Yes 21 80 26.3
10 LB Varian 10 MV FFF Two VMAT C AAA Yes 20 86 23.3
11 LB Novalis 6 MV SRS Four DCA NC Pencil Beam Yes 18 78 23.2
12 LB Varian 6 MV FFF One VMAT C AAA Yes 16 80 19.9
13 LB Varian 10 MV FFF One VMAT C AAA Yes 16 79 20.3
14 LB Elekta 6 MV Eight SCF NC Convolution Yes 21 89 23.5
15 LB Varian 6 MV Five DCA NC Pencil Beam Yes 18 79 22.7
16 LB Elekta 6 MV FFF Three VMAT NC Monte Carlo Yes 18 52 34.8
17 TT 6MV FFF Helical Tomo C NVBB Yes 18 87 20.7
18 GK PFX 60Co 21 shots NC TMR10 No 18 43 41.6
19 GK PFX 60Co 17 shots NC TMR10 No 20 50 40.3
20 GK Icon 60Co 20 shots NC TMR10 No 18 49 36.7
21 GK Icon 60Co 16 shots NC TMR10 No 18 50 36.0
22 GK PFX 60Co 16 shots NC TMR10 No 18 46 39.1
23 GK PFX 60Co 18 shots NC TMR10 No 18 43 41.7
24 GK PFX 60Co 22 shots NC TMR10 No 18 43 41.4
25 CK 6MV FFF 138 beams NC RayTracing Yes 21 65 32.3
26 CK 6MV FFF 123 beams NC RayTracing Yes 18 70 25.7
27 CK 6MV FFF 139 beams NC RayTracing Yes 18 53 34.0
28 CK 6MV FFF 109 beams NC RayTracing Yes 20 65 30.8
Table 8.1: Equipment, techniques and prescription practices of centres that participated in the audit.
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8.1.1 Output measurements
The output measurements performed by the centres and the auditors are presented in
Figure 8.1. All measurements from both the auditors and the centres where within
±2.4%, ranging from -1% to 2.4%. The di↵erence between centres and auditors was
0.5% on average with a maximum di↵erence of 1.2%. In all cases the di↵erences seen
between auditor and centre measurements, were within the measurement uncertainties
of the ionisation chambers used.
The linac group had the largest spread in the output measurements performed (3.2%)
ranging from -0.8 to 2.4%. CKs had a smaller spread (1.8%) ranging from -1.0 to 0.8%
and GKs had the smallest spread (1.6%) ranging from -0.9 to 0.7%.
Figure 8.1: Output measurements in local reference conditions for the 28 platforms that
participated in the audit. An uncertainty of ±0.7% (k=1) on the auditors’ measurement
is indicated by the error bars. The “acceptable” tolerances of ±2% are indicated.
8.1.2 EBT-XD film measurements
The passing rates for the criteria used in Section 6.3.3 were recorded, for the green
and red channels (with TCC), with and without dose-linear scaling. A section of the
spreadsheet developed to record and analyse passing rates is shown in Appendix D
with the results for three centres. Due to the large amount of data generated and the
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restricted time for analysis, it was decided that for the purpose of this thesis and for the
audit reports sent to the centres, only results for the conventionally used red channel
(with TCC) would be analysed. The passing rates for two criteria (one LG and one
GG), without dose-linear scaling applied, are shown in this section.
Figure 8.2 and Figure 8.3 show the passing rates for all centres for the criteria of 3% -
2 mm LG and 5% - 1 mm GG respectively.
Figure 8.2: Axial and Sagittal film passing rates for 3% - 2 mm Local Gamma.
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Figure 8.3: Axial and Sagittal film passing rates for 5% - 1 mm Global Gamma.
The results showed comparable passing rates between axial and sagittal films. As
expected, higher passing rates for all films were observed for GG criteria. For the 3%
- 2 mm LG criterion, all but two films showed passing rates above 75%. For the 5% -
1 mm GG criterion, all but 2 films showed passing rates above 90%.
When the regions of interest used for the gamma analysis were reduced to smaller areas
to include the target region only, passing rates improved significantly for all centres,
showing very good agreement between TPS-predicted and delivered dose distributions.
The majority of failed pixels for all films analysed were found to be outside the target,
between the 2 Gy (threshold level) and the 12 Gy isodose line. This is demonstrated
in Figure 8.4, which shows Film-TPS dose di↵erence maps for the axial and sagittal
films irradiated at Centre 1. In this example, the film is measuring higher doses than
predicted by the TPS.
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Figure 8.4: Film-TPS dose di↵erence maps for the axial and sagittal films from Centre
1. The legend indicates percentage dose di↵erences between the two dose distributions.
8.1.3 Exradin W1 measurements
The measurements with the Exradin W1 PSD were compared against the alanine pellet
placed in the same position but were also compared directly to the TPS-predicted dose.
One linac centre was excluded from the analysis due to poorly controlled environmen-
tal conditions in the treatment room which resulted to substantial noise and leakage
currents on the PSD measurement.
When compared to the alanine, PSD measurements in the target were within ±1.9%
for linacs, CKs and TT. The spread of the di↵erences observed was 3.4% (-1.5% to
1.9%). Linac and CK measurements showed spreads of 2.4% and 2.7% respectively.
Much larger percentage di↵erences were observed for target measurements on GKs
with the PSD consistently under-responding in all measurements. The spread of these
di↵erences was 9.5% (-12% to -2.5%). Target dose measurements compared to the
alanine are shown in Figure 8.5.
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Figure 8.5: Plastic scintillator measurements in the target compared to alanine pellet
measurements in the same position within the phantom. The “acceptable” tolerances
of ±3% are indicated.
When PSD measurements were compared directly to the TPS-predicted dose, the dif-
ferences observed doubled in magnitude and were within ±3.8% for linacs, TT and
CKs. The spread of the di↵erences observed for linacs was significantly larger in this
comparison reaching 5.1% (-1.3% to 3.8%). CK and GK measurements showed similar
spreads to those seen in the comparison with alanine, of 2.2% and 9.9% respectively.
PSD measurements in GKs showed the same under-response observed in the compari-
son with alanine. Target dose measurements compared to the TPS-predicted doses are
shown in Figure 8.6.
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Figure 8.6: Plastic scintillator measurements in the target compared to the Treatment
Planning System predicted mean dose for the scintillator contoured structure. The
“acceptable” tolerances of ±3% are indicated.
The measurements performed with the PSD in the OAR showed much larger disagree-
ments in comparison to target measurements. These large disagreements were observed
for both comparisons performed (to the dose measured by alanine and the dose pre-
dicted by the TPS). When compared to the alanine the deviations observed ranged from
-20.7% to 57% and when compared to the TPS they ranged from -16.5% to 70.1%. CK
measurements showed a consistent over-response of 5% to 57% when compared to the
alanine and 12.1% to 70.1% when compared to the TPS. As observed with GK mea-
surements in the target, under-response was seen again in GK measurements in the
OAR with deviations ranging from -17.5% to -3% when compared to alanine, and -11%
to -2.3% when compared to the TPS.
8.1.4 Alanine measurements
Due to steep dose gradients in the distributions delivered in SRS, individual pellet
measurements in the target showed di↵erences of up to 14% when compared to the
TPS-predicted mean dose in their individual contoured pellet structure. These devia-
tions decreased substantially when the measured mean dose for the alanine pellet stack
was compared to the mean dose predicted by the TPS for the whole stack of pellets.
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It was therefore considered appropriate to compare mean doses for all pellets used
in each stack, to account for positional uncertainties that can lead to large percentage
di↵erences between measured and predicted doses. Figure 8.7 shows the percentage dif-
ferences found between the mean dose measured by the 4 pellets in the target compared
to the mean dose predicted for these pellets by the TPS.
Figure 8.7: Alanine pellet measurements performed in the target during the audit.
Platform groups are indicated in the legend. The mean for all centres was 0.7%. The
dotted lines represent one standard deviation of the mean (±1.4%) and the dashed lines
represent two standard deviations of the mean (±2.8%).
Linacs showed the largest spread in percentage di↵erence of 5.2% (from -1.3% to 3.9%)
with a mean of 0.5%. CKs measurements had a spread of 2.6% (from 1.4% to 4%),
much smaller than linacs, with the highest mean di↵erence in comparison to the other
platforms (2.5%). GKs showed the smallest spread at 2.4% (from -0.8% to 1.5%) com-
parable to that of CKs, with the smallest mean percentage di↵erence (0.4%) comparable
to that of linacs.
TPS-predicted doses for the alanine pellets in the OAR ranged from 30 cGy up to 750
cGy. As OAR measurement were performed along a steep dose gradient, any positional
uncertainties may be expressed as large dose di↵erences. Moreover, due to the low
doses delivered by some centres, which were below the calibration threshold of alanine,
measurements had a higher uncertainty due to lower SNRs in the alanine readout. In
order to overcome these problems whilst providing useful information to the audited
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centres, it was decided to normalise the percentage di↵erence between alanine and TPS
to the 12 Gy dose level, a nominal brainstem tolerance dose used by many centres. This
analysis enabled a dosimetric comparison whilst assessing the plan quality in terms of
overdose to the OAR. Figure 8.8 shows the percentage di↵erence between the mean
dose measured by OAR alanine pellets the the TPS-predicted mean dose normalised
to 12 Gy.
Figure 8.8: Alanine pellet measurements performed in the organ at risk during the
audit. Platform groups are indicated in the legend. The mean for all centres was 1.0%.
The dotted lines represent one standard deviation of the mean (±1.2%) and the dashed
lines represent two standard deviations of the mean (±2.4%).
Similar trends were observed in the comparison of OAR alanine pellet measurements
to those observed in target alanine pellet measurements. Linac measurements showed
the largest spread at 4.6% ranging from -1% to 3.6% with a mean of 1.3%. CK mea-
surements ranged between 0% to 1.9% with a mean of 0.9%. GKs had a similar spread
to CKs (2%) ranging from -1.1% to 0.9% but with a lower mean of 0.1%.
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8.2 National SRS Audit - Discussion
During the audit, 28 treatment plans were generated, all for the same realistic patient
scenario of a single metastatic lesion located anterior to the brainstem. The approaches
adopted by the UK SRS practitioners to treat the presented indication di↵ered on many
aspects. Some of these di↵erences, with respect to the equipment, software and delivery
techniques used, were previously identified [179]. Apart from these, probably the most
influential and clinically relevant variation observed in the protocols assessed, was found
in prescription practices. The linac group was found to have the most heterogeneous
practices, compared to some small variations seen in CK practices, and more consistent
practices seen in the GK group. All of the SRS approaches followed in the UK were
assessed in this end-to-end audit.
The measurements performed with alanine pellets and Gafchromic EBT-XD film were
considered the class detectors used in this work. Their use in the 28 SRS plans assessed
enabled the analysis and comparison of all participating centres in terms of the accuracy
achieved during the delivery. It also led to the production of audit reports that were
sent to all participating centres. An example of one of the reports produced is shown
in Appendix E.
The results also enabled the assessment of the PSD system’s performance for dose
verification, via comparison with alanine pellet measurements and direct comparison
with the TPS-predicted dose.
8.2.1 Output measurements
The majority of output measurements were within ±2%, a basic output acceptance
range used by most of the centres visited, as recommended in IPEM 81 [200]. A few
linac centres were operating using a higher acceptance range of ±3% and some GK
centres were operating using a lower acceptance range of ±1%. Three measurements
in total, two performed by the auditor and one by a centre, were above the 2% toler-
ance but less than 2.5%. In all three cases, the comparative measurement performed
in the same conditions was within the 2% tolerance. Since the di↵erences between
comparative measurements of the auditors and the centres were within measurement
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uncertainties, all platforms tested were considered acceptable with regards to absolute
dose in reference conditions.
On average, the auditors’ measurements were 0.5% higher than the measurements per-
formed by the centres. This is partly attributed to the fact that the auditors used a
PTW Semiflex chamber for all output measurements whereas the majority of centres
were using larger ionisation chambers. This could result in di↵erent levels of volume
averaging e↵ects that may lead to a higher output measured by the smaller chamber,
especially in FFF beams where the dose profile presents a small peak in the centre of
the reference field. Evidence for this e↵ect was seen when calculating the mean per-
centage di↵erence between the two sets of measurements, separately for the 15 centres
using flattened beams and the 13 centres using FFF/SRS mode. In the 15 centres with
flattened beams, the mean percentage di↵erence was 0.3%, with mean outputs of 1.001
and 1.004 for centres and auditors respectively. In the 13 centres with FFF/SRS mode
beams, the mean percentage di↵erence doubled to 0.6%, with mean outputs of 1.002
and 1.008 for centres and auditors respectively.
Linac platforms showed a larger spread in output compared to the other platforms. The
reasons contributing to this may be related to the various reference conditions (SSD
and depth) used between linac centres, whereas CKs and GKs use the same reference
conditions within their equipment groups. Other factors contributing to this may be
related to the fact that most linacs tested were versatile, multi-modality platforms,
with more moving components and perhaps more prone to dosimetric uncertainties, as
opposed to single energy platforms like the CK or platforms with stable decaying sources
like the GK. The larger spread may also be partly attributed to the larger linac sample
group participating in the audit. However, it should be noted that the well-documented
Cobalt-60 source output of GKs and their simpler design are probably responsible for
the smaller output deviations seen (better than ±0.9%) in that equipment group.
8.2.2 EBT-XD film measurements
Film measurements were performed in all plans and analysed using red and green TCC
gamma analysis methods. The di↵erences seen in passing rates between red and green
colour channels were on average 2.3%. As both methods showed similar passing rates it
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was decided to adopt the more commonly used red colour channel with TCC. However,
the red channel appeared to be a↵ected by dose-linear scaling corrections more than
the green channel. On the other hand, dose linear scaling did not have a significant
impact on the majority of films assessed and it was therefore decided not to apply this
correction.
The passing rates recorded showed good agreement with the predicted dose distribu-
tions for both sagittal and axial films. All treatment modalities showed comparable
variations in passing rates between the centres assessed and the passing rates alone do
not suggest significant di↵erences between the di↵erent equipment groups. It is impor-
tant to note that gamma index analysis is not ideal for direct comparison between the
SRS deliveries assessed due to di↵erences in dose gradient and maximum dose in the
measured distributions. LG criteria may favour linac centres in which the dose gradient
could be less steep than GK and CK, and GG criteria may favour GK centres in which
the maximum (normalisation) dose is higher. Whilst the methodology for film analysis
was designed to diminish sensitivities to di↵erent dose distributions it is impossible to
achieve this with gamma index analysis. Gamma passing rates are also sensitive to
the position of the film relative to the dose plan, the position of the region of interest
used for the analysis and the 2 Gy threshold levels applied. Further work needs to be
conducted to develop an analysis method that is less sensitive to these dose distribution
di↵erences, enabling a more reliable direct comparison between competing plans.
Despite its pitfalls, the analysis method used enabled quantification of the dose shaping
abilities of all SRS platforms active in the UK. The results showed good performance
by all platforms with noticeable dosimetric di↵erences outside the target volume (See
Figure 8.4). These dosimetric inaccuracies, seen in the majority of centres, are related
to the TPSs limitation in simulating out of field doses and in most cases resulted to
underestimation of doses to the OAR. Nevertheless, the findings of the film results
suggest clinically acceptable dosimetric and geometric accuracies. However, as films
were optimally matched to the TPS dose planes, it may be argued that the results are
not representative of positional uncertainties in the delivery. Due to the steep dose
gradients present in SRS, even small positional deviations can result in high dosimetric
di↵erences that could be detrimental in clinical deliveries. Further analysis with the
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film measurements acquired during the audit will enable assessment of the positional
deviations of all plan deliveries.
8.2.3 Exradin W1 measurements
The Exradin W1 PSD was used for dose verification measurements in all 28 SRS plans.
Two measurements were performed in each plan, one in the target region and one in
the OAR. The performance of the PSD was evaluated by comparison to the alanine
measurements in the same region and by direct comparison to the TPS-predicted dose.
The PSD demonstrated good agreement with both alanine and TPS in target dose
measurements for Linacs and CKs, but showed poor agreement for GKs. The consistent
under-response shown by the detector in GKs is attributed to the di↵erent calibration
procedure performed for these centres. It is perceived that the di↵erence in source
geometry between GKs and the Theratron unit used for calibrating the PSD is the
major contributing factor to the under-response observed. These di↵erences will be
expressed in the Gain factor and further work involving measurements with the PSD
and Semiflex chamber in the GK reference field is needed to confirm this. Another,
smaller, contributing factor in this under-response for GK measurements, is the longer
measurement acquisition time that may contribute to larger (compared to linac and
CK) leakage currents occurring during the course of the measurement. In linacs and
CKs it was possible to calibrate the detector in the treatment beam and acquire accurate
Gain factors for these deliveries. The results demonstrate that the PSD is a suitable
tool for SRS dose verification, within the target volume, for Linac and CK deliveries.
Unexpectedly, much larger disagreements were observed for out-of-field measurements,
when the PSD was placed in the OAR. These are partly attributed to the steep dose
gradient present at the point of measurement and the lower SNRs observed in these
measurements. Despite these, the large disagreements seen cannot be fully attributed to
these factors. The perceived contributing factor is related to the out-of field stem e↵ect
and the CLR correction applied for its removal. The electron energy cut-o↵ threshold
for Cherenkov production in PMMA is approximately 150 keV. It is anticipated that
depending on the location of the PSD in an SRS delivery, during the course of the
measurement, the fibre will be irradiated by varying electron spectra, both in terms
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of angular distribution and energy. This in turn, may cause variations in Cherenkov
production as the proportion of electrons above the 150 keV threshold can vary signif-
icantly during the course of the measurement. It is therefore hypothesised that as the
fibre is moved further away from the target, into the OAR, the Cherenkov production
in the PMMA optical fibre (stem of PSD) will be significantly di↵erent and di cult to
predict. Considering the above, it is clear that a constant CLR factor for the removal
of stem signal is inadequate for acquiring accurate out-of-field measurements using the
chromatic removal method. Further work focusing on the development of improved
instrumentation for PSDs will enable the reduction or complete removal of Cherenkov
“noise” contributions.
8.2.4 Alanine measurements
The mean dose measured by each set of alanine pellets was compared to the TPS-
predicted dose in the target and OAR. Good overall agreement with the TPS was
observed with three centres falling outside (above) two standard deviations of the mean
(two centres in the target dose measurements and one in the OAR measurements).
Linacs showed the largest spread in comparison to GKs and CKs. This is not surprising
considering that the CK and GK centres visited had almost identical equipment, soft-
ware and prescription practices within their sub-groups. On the other hand, the linac
centres visited used a range of beam energies, delivery techniques, TPSs calculation
algorithms and prescription practices. Linac practices appear to be influenced by the
equipment and software available, clinician preferences and influences from the local
radiotherapy practices.
CK measurements in the target, showed that the TPS (Multiplan) under-estimated
the dose in all four centres visited. This finding is in agreement with another study
utilising the same alanine service for target dose measurements in CK plans [111].
Interestingly, one CK centre (centre number 8) prescribed at a much lower prescription
isodose (53%) than the other CK centres (65-70%), due to the clinician’s preference
who had previous GK experience. The alanine measurements in the target were found
to have a percentage di↵erence to the TPS that was 2% higher than the mean of the
other 3 CK centres. This may be related to MultiPlan’s limitations in calculating the
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dose when lower prescription isodoses are chosen, but more investigations are required
to verify this.
Alanine measurements in GK centres showed good agreement with the TPS (Gamma-
Plan). This was somewhat unexpected as the GammaPlan algorithm (TMR10) does
not take into account density inhomogeneities and assumes water density within the
skull contour. Moreover, the patient (skull) contour can be less accurate in comparison
to other SRS practices as it may be generated by interpolating between multiple depth
helmet measurements. A recent study [201] investigated the GammaPlan convolution
algorithm (employs density heterogeneity corrections) for 50 clinical plans by assessing
the change in beam-on time. Their results showed a 6% di↵erence between the two
algorithms, with the TMR10 having lower beam-on times. This study also found that
about 1.5% was attributed to depth helmet measurements. On the contrary, the re-
sults of this work suggest that these factors do not contribute significantly to dosimetric
inaccuracies. Further work investigating the GammaPlan convolution algorithm using
the audit methodology can provide conclusive evidence to understand the discrepancies
seen between these two studies.
Despite the lower SNRs observed in the OAR measurements the results showed good
agreement with the TPS. All pellets measured doses below 7.5 Gy and 86% of pellets
measured doses below 5 Gy. The majority of pellets were therefore exposed to dose
levels below the acceptable level previously operated by the NPL Chemical dosimetry
service. The Chemical dosimetry group performed additional measurements at lower
doses to extend the calibration range to lower doses. The results of the audit suggest
that reliable alanine measurements can be performed in clinical plans at out-of-field
dose levels below 5 Gy.
Finally, it should be noted that the mean and standard deviations indicated in Fig-
ures 8.7 and 8.8 are statistical tools used to describe and compare the distribution of
the data and should not be interpreted as clinically acceptable tolerances.
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8.3 National SRS Audit - Conclusions
This national SRS audit has provided a means of comparison between all UK SRS
practices for the same realistic patient scenario whilst enabling assessment of three
detector systems in SRS dosimetry. The results provide a useful record of detector
performance in SRS that can be utilised to optimise these systems further for plan dose
verification. As far as the audit results are concerned, the dosimetric performance of all
centres is considered clinically acceptable, despite the tendency for poorer agreement
observed in the low dose regions. However, concerns are raised regarding the variations
seen in clinical practice. These variations are more prominent in the linac subgroup
which raises the need for steps to be taken towards standardisation and consensus.
Chapter 9
Conclusions and Further Work
9.1 Conclusions
With reference to the initial objectives defined in Section 1.6, this thesis has shown
the investigations conducted to identify and understand current SRS practices in the
UK. These investigations helped to develop a better understanding of the complexities
involved in performing accurate dosimetry in clinical SRS plans. Subsequently, novel
detector systems were characterised and tested for suitability in SRS dosimetry. These
were then incorporated into the development of a novel methodology for the end-to-
end assessment of stereotactic radiosurgery. The methods adopted showed consistency
and reliability to a large extent, but areas of improvement and optimisation in their
performance were also identified. The methods were used to evaluate SRS practices
in the UK and have provided a snapshot of their dosimetric and geometric accuracy.
Areas of standardisation in SRS have been identified through the course of this work
and they are outlined in this chapter.
9.1.1 Dosimetric accuracy
Dosimetric di↵erences of up to 4% of the TPS-predicted dose have been observed in
the target region and even larger di↵erences have been observed outside the target.
These results have been corrected for output variations of the delivery unit, but if
these corrections are not applied the deviations would, in some instances, be slightly
larger. The need for stringent quality assurance procedures to ensure consistency in
clinical deliveries is therefore highlighted. However, on a national scale, the clinical
impact of the dosimetric di↵erences observed in the audit is more than likely negligible.
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Considering the variations seen in prescription dose and prescription isodose, the dose
delivered to patient is subject to much larger di↵erences depending on the protocol
used for treatment. As mentioned previously in Section 8.1, prescription doses for the
presented indication varied from 16 to 21 Gy and maximum doses inside the target
varied from 19.9 to 41.7 Gy. This range is translated to di↵erences of up to 24% in
prescription dose and up to 52% in maximum dose. Therefore, the need for more
consistent prescription practices is also highlighted.
9.1.2 Geometric accuracy
The dose distribution shaping abilities of all SRS systems in the UK were also tested
and their performance has been quantified. Geometric accuracy is imperative in SRS,
and arguably more important than dosimetric accuracy. Due to the steep dose gradients
inherent to radiosurgical deliveries, a small geometric inaccuracy may result in signif-
icant under-dose to the target or significant over-dose to an OAR. This is extremely
important in clinical cases where OARs are abutting or even surrounding the target
volume. The results of this work showed that all centres were able to achieve accept-
able agreement between predicted and delivered dose distributions. Nevertheless, the
positional accuracy of the dose distributions measured was not thoroughly assessed in
this work and would benefit from further analysis. Moreover, the evaluation methods
that were available for this analysis are sensitive to the dosimetric di↵erences between
the deliveries. Therefore, a direct comparison of the geometric accuracy of competing
platforms was not possible.
9.1.3 Treatment Plan Quality
The collection of treatment plans generated by the centres that participated in the
audit was assessed by various plan metrics1. Another similar study was performed by
the RTTQA group, in which centres were asked to submit a treatment plan for six
di↵erent clinical scenarios. Both these studies showed that there were large variations
in conformity and dose fall-o↵ outside the target for the treatment plans assessed.
The di↵erences observed are related to the techniques and prescription practices used.
1This work was performed by Shaik M Usman Ghouse Mohiuddin as part of his MSc dissertation.
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There are currently no universal guidelines for acceptable treatment plan quality in
radiosurgery and their importance is emphasised by the large variations observed.
Another major variation in radiosurgery planning practice is the use of a margin around
the treatment volume to account for treatment uncertainties. This practice is typically
not followed by GK radiosurgery centres but is common in linac-based radiosurgery. In
this work, the use of margins was not assessed, in an attempt to produce comparable
treatment plans by all participating centres. However, these di↵erences should be
investigated further with the aim of achieving standardised practise.
9.1.4 Biologically E↵ective Dose
The concept of Biologically E↵ective Dose (BED) was proposed in 1989 and has since
then been extensively used in fractionated radiotherapy studies [202]. This concept was
quickly adopted in radiosurgery [203] but has not received as much attention since then.
BEDs in radiosurgery are susceptible to di↵erent influences, including the technique
used and the length of the delivery [204].
In the scenario presented in the audit, both the techniques and length of treatments
varied significantly. The quickest delivery was performed using a single VMAT arc that
was delivered in less than 2 minutes and the longest treatment was a 12 shot GK plan
that took over 2 hours to deliver. The di↵erences in BED between these two treatments
are not fully appreciated and they are currently not considered at all in clinical practice.
BED variations should receive more attention to allow their introduction into the clinic
in order to optimise treatments and achieve better outcomes.
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9.2 Further work
9.2.1 Dosimetric accuracy
It is essential that future trials steer their focus on developing more consistent prescrip-
tion practices for the management of brain metastasis using stereotactic radiosurgery.
This should develop a cohesive national approach that would make it possible to com-
pare patient outcomes and enable optimisation of SRS treatments. This, in combination
with reliable clinical deliveries, could guarantee improvements in tumour control and
complications for patients receiving SRS.
9.2.2 Geometric accuracy
Due to inherent di↵erences in the coordinate systems between treatment platforms and
compatibility issues with some TPSs it was not possible to assess positional deviations
in the delivered isodoses. Further work in the development of a stand-alone software
could enable this assessment and provide valuable comparisons between the di↵erent
delivery platforms. This work may also provide an assessment of the accuracy of various
immobilisation devices. As these film measurements were performed in a phantom,
patient variations can be factored out, and the results will be representative of the
accuracy associated with the immobilisation and delivery equipment.
9.2.3 Dosimetry systems
This thesis has presented the use of three di↵erent dosimetry systems for dose verifi-
cation. The detectors demonstrated suitability for SRS measurements and were used
to perform semi-3D plan dose verification. Furthermore, two detectors of di↵erent ge-
ometries, alanine and scintillator, were used interchangeably to allow comparisons of
the absolute dose measured in clinical plan deliveries.
Alanine dosimetry was found to be a suitable reference dosimeter for audit purposes
with reliable performance, not only for measurements above 10 Gy, but also for mea-
surements in the region of 2 - 10 Gy. With further optimisation and automation in the
labour intensive read-out process, alanine will become even closer to the ideal dosimetry
system.
9.2. Further work 148
EBT-XD film was found to be an excellent dosimeter for the assessment of high-dose and
steep-gradient dose distributions seen in SRS. The less commonly used green channel
produced results comparable to the red channel method. However, the green channel
appeared to be less susceptible to post-irradiation darkening and should be investigated
further as it may present a favourable method for audit or postal dosimetry where
consistent scanning times are not always possible.
The film analysis revealed weaknesses in the local and global (maximum) gamma index
method for comparing the performance of competing plans with di↵erent dose-gradients
and maximum doses. Alternative analysis methods may allow more meaningful com-
parisons. For example, global gamma analysis normalised to the prescription dose
should be less susceptible to di↵erences in maximum dose. Also, as mentioned pre-
viously, the positional accuracy of dose distributions was not fully assessed with the
analysis method in place. Further work should be conducted to develop a stand-alone
method purposed to assess the positional deviation of an SRS delivery.
The Exradin W1 plastic scintillator performed reliable measurements inside the target
volume but requires refinement to improve its performance both inside and outside the
target. Key objectives in its refinement should be focused on developing less sensitive
electronics and improving the Cherenkov removal methods. The main limitation of
the chromatic removal method used in this work is that it assumes constant CLR and
Gain factors during a clinical delivery, which is not the case in most SRS deliveries.
There are however, some promising approaches for removing Cherenkov noise more
e ciently. One of these relies on using red emitting scintillators to further separate the
two spectra and achieve a more e cient chromatic removal at the expense of detector
water-equivalence [205]. The development of water-equivalent red emitting scintilla-
tors may have an important role to play in scintillation dosimetry. Other promising
approaches in removing Cherenkov noise rely on multiple photodiodes, CCDs or spec-
trometers to perform multi-spectral and hyper-spectral analysis of the light emitted by
scintillation systems [206]. Such approaches will produce more accurate measurements
in clinical deliveries where varying levels of Cherenkov and scintillation are emitted in
the course of a measurement.
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During the audits conducted, TLD measurements of the dose to the eyes of the phantom
were also performed. These were performed using a 3D-printed plastic goggle-shaped
insert. The insert was manufactured to accommodate small plastic TLD holders with
three types of TLDs: Ge-doped optical fibres, glass beads and Lithium Fluoride (TL-
100). The goal of this study is to compare the performance these TLDs in the mea-
surement of typical lens doses from CT scans and SRS treatments. Further work in
analysing these TLD measurements will provide evidence of the typical doses received
during these procedures.
9.2.4 Standardisation in SRS
SRS practice in the UK, at its current state, would benefit from standardisation. The
initial focus of this standardisation should be aimed at prescription doses and prescrip-
tion isodoses. These need to be more cohesive in order to facilitate clinical trials for
producing consistent data, allowing the investigation of treatment e↵ectiveness through
patient outcomes.
As practice variations are more prominent in the linac subgroup, it would be beneficial
if standardisation was introduced in this group first. In the audit conducted, there have
been examples of CK and linac centres following GK inspired practices. This is indica-
tive of other equipment subgroups acknowledging value in GK planning practices. Out
of 28 centres, only 4 used a prescription isodose above 80%. It is now widely acceptable
that dose homogeneity within the target is not essential for radiosurgery and there is
no evidence to suggest that it is unsafe. Therefore, a reasonable and e↵ective point of
standardisation, ideally introduced immediately, would be to limit centres in only using
prescription isodoses between 40-80% of the maximum dose. This should be followed
up closely and subject to further revision, possibly in narrowing the range to 40-60%.
The recommendations should also allow for deviations from this practice when a target
volume is small (below 0.5 cm3) where a steep dose gradient is not achievable or even
important. Such an introduction should show improvements in normal tissue toxic-
ity whist steering towards consistent prescription practices. Subsequently, prescription
doses can be revised to produce recommendations for appropriate clinical protocols.
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Treatment plan quality is another area of SRS that would benefit from standardisa-
tion. This is mainly assessed by target conformity and dose gradient outside the target,
both of which can be scored using various indices [85, 86, 198, 207, 208]. There are also
a number of treatment planning parameters (volume of 12 Gy and 10 Gy) that have
shown correlation with patient complications and can be used as prognostic factors or
thresholds for improving treatment plan quality [209, 210]. It was noted that only 4
out of 28 centres that participated in the audit used coplanar delivery techniques. It is
anticipated that centres are utilising non-coplanar deliveries to benefit from improve-
ments in conformity, gradient and reduction in the volume of 10 and 12 Gy. Therefore
another appropriate step for standardisation would be to restrict the use of coplanar
SRS. There are currently no SRS-specific guidelines in the UK recommending mini-
mum acceptable plan quality. Following the recent commissioning of SRS provision in
England, it is now an appropriate time to develop such documentation to ensure high
quality treatments throughout the country. This e↵ort would also be supported with
the development of plan quality indices that are intuitive and practical for all subgroups
to calculate.
Treatment margins have not been assessed in this study and the results would have been
more di cult to interpret if this variable was included. Their clinical impact on treat-
ment e↵ectiveness and treatment complications in SRS is still questioned and should
be examined further. However, this assessment will not be possible if the variations
outlined above are not tackled first.
Finally, another variable in SRS practice is treatment technique and the length of
treatments, which both have a significant impact on the BED. Further work should be
undertaken in radio-biological experiments and modelling to understand how these fac-
tors impact treatment e↵ectiveness. Moreover, once treatment practices become more
consistent, patient data could be analysed retrospectively to determine correlations be-
tween BED and patient outcomes. The lessons learned from these studies should then
be translated to the clinical environment for further optimisation of SRS treatments.
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9.3 Closing remarks
Improvements in dosimetry systems, dose verification methods, audit and QA will
increase the confidence of the medical physics community in delivering highly focused
radiation treatments. These e↵orts will be in vain if they are not accompanied by
e↵orts for achieving consistent prescription practices, consistent planning philosophies,
consistent treatment plan quality, consensus with regards to treatment margins and
BED-optimised treatments. However, if these e↵orts are synergistic, the next human
generation will witness extraordinary cure rates with negligible complications, not only
for malignancy but also for benign tumours, functional disorders using radiosurgical
lesioning or thalamotomy, even mental disorders using psycho-radiosurgery.
‘„n o⁄da Ìti oŒd‡n o⁄da’
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Appendix A
Questions included in the survey
questionnaire (Section 3.2)
• 1. What is your centre’s experience with Cranial Stereotactic Radiosurgery?
• 2. Estimate how many Cranial SRS patients your centre has treated
• 3. State the number of machines in your centre used clinically for SRS
• 4. What make and model are the machines that you use for Cranial SRS?
• 5. Estimate on average how many new Cranial SRS patients your centre treats
each month
• 6. Does your centre wish to expand its current SRS program in the future?
• 7. Does your centre limit the number of new Intracranial SRS cases starting each
week/month?
• 8. Which technique for Cranial SRS does your centre perform? (multiple answers
permitted)
• 9. Which photon energies are you using for Cranial SRS?
• 10. Do you use flattening filter free beams for SRS clinically at present?
• 11. Are you using any of the following beam collimating systems? (list of options
available)
• 12. On average, how long does it take to complete the delivery of a Cranial SRS
patient treatment? (Time from the point the patient lies on the treatment couch
to the point he/she sits up)
• 13. For the pathologies listed below, please select the number of cases you treat
per month for each indication
• 14. Which imaging modalities are used for Outlining?
• 15. Which imaging modalities are used for Planning?
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• 16. Which software package do you use for volume delineation / outlining?
• 17. Which tissues are normally outlined?
• 18. On average, how long does it take to delineate all the necessary structures
for planning?
• 19. Which Treatment Planning System (TPS) and which algorithms do you use
for SRS planning?
• 20. On average, how long does it take to complete a plan for SRS?
• 21. What is the most common isodose distribution that you prescribe to?
• 22. How often are patient-specific QA measurements performed for SRS?
• 23. If patient-specific QA measurements are not performed regularly, please state
primary reasons for this
• 24. If patient-specific QA measurements were reduced after being performed for
every plan, after how many plans did you decide to reduce the workload?
• 25. Do you use any phantom(s) for measurement-based verification/QA of Cranial
SRS?
• 26. Do you use any detector(s) for Cranial SRS verification?
• 27. On average, how long does it take to complete your measurement-based
verification/QA procedure?
• 28. Which immobilisation systems do you have in place for Cranial SRS?
• 29. Do you use any pre-treatment imaging for localisation?
• 30. Do you use any imaging during treatment (between fields) for localisation?
• 31. What is the action level below which setup accuracy would be considered
acceptable?
Appendix B
Protocol followed for film
handling and scanning
• 1. Prepare a clean surface and wear latex gloves. It is important to keep films
clean, dust-free, scratch-free and avoid bending it. Keep films in a controlled
environment at room temperatures and low moisture.
• 2. Prepare a black light-tight envelope for placing the film inside after cutting it.
It is important to minimise exposure to ambient light.
• 3. Take a sheet (25.4 x 20.3 cm) of EBT-XD film out of the packet and measure
the piece you would like to cut. Ensure that the maximum width of the film is
less than 6 cm.(Note: the orientation used for calibration, had the long side of the
film sheet parallel to the scanning direction - ensure that all film samples follow
this orientation too).
• 4. Using a thin permanent marker, mark dotted lines along the edges of the
sample that will be cut and use a guillotine or sharp scissors to cut the film in
order to avoid delamination along the edges.
• 5. Avoid placing films on top of each other as they can cause scratches. If more
than one samples are placed in an envelope, use a piece of paper to separating
them and minimise friction between them.
• 6. When setting up films for irradiation avoid friction between films and phan-
toms. Any film not intended for irradiation must be kept outside the bunker and
away from scatter radiation.
• 7.After irradiation, place films in the light-tight envelope and store in a safe
location at standard room temperatures. Allow 72 hours for post-irradiation
darkening to occur.
• 8. Before scanning the film, switch on the scanner and allow at least ten minutes
for it to acclimatise. Perform 5 warm-up scans at 96dpi for the full length of
the scanner. Scan the films within a few minutes of the warm-up scans. If the
scanner has been idle for a long time perform warm-up scans again.
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• 9. Place the positioning jig on the scanner bed and align it with the markings on
the scanner axis.
• 10. Thoroughly clean the scanner bed to remove any dust. Clean the test films
and glass compression plate too.
• 11. Position test films within the frame of the positioning jig and in the centre
of the scanner. Rest the compression plate above the film and check that it has
not moved and that it is flat against the scanner.
• 12. Close the scanner lid and perform a preview scan. Select a rectangular
scanning area aligned with the edges of the film.
• 13. The scanner should be in transmission mode, the resolution should be 96 dpi,
colour and sharpness corrections should be deactivated and the image should be
saved in 48 bit ti↵ format.
Appendix C
Contouring for SRS audit
Figure C.1: Diagram with schematic representation of contoured structures required
for audit
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Appendix D
Film analysis results for three
centres
Figure D.1: Gamma passing rates recorded for three centres
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Appendix E
Example of an Audit Report
Figure E.1: Example of an Audit report - Page 1 of 8.
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Figure E.2: Example of an Audit report - Page 2 of 8.
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Figure E.3: Example of an Audit report - Page 3 of 8.
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Figure E.4: Example of an Audit report - Page 4 of 8.
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Figure E.5: Example of an Audit report - Page 5 of 8.
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Figure E.6: Example of an Audit report - Page 6 of 8.
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Figure E.7: Example of an Audit report - Page 7 of 8.
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Figure E.8: Example of an Audit report - Page 8 of 8.
Appendix F
Published abstracts
F.1 Journal publications
A. Dimitriadis, K. J. Kirkby, A. Nisbet, and C. H. Clark, “Current status of cranial
stereotactic radiosurgery in the UK” The British journal of radiology,vol. 89, no.
1058, p. 20150452, 2016
Objective: To investigate and benchmark the current clinical and dosimetric practices
in stereotactic radiosurgery (SRS) in the UK.
Methods: A detailed questionnaire was sent to 70 radiotherapy centres in the UK.
97% (68/70) of centres replied between June and December 2014.
Results: 21 centres stated that they are practising SRS and a further 12 centres plan
to start SRS by the end of 2016. The most commonly treated indications are brain
metastases and acoustic neuromas. A large range of prescription isodoses that range
from 45% to 100% between di↵erent radiotherapy centres was seen. Ionisation chambers
and solid water phantoms are used by the majority of centres for patient-specific quality
assurance and thermoplastic masks for patient immobilisation are more commonly used
than fixed stereotactic frames. The majority of centres perform orthogonal kV X-rays
for localisation before and during delivery. The acceptable set-up accuracy reported
ranges from 0.1 - 2 mm with a mean of 0.8 mm.
Conclusion: SRS has been increasing in use in the UK and will continue to increase
in the next two years. There is no current consensus between SRS centres as a whole,
or even between SRS centres with the same equipment, on the practices followed. This
indicates the need for benchmarking and standardisation in SRS practices within the
UK.
Advances in knowledge: This article outlines the current practices in SRS and pro-
vides a benchmark for reference and comparison with future research in this technique.
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A. L. Palmer, A. Dimitriadis, A. Nisbet, and C. H. Clark, “Evaluation of Gafchromic
EBT-XD film, with comparison to EBT3 film, and application in high dose
radiotherapy verification” Physics in Medicine and Biology, vol. 60,no. 22, pp.
8741–8752, 2015
Abstract: There is renewed interest in film dosimetry for the verification of dose de-
livery of complex treatments, particularly small fields, compared to treatment planning
system calculations. A new radiochromic film, Gafchromic EBT-XD, is available for
high-dose treatment verification and we present the first published evaluation of its use.
We evaluate the new film for MV photon dosimetry, including calibration curves, per-
formance with single- and triple-channel dosimetry, and comparison to existing EBT3
film. In the verification of a typical 25 Gy stereotactic radiotherapy (SRS) treatment,
compared to TPS planned dose distribution, excellent agreement was seen with EBT-
XD using triple-channel dosimetry, in isodose overlay, maximum 1.0 mm di↵erence over
200–2400 cGy, and gamma evaluation, mean passing rate 97% at 3% locally-normalised,
1.5 mm criteria. In comparison to EBT3, EBT-XD gave improved evaluation results
for the SRS-plan, had improved calibration curve gradients at high doses, and had
reduced lateral scanner e↵ect. The dimensions of the two films are identical. The op-
tical density of EBT-XD is lower than EBT3 for the same dose. The e↵ective atomic
number for both may be considered water-equivalent in MV radiotherapy. We have
validated the use of EBT-XD for high-dose, small-field radiotherapy, for routine QC
and a forthcoming multi-centre SRS dosimetry intercomparison.
A. Dimitriadis, A.L. Palmer, R.A.S. Thomas, K. Kirkby, A. Nisbet, C.H. Clark, “Adap-
tation and validation of a commercial phantom for cranial radiosurgery
dosimetry audit” British Journal of Radiology (Under review)
Abstract: Anthropomorphic phantoms are considered ideal for performing quality
assurance procedures in radiotherapy as they are more representative of patient-like
conditions. In this work we present the adaptation and validation of a commercial
anthropomorphic head phantom to be used for cranial radiosurgery audit. Two bespoke
inserts were designed and produced for the phantom: one for providing the target and
organ at risk for delineation and one for performing dose measurements. Each insert
showed reproducible positioning within 0.5 mm and the positional agreement between
the two inserts was within 0.6 mm. An initial basic treatment plan dose verification
with a PTW Semiflex ionisation chamber showed agreement to the TPS within 0.5%.
The phantom and inserts were then used to perform dose verification measurements of
a 7-field IMRT linac radiosurgery plan, delivered by a Varian TrueBeam with 10FFF
beam energy. The dose was measured with alanine pellets, EBT-XD Gafchromic film
and the Exradin W1 plastic scintillation detector (PSD). Repeated film measurements
showed consistent results for all gamma passing criteria investigated with very good
agreement to the treatment planning system (TPS). For 2%-2mm global gamma the
mean passing rate was 96.7% and the variation in passing rates did not exceed 2.1%.
The alanine pellets and PSD showed good agreement with TPS predicted doses (-0.1
and 0.3% dose di↵erence in the target). Good agreement was also observed between the
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two dose detection systems (within 1%). The results demonstrated that the presence
of the alanine and PSD does not a↵ect the film measurement significantly, enabling
simultaneous use of all three detectors and allowing a more e cient audit method.
The developed methods presented in this study provide a thorough end-to-end test for
stereotactic radiosurgery, with capability to incorporate all steps of the clinical pathway
in a time-e cient and reproducible manner, making it suitable for a national audit.
A. Dimitriadis, I. Silvestre Patallo, I. Billas, S. Duane, A. Nisbet, C. H. Clark, “Char-
acterisation of a plastic scintillation detector to be used in a multicentre
stereotactic radiosurgery audit” Journal of Radiation Physics and Chemistry,
ICDA2 Special Edition, 2017.
Abstract: Scintillation detectors are considered ideal for dosimetric measurement of
small fields in radiotherapy due to their near-tissue equivalence and their small sizes. A
commercially available detector, the Exradin W1 (Standard Imaging, Middleton, USA),
was previously characterised by two independent studies (Beierholm et al., 2014; Car-
rasco et al., 2015) and the results from these publications di↵ered in some aspects (e.g.
energy dependence, long term stability). The authors highlighted the need for more
studies to be published (Beierholm et al., 2015; Carrasco et al., 2015). In this work,
the Exradin W1 was characterised in terms of response to dose, dependence on dose
rate, energy, temperature, angle of irradiation and long-term stability. The dose linear-
ity, short-term repeatability, temperature dependence and energy dependence observed
were in good agreement with published data, and corrections should be applied where
possible in order to achieve low-uncertainty measurements. The angular dependence
was characterised along the symmetry and polar axis of the detector for the first time
and little dependence was observed, up to 1%. The long-term stability of the detector
was observed to decrease at a rate of approximately 1.6% kGy-1 of exposure for the
first 5 kGy recorded, but improved to a more manageable rate of 0.2% kGy-1 in the
subsequent 20 kGy. The main goal of this dosimetric characterisation, was to assess
the suitability of the Exradin W1 for its application to dose verification measurements
in stereotactic radiosurgery. The results confirm that the detector is suitable for use in
such situations. With the application of appropriate correction factors, the detector is
now utilized in a multi-centre stereotactic radiosurgery dosimetric audit.
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I. Silvestre Patallo, A. Dimitriadis and A. Subiel. “Relative output factors for
TPS beam data acquisition with emphasis on small fields. Comparison of
multiple detectors and multiple approaches”, in Conference Proceedings - 7th
Latin American Congress of Medical Physics, (Cordoba, Argentina), 2016
Abstract: Small field dosimetry is a developing area of research with a substantial
number of studies published so far. Corrections to direct output factors (OF) mea-
surements could be considered machine-specific for each beam quality and detector
combination. Several groups are currently working on dosimetric protocols for small
fields. It is, therefore however, possible for individual institutions to establish their
own procedures, based on their experience and the equipment available. As part of
Pinnacle commissioning, a practical approach for OF determination for small fields
(from 3 x 3 down to 0.5 x 0.5 cm2) using the Daisy chain was investigated. Field
size and detector specific correction factors were also experimentally determined. The
Exradin W1 plastic scintillator was selected as class detector. The two methodologies
were compared. NPL-Elekta linac is a Versa-HD with an Agility MLC, enabling de-
livery of flattened (FF) and unflatenned (FFF) beams. Measurements were performed
for 6 MV FF, 10 MV FF, 6 MV FFF, and 10 MV FFF. Field sizes from 0.5 x 0.5 to
40 x 40 cm2 were organized in a Stored Beam Sequence. Three solid-state detectors
(IBA SFD diode, PTW E diode 60012 and Exradin W1 scintillator) together with four
ionization chambers (PTW 30013 Farmer, 31010 Semiflex, IBA CC13 and Exradin A26
micro chamber) and EBT-XD films were employed in this study. IBA Blue phantom
with OmniPro-Accept was used to position the detectors precisely at the centre of the
radiation field. Films were analysed using OmniPro-IMRT and Verisoft. The detectors
were used with a Dose 1 electrometer except for the W1 detector, where a Super-
Max electrometer was employed. CAX analysis of 6 MV FFF profiles for small fields
(for four di↵erent detectors) showed a consistent averaged crossline deviation of 1.15
mm. Two di↵erent approaches of profile analysis for FFF beams in OmniPro-Accept
((i) field width at 50% and (ii) at maximum slope), were compared with film based
measured E↵ective Field Sizes (FSe↵). Average di↵erence between FSe↵ was larger
using maximum slope definition by -0.81 - 0.07 mm (across all fields, both diodes and
FFF beams). Daisy chained OFs with the two diodes were on average 1.3% larger
in comparison to the OFs calculated using the specific correction factors. The use of
correction factors reduces di↵erence in OFs obtained for the two diodes (from -0.61%
to -0.1%). An overall uncertainty of 0.9% was determined for diodes’ specific correction
factors, based on W1 as class detector. OFs for small fields were characterised with
two available diodes and a micro ionisation chamber. Two experimental approaches
were compared. The study provided a comprehensive set of OFs, which are used as
baseline for linac quality assurance (QA) and Pinnacle commissioning. Additionally,
the measured OFs are of high importance as a guidance for the beam data acquisition
service and for comparison with measurements carried out for other linacs in similar
conditions. Further investigation is needed to evaluate the influence of small fields OFs
in Pinnacle models.
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Dimitriadis A, Kirkby K J, Nisbet A and Clark C H (2015) EP-1578: “Current
practice of cranial stereotactic radiosurgery (CSRS) in the UK” Radiother.
Oncol.115 S863
Purpose: To examine the UK’s current practices in CSRS
Methods: A questionnaire, designed to include Gamma Knife (GK), Cyberknife (CK),
Linac-Based (LB) and TomoTherapy (TT), was sent to 70 radiotherapy and radio-
surgery centres in the UK between June and November 2014.
Results: 87.1% (61/70) of centres responded. Of these, 32.8% (20/61) were performing
CSRS, 8.2% (5/61) are in the process of implementing CSRS and are planning to be
clinical by August 2015 and 8.2% (5/61) are planning to implement CSRS by October
2016. The remaining 50.8% (31/61) are not performing CSRS and do not plan to
implement it before October 2016. 25% (5/20) treat up to 4 patients per month, 45%
(9/20) treat 5-15 patients per month and 30% (6/20) treat more than 16 patients per
month. There are 29 machines used for CSRS in the country (14 LB, 6 CK, 7 GK and
1 TT) but they are not all dedicated to CSRS. The most commonly used techniques are
non-coplanar static fields (used by 85% of centres), non-coplanar dynamic conformal
arcs (20%) and circular collimator arcs (20%). 70% are using 6MV photons and 30%
using Cobalt-60 (⇡1.25MV). A range of imaging modalities is used for outlining: Fused
CT&MR (70%), MR (60%), CT (50%), Angiogram (45%), PET (20%) and Fused
CT&PET (10%). A large range of answers were given for the most common prescription
isodose. Two peaks were seen: 20% (4/20) usually prescribe to the 45-50% isodose,
20% (4/20) to the 80-85% isodose, with the remaining centres prescribing between
these 2 groups and up to the 95-100% isodose. Patient specific QA measurements are
performed on every plan by 35% (7/20) and 65% (13/20) decreased the measurements
taken after 10-25 plans. The results show a wide range of detectors and phantoms
being used for QA measurements. The most common treatment sites are solitary and
multiple brain metastases, followed by acoustic neuromas, meningiomas and AVMs.
The majority of centres (70%) stated that treatment delivery usually takes less than 1
hour. The results show that pre-treatment and during-treatment imaging is used in the
majority of CK and LB treatments but not used at all in GK. When asked for a figure
of acceptable setup accuracy, 50% stated sub-millimetre accuracies with the remaining
ranging from 1-2mm.
Conclusions: The number of centres delivering CSRS is increasing and will continue
to increase in the next 2-3 years. This is particularly the case with LB radiosurgery.
Most centres are aiming to expand their service to treat more indications and more
patients. There is a wide variety of planning procedures, QA methods, prescription
protocols and delivery practices despite the fact that the indications treated by all
centres are comparable.
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A. Dimitriadis, L. Archambault, C. H. Clark, and H. Bouchard, “Modelling the
energy dependence of cherenkov light in plastic scintillation detectors” Ra-
diotherapy and Oncology, vol. 119, no. 1, pp. 7167, 2016
Purpose/objectives: Plastic scintillation detectors (PSD) are highly valuable for
a variety of dosimetry applications, since their atomic composition and volume size
produce small perturbation e↵ects. A commercial PSD provided by Standard Imaging
Inc (Exradin W1) is available and its Cherenkov light correction is based on the method
proposed by Guillot et al. However, recent studies showed that the Cherenkov light ratio
(CLR) is energy dependent, which could compromise its performance in clinical photon
beams. The goal of this work is to investigate a theoretical model to characterise the
energy dependence of the CLR and evaluate its e↵ect on photon beam measurements.
Materials/Methods: The electron energy cut-o↵ at which Cherenkov light is pro-
duced varies with the wavelength-dependent refractive index. Based on this rationale,
the theoretical CLR, describing the relative amount of blue to green light, is formalised
analytically using the Cherenkov emission distribution and the detection e ciency func-
tions of the blue and green channels. As the analytic expression depends on the electron
spectrum, Monte Carlo simulations of several photon beam qualities are performed to
evaluate the spectrum. This allows predicting the theoretical CLR as a function of the
TPR2010 quality index (QI), which includes cobalt-60 and mega-voltage (MV) beams.
Experiments are performed to evaluate CLR over a wide range of QI in cobalt-60 and
clinical MV beams.
Results: Comparison between experiments and theory show that the model reproduces
the behaviour of the CLR energy dependence. However, the model under predicts the
magnitude of the e↵ect. For clinical MV beams, the variation of the theoretical CLR
is about 0.5% while it is found to be about 1.8% with experiments. For cobalt-60
beam, the theoretical CLR is found to be about 1.005 of the value at the reference
QI while the experiment reports a value of 1.017. Discrepancies between experiments
suggest that other e↵ects play a role in the energy dependence. More specifically, the
model implicitly assumes isotropic Cherenkov emission, while the angular distribution
of the light varies with the electron kinetic energy and the optical fibre only guides
light emitted at a specific angular range. Further improvements modelling Cherenkov
light transport explicitly should confirm these hypotheses.
Conclusions: The theoretical model proposed in this work is promising to evaluate the
energy dependence of the Cerenkov correction in commercial PSD. Potential applica-
tions of this work could allow determining the energy dependence of PSD measurements
using the CLR technique in small photon fields.
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Nisbet A, Dimitriadis A, Palmer A. and Clark C. H (2016) “Is EBT-XD Film Suit-
able for Linac and Gammaknife radiosurgery dosimetry verification and
audit?” Radiother. Oncol. 119 75
Purpose: The validation of radiotherapy treatments by dosimetric measurement is
essential for the introduction of new techniques, pre-treatment verification and dosime-
try audit. Film dosimetry has the advantage of high spatial resolution, low energy
dependence and water equivalence. A new film (EBT-XD) has been assessed for its
suitability for the dosimetry of stereotactic radiosurgery (SRS) applications.
Methods: Calibration curves for red, green and blue channels were created in the
range of 0-4000 cGy for EBT-XD and its predecessor EBT3. Ten film pieces were
irradiated in a nominal 6MV linac. The film was scanned using an EPSON Expression
11000XL scanner and the analysis was performed in FilmQA Pro software (Ashland
ISP Inc, NJ, USA). Film dosimetry uncertainties were assessed for typical SRS fields,
including lateral scanner e↵ect at high doses. Both EBT-XD and EBT3 films were used
in-phantom for treatment dose verification of typical Linac-based and Gamma Knife
(GK) stereotactic radiosurgery within the STE2EV anthropomorphic phantom (CIRS,
VA, USA). The dosimetry methodology for a forthcoming UK dosimetry audit of SRS
treatment was utilised.
Results: EBT-XD film has lower optical density than EBT-3 throughout the dose
range tested. EBT-XD was more suitable for high-dose applications because of a lower
lateral scanner uncertainty. For the width of the film sizes that will be used in the SRS
audit (50 mm) and the typical doses measured, the lateral scanner e↵ect was estimated
to be of the range of 0.5% for EBT-XD and 3% for EBT-3. Higher agreement between
TPS and film dose distributions was seen for EBT-XD using both single and triple
channel dosimetry at 2% (local normalisation),1 mm gamma index analysis criteria,
with the recommended triple channel used for EBT-XD having a 95.5% passing rate,
compared to conventional single channel EBT3 having only 89.1%. Single channel EBT-
XD had 89.7% passing rates and triple channel EBT-3 38.9%. An example is shown in
figure 1, of EBT-XD showing a 98.3% gamma passing rate for a GK radiosurgery plan
at 3% (local), 1.5 mm criteria.
Conclusions: We have evaluated the use of a new film, EBT-XD, for SRS dosimetry
verification and demonstrated its suitability for a forthcoming audit of radiosurgery
services in the UK. EBT-XD is less susceptible to lateral scanner e↵ects and shows bet-
ter agreement to TPS dose distributions than EBT-3 in linac-based radiosurgery dose
verifications. EBT-XD also showed excellent agreement with TPS dose distributions in
GK radiosurgery.
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A. Dimitriadis, R.A.S. Thomas, A.L. Palmer, D. Eaton, J. Lee, R. Patel, I. Silvestre
Patallo, A. Nisbet, C.H. Clark, “A national cranial stereotactic radiosurgery
end-to-end dosimetry audit” Radiotherapy and Oncology (Accepted for oral pre-
sentation)
Purpose: To assess the geometric and dosimetric accuracy of stereotactic radiosurgery
(SRS) in the UK for linac-based (LB), TomoTherapy (TT), Cyberknife (CK) and
Gamma Knife (GK) radiosurgery.
Methods: 26 SRS centres were visited and 28 treatment plans were assessed (16
LB, 7 GK, 4 CK, 1 TT). The audit methodology employed an anthropomorphic head
phantom with realistic tissue densities with one irregularly-shaped target (PTV), mod-
elled on a brain metastasis, located centrally in the brain and in close proximity to the
brainstem (OAR). The phantom was immobilised, scanned, planned and treated follow-
ing the local protocol. Previously characterised near-water equivalent dosimeters were
placed inside the phantom (EBT-XD film and alanine pellets) to measure absolute dose,
both inside the PTV and OAR (Figure 1), and compare with TPS predictions. Film
measurements were digitised with triple-channel-correction and compared to TPS dose
planes on FilmQA Pro using gamma-analysis for a range of global and local criteria.
Results: Figure 2 shows the alanine measurements inside the PTV. LB showed the
largest range in percentage di↵erence to the TPS of 5.2% (-1.3% to +3.9%) with a mean
of +0.5%. CK had a range of 2.6% (+1.4% to +4%), with the highest mean di↵erence
in comparison to the other platforms (+2.5%). GK showed the smallest range at 2.4%
(-0.8% to +1.5%) being comparable to that of CK, with the smallest mean percentage
di↵erence (+0.4%) comparable to that of LB. Similar trends were observed in the OAR
with alanine measurements showing a range from -1% to +3.6% (mean= +1.3%), 0%
to +1.9% (mean= +0.9%) and -1.1% to +0.9% (mean= +0.1%), for LB, CK and GK
respectively. The film measurements showed comparable passing rates between axial
and sagittal films, regardless of the platform used. As expected, higher passing rates
were observed for Global-gamma criteria. For 3%-2 mm Local-gamma, all except two
films showed passing rates above 75%. For 5%-1 mm Global-gamma, all except 2 films
showed passing rates above 90%.
Conclusion: This audit enabled the comparison of all participating centres in terms
of the accuracy achieved during the delivery. The techniques used di↵ered in many
aspects. The LB group showed the largest variations in agreement to the TPS, related
to more heterogeneous practices within the group, compared to small variations seen
in CK, and more consistent practices seen in GK. Good overall agreement with the
TPS was observed with only 3 centres falling above two standard deviations of the
mean (2 centres in the target measurements and 1 in the OAR). Film measurements
showed comparable gamma-passing rates for all centres assessed with small di↵erences
between platform groups. The results suggest that good agreement with the predicted
dose distributions is achievable by all treatment modalities but highlight the need for
standardisation in SRS practices.
